日本臨牀 増刊60/8 新時代の糖尿病学2

出版社: 日本臨牀社
発行日: 2002-08-28
分野: 臨床医学:一般  >  雑誌
雑誌名:
電子書籍版: 2002-08-28 (初版第1刷)
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安:8~14営業日

15,620 円(税込)

電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

15,620 円(税込)

商品紹介

人間社会の発達に伴って糖尿病は増加し、その病態も修飾されたが、疾患そのものは本質的に変わらないはずである。糖尿病は変わった、常に新しい疾患だといわれるのは、医学の進歩に伴ってこの疾患が、本来備えていた複雑な内容が順次明らかにされてきたためである。特に、近代医学は、綿密な臨床観察によってとらえた疾患を、いったん病人から切り離して生物現象としてとらえ、自然科学的手法を用いて分析し、体系化し、病気の科学として進歩してきた。糖尿病学はその典型であるばかりでなく、常にその先頭を歩いてきた。糖尿病学のあゆみの中にも、科学の伝統ともいうべき継続的発展があり、新しく開発された研究技術を応用した飛躍的発展があり、更に、研究者の健全な知性から生まれた創造的発展がある。これらの継続的・飛躍的・創造的研究によって、これまでそうであったように、これからも、過去を鏡としながら糖尿病学の未来が展開されるであろう。(「序文」より)

目次

  • 日本臨牀 増刊60/8 新時代の糖尿病学(2)

    ―目 次―

    序文:臨床糖尿病学のあゆみと展望

    B.糖尿病基礎研究の進歩

    IV.糖尿病モデル動物
    1.糖尿病モデル動物―概論―
    2.自然発症糖尿病モデル動物
    3.実験的糖尿病モデル動物

    C.糖尿病の疫学・病態・診断学の進歩

    I.糖尿病の疫学
    1.我が国における糖尿病の疫学―諸外国との比較(概論)―
    2.1型糖尿病の実態調査―Ehime Studyから―
    3.OGTTの経年観察結果と2型糖尿病
    4.我が国における肥満の動向

    II.糖尿病の病理

    III.糖尿病にみられる各種病態
    1.糖質代謝異常
    2.脂質代謝異常
    3.蛋白およびアミノ酸代謝異常
    4.有機酸代謝異常(ケトン体を中心に)
    5.尿酸代謝異常
    6.ビタミン代謝異常
    7.水・電解質異常と酸・塩基平衡異常
    8.糖尿病と微量元素異常
    9.糖尿病における内分泌異常
    10.血小板異常
    11.凝固線溶系異常
    12.イノシトールリン脂質代謝異常
    13.糖尿病における血管内皮細胞機能異常―酸化ストレスと細胞機能異常―

    IV.糖尿病診断学の進歩
    1.糖尿病診断法の現状
    2.糖尿病遺伝子診断の展望

    V.糖尿病検査学の進歩
    1.インスリン分泌の評価法
    2.インスリン抵抗性の評価法
    3.糖尿病関連諸検査―測定法と臨床的意義―
    4.簡易血糖測定機器

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

序文 : 臨床糖尿病学のあゆみと展望

P.15 掲載の参考文献
1) 小坂樹徳 : 糖尿病とはいかなる疾患か-疾病概念の変遷と最近の考え方. 東京医学 83 : 1-10, 1975.
2) 小坂樹徳 : 糖尿病におけるインスリン初期分泌反応. Diabetes Frontier 16 : 7-22, 1995.
3) 小坂樹徳 : 糖尿病の診断. ホルモンと臨床 47 : 32-39, 1999.
4) 小坂樹徳 : ADA専門委員会 (1997). WHO諮問委員会 (1998) の糖尿病診断基準の問題点と糖尿病の診断規準のあり方, 糖尿病学 1999 (小坂樹徳編), p68-85, 診断と治療社, 1999.
5) 小坂樹徳 : 糖尿病研究への期待. 糖尿病学 2000 (小坂樹徳編), p1-20, 診断と治療社, 2000.
6) 小坂樹徳 : 糖尿病学-過去・現在・未来. (2) 診断と治療 89 : 1705-1711, 2001.
6) 小坂樹徳 : 糖尿病学-過去・現在・未来. (1) 診断と治療 89 : 1355-1361, 2001.
6) 小坂樹徳 : 糖尿病学-過去・現在・未来. (3) 診断と治療 89 : 1871-1878, 2001.

B. 糖尿病基礎研究の進歩

P.24 掲載の参考文献
1) Brunner JC (1653-1727) : Experimenta nova circa pancreas. Amsterdam 1683 ; engl. z. T. Annals of Medical History 3 : 91-100, 1941.
2) von Mering J (1849-1908) : Uber experimentellen Diabetes. Verhandlungen des Congresses fur Innere Medicin 5 : 185-189, 1890.
3) Renold AE : Der Alloxan Diabetes. In : Thesis, p 45, Univ of Zurich, Zurich, 1945.
4) 岡本耕造 : 糖尿病の実験病理学, 日本医書出版, 1951.
5) Shafrir E, Renold AE (ed) : Preface of Proceedings of 1st Lessons from Animal Diabetes, in Jerusalem, John & Libbey Ltd, London, Paris, 1982.
6) Abstracts from The 8th International Workshop on Lessons from Animal Diabetes joint-by with The 15th Japan Association of Animal Diabetes Research. Int J Exptl Diabetes Res 2 : 261-272, 2001.
7) 米田嘉重郎 : 糖尿病モデル動物の現状とその扱い方. 内分泌・糖尿病科 5 : 253-260, 1997.
8) Lenzen S, et al : The LEW. 1AR1/Ztm-iddm rat : a new model of spontaneous insulin-dependent diabetes mellitus. Diabetologia 44 : 1189-1196, 2001.
9) Shinohara S, et al : A new Spontaneously Diabetic non-obese Torii rat strain with severe ocular complications. Int Jnl Experimental Diab Res 1 : 89-100, 2000.
10) Suzuki W, et al : A new mouse model of Spontaneous Diabetes derived from ddY strain. Exp Anim 48 (3) : 181-189, 1999.
11) Yoshioka M, et al : A novel locus, Mody 4, distal to D7Mit189 on chromosome 7 determines early-onset NIDDM in nonobese C57BL/6 (Akita) mutant mice. Diabetes 46 : 887-894, 1997.
P.31 掲載の参考文献
1) Makino S, et al : Bleeding of non-obese, diabetic strain of mice. Jikken Dobutsu 29 : 1-13, 1980.
2) Eisenbarth SG, et al : Pathogenesis of insulin-dependent (Type I) diabetes mellitus. In : Joslin's Diabetes Mellitus, 13th ed (ed by Kahn CR, Weir GC), p 216-239, Lea & Febiger, Philadelphia, 1994.
3) Podolin PL, et al : Localization of two insulin-dependent diabetes (Idd) genes to the Idd10 region on mouse chromosome 3. Mamm Genome 9 : 283-286, 1998.
4) Thiessen S, et al : T-cell tolerance by dendritic cells and macrophages as a mechanism for the major histocompatibility complex-linked resistance to autoimmune diabetes. Diabetes 51 : 325-338, 2002.
6) Yoon JW, et al : Virus as triggering factors of type I diabetes. Frontiers in Diabetes III, 1990.
7) Chiu PPL, et al : Genetic control of T and B lymphocyte activation in nonobese diabetic mice. J Immunol 167 : 7169-7179, 2001.
8) Serreze DV, et al : Acceleration of type 1 diabetes by a coxsackievirus infection requires a preexisting critical mass of autoreactive T-cells in pancreatic islets. Diabetes 49 : 708-711, 2000.
9) Bonifacio E, et al : Intemational workshop on lessons from animal models for human type 1 diabetes-Identification of insulin but not glutamic acid decarboxylase or IA-2 as specific autoantigens of humoral autoimmunity in nonobese diabetic mice. Diabetes 50 : 2451-2458, 2001.
10) Chiu PP, et al : Development and function of diabetogenic T-cells in B-cell-deficient nonobese diabetic mice. Diabetes 50 : 763-770, 2001.
12) Fujihira K, et al : Suppression and acceleration of autoimmune diabetes by neutralization of endogenous interleukin-12 in NOD mice. Diabetes 49 : 1998-2006, 2000.
13) Hultgren B, et al : Genetic absence of gamma-interferon delays but does not prevent diabetes in NOD mice. Diabetes 45 : 812-817, 1996.
14) Tisch R, et al : A glutamic acid decarboxylase 65-specific Th2 cell clone immunoregulates autoimmune diabetes in nonobese diabetic mice. J Immunol 166 : 6925-6936, 2001.
15) Hammond KJL, et al : Alpha/beta-T cell receptor (TCR)+ CD4+ CD8+ (NKT) thymocytes prevent insulin-dependent diabetes mellitus in nonobese diabetic (NOD) /Lt mice by the influence of interleukin (IL)-4 and/or IL-10. J Exp Med 187 : 1047-1056, 1998.
16) Kagi D, et al : Reduced incidence and delayed onset of diabetes in perforin-deficient nonobese diabetic mice. J Exp Med 186 : 989, 1997.
17) Amrani A, et al : IL-1α, IL-1β, and IFN-γ mark β cells for Fas-dependent destruction by diabetogenic CD4+ T lymphocytes. J Clin Invest 105 : 459-468, 2000.
18) Amrani A, et al : Perforin-independent β-cell destruction by diabetogenic CD8+ T lymphocytes in transgenic nonobese diabetic mice. J Clin Invest 103 : 1201-1209, 1999.
19) Nakayama M, et al : Fas/FasL interactions play an essential role in the initiation of murine autoimmune diabetes. Diabetes, 2002. (in press)
20) Darville MI, Eizirik DL : Cytokine induction of Fas gene expression in insulin-producing cells requires the transcription factors NF-κB and C/EBP. Diabetes 50 : 1741, 2001.
21) Suk L et al : IFN-γ/TNF-α synergism as the final effector in autoimmune diabetes : A key role for STAT1/IFN regulatory Factor-1 pathway in pancreatic β cell death. J Immunol 166 : 4481, 2001.
22) Herrera P, et al : A mouse CD8 T cell-mediated acute autoimmune diabetes independent of the perforin and Fas cytotoxic pathways : possible role of membrane TNF. Proc Natl Acad Sci USA 97 : 279, 2000.
23) Kim S, et al : Inhibition of autoimmune diabetes by Fas ligand : The paradox is solved. J Immunol 164 : 2931, 2000.
P.37 掲載の参考文献
1) Goto Y, et al : Spontaneous diabetes produced by selective breeding of normal Wistar rats. Proc Jap Acad 51 : 80-85, 1975.
2) Mavassat J, et al : Impaired development of pancreatic beta-cell mass is a primary event during the progression to diabetes in the GK rats. Diabetologia 40 : 916-925, 1997.
3) Serradas P, et al : Fetal insulin-like growth factor-2 production is impaired in the GK rat model of type 2 diabetes. Diabetes 51 : 392-397, 2002.
4) Portha B, et al : B-cell insensitivity to glucose in the GK rats, a spontaneous non-obese model for type II diabetes. Diabetes 40 : 486-491, 1991.
5) Tuura Y, et al : Glucose sensitivity of ATP sensitive K+ channels is impaired in β cells of the GK rat. A new Genetic model of NIDDM. Diabetes 42 : 1446-1453, 1993.
6) Picarel-Blanchot F, et al : Impaired insulin secretion and excessive hepatic glucose production are both early events in the diabetic GK rats. Am J Phys Endcrinol Metab 271 : E755-E762, 1996.
7) 杉山泰雄ほか : 自然発症糖尿病GKラットの高血糖発症における肝インスリン感受性の役割. 糖尿病 32 : 593-599, 1989.
8) Berthelier C, et al : Lack of deterioration of insulin action with aging in the GK rats : Acontrasted adaptation as compared with nondiabetic rats. Metabolism 46 : 890-896, 1997.
9) Galli J, et al : Genetic analysis of non-insulin dependent diabetes mellitus in the GK rats. Nat Genet 12 : 31-37, 1996.
10) Gauguier D, et al : Chromosomal mapping of genetic loci associated with non-insulin dependent diabetes in the GK rats. Nat Genet 12 : 38-43, 1996.
11) Galli J, et al : Pathophysiological and genetic characterization of the major diabetes locus in GK rats. Diabetes 48 : 2463-2470, 1999.
12) Lin JM, et al : Phenotyping of individual pancreatic islets locates genetic defects in stimulus secretion coupling to Niddmli within the major diabetes locus in GK rats. Diabetes 50 : 2737-2743, 2001.
13) Ohashi K, et al : WBN/Kob rats. A new spontaneously occurring model of chronic pancreatitis. Int J Pancreatol 6 : 231-247, 1990.
15) Shinohara M, et al : A new spontaneously diabetic non-obese Torii rat strain with severe ocular complications. Int J Exp Diab Res 1 : 89-100, 2000.
16) 益山拓ほか : 2型糖尿病モデルSDTラットの耐糖能低下に関する遺伝学的解析. Diabetes Frontier 12 : 818-819, 2001.
P.43 掲載の参考文献
1) 近藤恭司ほか : 日本在来マウスから育成した系統. 実験動物 6 : 107-112, 1957.
2) Nakamura M : A diabetic strain of the mouse. Proc Jap Acad 38 : 348-352, 1962.
3) Nishimura M : Breeding of mice strains for diabetes mellitus. Exp Anim (Tokyo) 18 : 147-157, 1969.
4) Iwatsuka H, et al : Metabolic disturbance of KK mice in chemical diabetes. J Takeda Res Lab 29 : 685-692, 1970.
6) Neel JV : Diabetes mellitus. A 'thrifty'genotype rendered detrimental by 'progress'? Am J Hum Genet 14 : 353-362, 1962.
7) Iwatsuka H, et al : Congenitally impaired hormone sensitivity of the adipose tissue of spontaneously diabetic mice, KK. Validity of thrifty genotype in KK mice. Diabetologia 10 : 611-616, 1974.
8) Iwatsuka H, et al : General survey of diabetic features of yellow KK mice. Endocr J 17 : 23-35, 1970.
9) Iwatsuka H, Shino A : Studies on diabetogenic action of obesity in mice : congenital insulin resistance of KK mice. Endocr J 17 : 535-540, 1970.
10) Matsuo T, Shino A : Induction of diabetic alterations by goldthioglucose-obesity in KK, ICR and C57BL mice. Diabetologia 8 : 391-397, 1972.
11) Suto J, et al : Genetic analysis of non-insulin-dependent diabetes mellitus in KK and KK-AY mice. Eur J Endocr 139 : 654-661, 1998.
12) Suto J, et al : Genetics of obesity in KK mouse and effects of Ay allele on quantitative regulation. Mamm Genome 9 : 506-510, 1998.
13) Suto J, et al : Quantitative trait loci that regulate plasma lipid concentration in hereditary obese KK and KK-AY mice. Biochim Biophys Acta 1453 : 385-395, 1999.
14) Taylor BA, et al : Gender-influenced obesity QTLs identified in a cross involving the KK type II diabetes-prone mouse strain. Mamm Genome 10 : 963-968, 1999.
15) Shike T, et al : Susceptibility and negative epistatic loci contributing to type 2 diabetes and related phenotypes in a KK/Ta mouse model. Diabetes 50 : 1943-1948, 2001.
17) Ikeda H, et al : Effects of pioglitazone on glucose and lipid metabolism in normal and insulin resistant animals. Arzneim Forsch/Drug Res 40 : 156-162, 1990.
18) 門脇孝 : インスリン抵抗性改善薬開発の動向. 日本臨牀 59 : 2186-2190, 2001.
19) Ikeda H, et al : A new genetically obese-hyperglycemic rat (Wistar fatty). Diabetes 30 : 1045-1050, 1981.
20) Sugiyama Y, et al : Effects of pioglitazone on hepatic and peripheral insulin resistance in Wistar fatty rats. Arzneim Forsch/Drug Res 40 : 436-440, 1990.
22) Murase K, et al : Pioglitazone time-dependently reduces tumor necrosis factor-α level in muscle and improves metabolic abnormalities in Wistar fatty rats. Diabetologia 41 : 257-264, 1998.
23) Suzuki M, et al : Nephropathy in genetically obese-diabetic Wistar fatty rats-Characterization and prevention. Jpn Pharmacol Ther 25 : 363-371, 1997.
24) Coleman DL : Obesity and diabetes. Two mutant genes causing diabetes-obesity syndromes in mice. Diabetologia 14 : 141-148, 1978.
28) Kawano K, et al : Spontaneous long-term hyperglycemic rat with diabetic complications, Otsuka Long-Evans-Tokushima Fatty (OLETF) strains. Diabetes 41 : 1422-1428, 1992.
29) Zhu M, et al : Poor capacity for proliferation of pancreatic β-cells in Otsuka Long-Evans-Tokushima Fatty (OLETF) rat, model of spontaneous non-insulin-dependent diabetes mellitus (NIDDM). Diabetes 45 : 941-946, 1996.
31) Yamasaki Y, et al : Quantitative trait loci for lipid metabolism in the study of OLETF X (OLETF X Fischer 344) backcross rats. Clin Exp Pharmacol Physiol 27 : 881-886, 2000.
32) Ogino T, et al : Genetic evidence for obesity loci involved in the regulation of body fat distribution in obese type 2 diabetes rat, OLETF. Genomics 70 : 19-25, 2000.
33) Castle CK, et al : Remodeling of the HDL in NIDDM : a fundamental role for cholesteryl ester transfer protein. Am J Physiol 274 : E1091-E1098, 1998.
34) Hirayama I, et al : Genetic analysis of obese diabetes in the TSOD mouse. Diabetes 48 : 1183-1191, 1999.
P.51 掲載の参考文献
1) Herr RR, et al : Isolation and characterization of streptozotocin. In : Antibiot Ann 1959-1960, p 236-240, Medical Encyclopedia, New York, 1960.
2) Rakieten N, et al : Studies on the diabetogenic action of strepto-zotocin. Cancer Chemother Rep 29 : 91-98, 1963.
3) Schein P, et al : The use of nicotinamide to modify the toxicity of streptozotocin diabetes without loss of antitumor activity. Cancer Res 27 : 2324-2332, 1967.
4) Yamamoto H, et al : Streptozotocin and alloxan induce DNA strand breaks and poly (ADP-ribose) synthetase in pancreatic islets. Nature 294 : 284-286, 1981.
5) 岡本宏 : 膵β細胞破壊と防止についての岡本モデルとその展開. 糖尿病 37 : 99-102, 1994.
6) Junod A, et al : Diabetogenic action of streptozotocin : Relationship of dose to metabolic response. J Clin Invest 48 : 2129-2139, 1972.
7) Portha B, et al : Diabetogenic effect of streptozotocin in the rat during the perinatal period. Diabetes 23 : 889-895, 1974.
8) Weir GC, et al : Islet secretion in a new experimental model for non-insulin-dependent diabetes. Diabetes 30 : 590-595, 1981.
9) Wang RN, et al : Beta-cell proliferation in normal and streptozotocin-treated newborn rats ; site, dynamics and capacity. Diabetologia 37 : 1088-1096, 1994.
10) Portha B, et al : The rat models of non-insulin dependent diabetes induced by neonatal streptozotocin. Diabetes Metab 15 : 61-75, 1989,
11) Iwashima Y, et al : Expression of calcium channel mRNAs in rat pancreatic islets and downregulation after glucose infusion. Diabetes 42 : 948-955, 1993.
13) Iwashima Y, et al : Downregulation of the voltage-dependent calcium channel (VDCC) -β subunit mRNAs in pancreatic islets of type 2 diabetic rats. Biochem Biophys Res Commun 280 : 923-932, 2001.
14) Ihara Y, et al : Molecular diversity and functional characterization of voltage-dependent calcium channels (CACN4) expressed in pancreatic β-cells. Mol Endocrinol 9 : 121-130, 1995.
15) Dunn JS, McLetchie NGB : Experimental alloxan diabetes in rat. Lancet ii : 384-387, 1943.
P.56 掲載の参考文献
1) Green EA, et al : Neonatal tumor necrosis factor-α promotes diabetes in nonobese diabetic mice by CD154-independent antigen presentation to CD8+ T cells. J Exp Med 191 (2) : 225-237, 2000.
2) Kagi D, et al : TNF receptor 1-dependent β cell toxicity as an effector pathway in autoimmune diabetes. J Immunol 162 : 4598-4605, 1999.
3) Wang B, et al : CD1-restricted NK T cells protect nonobese diabetic mice from developing diabetes. J Exp Med 194 (3) : 313-319, 2001.
4) Hong S, et al : The natural killer T-cell ligand α-galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice. Nat Med 7 (9) : 1052-1056, 2001.
5) Sharif S, et al : Activation of natural killer T cells by α-galactosylceramide treatment prevents the onset and recurrence of autoimmune type 1 diabetes. Nat Med 7 (9) : 1057-1062, 2001.
6) Holz A, et al : Disruption of the STAT4 signaling pathway protects from autoimmune diabetes while retaining antiviral immune competence. J Immunol 163 : 5347-5382, 1999.
7) Serreze DV, et al : Th1 to Th2 cytokine shifts in nonobese diabetic mice : sometimes an outcome, rather than the cause, of diabetic resistance elicited by immunostimulation. J Immunol 166 : 1352-1359, 2001.
8) Balasa B, et al : Amechanism for IL-10-mediated diabetes in the nonobese diabetic (NOD) mouse : ICAM-1 deficiency blocks accerelated diabetes. J Immunol 165 : 7330-7337, 2000.
9) Liu D, et al : Cytokines induce apoptosis in β-cells isolated from mice lacking the inducible isoform of nitric oxide synthase (iNOS-/-). Diabetes 49 : 1116-1122, 2000.
11) Harding HP, et al : Diabetes mellitus and exocrine pancreatic dysfunction in perk -/- mice reveals a role for translational control in secretory cell survival. Mol Cell 7 : 1153-1163, 2001.
12) Oyadomari S, et al : Nitric oxide-induced apoptosis in pancreatic β cells is mediated by the endoplasmic reticulum stress pathway. Proc Natl Acad Sci USA 98 (19) : 10845-10850, 2001.
14) Chatila TA, et al : JM2, encoding a forkhead-related protein, is mutated in X-linked autoimmunityallergic disregulation syndrome. J Clin Invest 106 : R75-R81, 2000.
P.62 掲載の参考文献
1) Terauchi Y, et al : Pancreatic β-cell-specific targeted disruption of glucokinase gene. J Biol Chem 270 : 30253-30256, 1995.
3) Miki T, et al : Defective insulin secretion and enhanced insulin action in KATP channel-deficient mice. Proc Natl Acad Sci USA 95 : 10402-10406, 1998.
4) Kulkami RN, et al : Tissue-specific knockout of the insulin receptor in pancreatic β cells creates an insulin secretory defect similar to that in type 2 diabetes. Cell 96 : 329-339, 1999.
8) Kubota N, et al : Disruption of insulin receptor substrate-2 causes type 2 diabetes due to liver insulin resistance and lack of compensatory β-cell hyperplasia. Diabetes 49 : 1880-1889, 2000.
9) Terauchi Y, et al : Development of non-insulin-dependent diabetes mellitus in the double knockout mice with disruption of insulin receptor substrate-1 and β-cell glucokinase genes. J Clin Invest 99 : 861-866, 1997.
13) Ahlgren U, et al : Beta-cell-specific inactivation of the mouse Ipf1/Pdx1 gene results in loss of the beta-cell phenotype and maturity onset diabetes. Genes Dev 12 : 1763-1768, 1998.
14) Sosa-Pineda B, et al : The Pax4 gene is essential for differentiation of insulin-producing β cells in the mammalian pancreas. Nature 386 : 399-403, 1997.
15) Sussel L, et al : Mice lacking the homeodomain transcription factor Nkx2. 2 have diabetes due to arrested differentiation of pancreatic β cells. Development 125 : 2213-2221, 1998.
16) Pontoglio M, et al : Defective insulin secretion in hepatocyte nuclear factor 1α-deficient mice. J Clin Invest 101 : 2215-2222, 1998.
P.68 掲載の参考文献
2) Bruning JC, et al : A muscle-specific insulin receptor knockout exhibits features of the metabolic syndrome of NIDDM without altering glucose tolerance. Mol Cell 2 : 559-569, 1998.
5) Michael MD, et al : Loss of insulin signaling in hepatocytes leads to severe insulin resistance and progressive hepatic dysfunction. Mol Cell 6 : 87-97, 2000.
8) Kubota N, et al : Disruption of insulin receptor substrate-2 causes type 2 diabetes due to liver insulin resistance and lack of compensatory β-cell hyperplasia. Diabetes 49 : 1880-1889, 2000.
12) Terauchi Y, et al : Increased insulin sensitivity and hypoglycaemia in mice lacking p85α phosphoinositide 3-kinase. Nat Genet 21 : 230-235, 1999.
13) Elchebly M, et al : Increased insulin sensitivity and obesity in mice lacking the protein tyrosine phosphatase-1B gene. Science 283 : 1544-1548, 1999.
15) Kubota N, et al : PPARγ mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Mol Cell 4 : 595-607, 1999.
17) Terauchi Y, et al : Development of non-insulin-dependent diabetes mellitus in the double knockout mice with disruption of insulin receptor substrate-1 and β-cell glucokinase genes. J Clin Invest 99 : 861-866, 1997.
18) Brtining JC, et al : Development of a novel polygenic model of NIDDM in mice heterozygous for IR and IRS-1 null alleles. Cell 88 : 561-572, 1997.
19) Withers DJ, et al : Irs-2 coordinates Igf 1 receptor-mediated β-cell development and peripheral insulin signalling. Nat Genet 23 : 32-40, 1999.
P.74 掲載の参考文献
1) 宮崎純一 : 医学と医療の最前線トランスジェニックマウスの糖尿病学への貢献. 日内会誌 85 : 131-136, 1998.
2) 門脇孝 : 糖尿病ナビゲーター, メディカルレビュー社, 2002.
4) Nishinoto H, et al : Prevention of autoimmune insulitis by expression of I-E molecules in NOD mice. Nature 328 : 432-434, 1987.
6) 森谷眞紀, 板倉光夫 : IDDM発症機構とサイトカイン. 分子糖尿病学の進歩基礎から臨床まで 1998 (矢崎義雄編), p 99-104, 金原出版, 1998.
8) Hotta M, et al : Pancreatic beta cell-specific expression of thioredoxin, an antioxidative and antiapoptotic protein, prevents autoimmune and streptozotocin-induced diabetes. J Exp Med 188 : 1445-1451, 1998.
P.78 掲載の参考文献
1) 三家登喜夫 : アミリン. 糖尿病ナビゲーター (門脇孝編), p72-73, メディカルレビュー社, 2002.
2) Wang F, et al : Islet amyloid develops diffusely throughout the pancreas before becoming severe and replacing endocrine cells. Diabetes 50 : 2514-2520, 2001.
3) Hurlbert M, et al : Mice transgenic for an expanded CAG repeat in the Huntington's disease gene develop diabetes. Diabetes 48 : 649-651, 1999.
4) Allison J, et al : Overexpression of beta 2-microglobulin in transgenic mouse islet beta cells results in defective insulin secretion. Proc Natl Acad Sci USA 88 : 2070-2074, 1991.
5) Epstein PN, et al : Calmodulin-induced early-onset diabetes in transgenic mice. Cell 58 : 1067-1073, 1989.
6) Erfat S, et al : Diabetes induced in male transgenic mice by expression of human H-ras oncoprotein in pancreatic beta cells. Mol Cell Biol 10 : 1779-1783, 1990.
7) Yamagata K, et al : Overexpression of dominant-negative mutant hepatocyte nuclear factor-1α in pancreatic β-cells causes abnormal islet architecture with decreased expression of E-Cadherin, reduced β-cell proliferation, and diabetes. Diabetes 51 : 114-123, 2002.
8) Lottmann H, et al : The Tet-On system in transgenic mice : inhibition of the mouse pdx-1gene activity by antisense RNA expression in pancreatic beta-cells. J Mol Med 79 : 321-328, 2001.
11) Valera A, et al : Expression of GLUT-2 antisense RNA in beta cells of transgenic mice leads to diabetes. J Biol Chem 269 : 28543-28546, 1994.
12) Ishihara H, et al : Inhibition of pancreatic beta-cell glucokinase by antisense RNA expression in transgenic mice : mouse strain-dependent alteration of glucose tolerance. FEBS Lett 371 (3) : 329-332, 1995.
13) Miki T, et al : Abnormalities of pancreatic islets by targeted expression of a dominant-negative KATP channel. Proc Natl Acad Sci USA 94 : 11969-11973, 1997.
14) Miki T, et al : Defective insulin secretion and enhanced insulin action in KATP channel-deficient mice. Proc Natl Acad Sci USA 95 : 10402-10406, 1998.
P.84 掲載の参考文献
1) Valera A, et al : Transgenic mice overexpressing phosphoenolpyruvate carboxykinase develop non-insulin-dependent diabetes mellitus. Proc Natl Acad Sci USA 91 : 9151-9154, 1994.
3) Kim JK, et al : Tissue-specific overexpression of lipoprotein lipase causes tissue-specific insulin resistance. Proc Natl Acad Sci USA 98 : 7522-7527, 2000.
5) Klebic ML, et al : Ectopic expression of the agouti gene in transgenic mice causes obesity, features of type II diabetes, and yellow fur. Proc Natl Acad Sci USA 92 : 4728-4732, 1995.
7) Moitra JM, et al : Life without white fat : atransgenic mouse. Genes Dev 12 : 3168-3181, 1998.
8) Ogawa Y, et al : Increased glucose metabolism and insulin sensitivity in transgenic skinny mice over-expressing leptin. Diabetes 48 : 1822-1829, 1999.
10) Shimomura I, et al : Insulin resistance and diabetes mellitus in transgenic mice overexpressing nuclear SREBP-1c in adipose tissue : model for congenital generalized lipodystrophy. Genes Dev 12 : 3182-3194, 1998.
P.90 掲載の参考文献
1) Ferraris JD, et al : ORE, a eukaryotic minimal essential osmotic response element. The aldose reductase gene in hyperosmotic stress. J Biol Chem 271 : 18318-18321, 1996.
2) Ho HTB, et al : Aldose reductase deficient mice develop nephrogenic diabetes incipidus. Mol Cell Biol 20 : 5840-5846, 2000.
3) Jeffery JA, et al : Sorbitol dehydrogenase. The primary structure of the sheep-liver enzyme. Eur J Biochem 140 : 7-16, 1984.
4) Holmes RS, et al : Sorbitol dehydrogenase genetics in the mouse ; a null mutant in a 'European' C57BL strain. Anim Blood Groups Biochem Genet 13 : 263-272, 1982.
5) Chang WP, et al : The effect of aldose reductase inhibitors on glomerular prostaglandin production and urinary albumin excretion in experimental diabetes mellitus. Diabetologia 34 : 225-231, 1991.
6) Tilton RG, et al : Discordant effects of the aldose reductase inhibitor, sorbinil, on vascular structure and function in chronically diabetic and galactosemic rats. J Diabet Complications 5 : 230-237, 1991.
7) 伊井節子, 板倉光夫 : ヒトアルドース還元酵素 (hAR) の遺伝子を導入したトランスジェニックマウス (hAR-Tg) を使った糖尿病性合併症の発症機序に関する解析. 日本臨牀 56 : 753-757. 1998.
8) Lee AYW, et al : Demonstration that polyol accumulation is responsible for diabetic cataract by the use of transgenic mice expressing the aldose reductase gene in the lens. Proc Natl Acad Sci USA 92 : 2780-2784, 1995.
9) Yagihashi S, et al : Galactosemic neuropathy in transgenic mice for human aldose reductase. Diabetes 45 : 56-59, 1996.
10) Tilton RG, et al : Inhibition of sorbitol dehydrogenase. Effects on vascular and neural dysfunction in streptozocin-induced diabetic rats. Diabetes 44 : 234-242, 1995.
12) Ng DTF, et al : Effects of sorbitol dehydrogenase deficiency on nerve conduction in experimental diabetes mice. Diabetes 47 : 961-966, 1998.
13) Cameron NE, et al : Aldose reductase inhibition, nerve perfusion, oxygenation and function in streptozotocin-diabetic rats : dose-response considerations and independence from a myo-inositol mechanism. Diabetologia 37 : 651-663, 1994.

C. 糖尿病の疫学・病態・診断学の進歩

P.102 掲載の参考文献
1) King H, et al : Global burden of diabetes, 1995-2025. Diabetes Care 21 (9) : 1414-1430, 1998.
2) Diabetes Mellitus-Report of WHO Study Group : 糖尿病第三報最新の知見, WHO研究グループの報告, 定義, 診断および分類, World Health Organization Technical Report Series 723, World Health Organization, Geneva, 1985 (片岡邦三監訳), 日本公衆衛生協会, 1986.
3) American Diabetes Association : Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 25 (Suppl 1) : S5-S20, 2002.
4) Curt LR, et al : Use of GHb (HbA1C) in screening for undiagnosed diabetes in the U. S. population. Diabetes Care 23 (2) : 187-191, 2000.
5) Curt LR, et al : Defining the relationship between plasma glucose and HbA1C . Diabetes Care 25 (2) : 275-278, 2002.
6) 厚生の指標, 国民衛生の動向, 2001年第48巻第9号, 第2章, 生活習慣病対策, 糖尿病について, p93-94, 財団法人, 厚生統計協会.
7) 大石まり子, 赤澤好温 : わが国における2型糖尿病と将来予測. 1998糖尿病学 (小坂樹徳ほか編), p46-54, 診断と治療社, 1998.
8) Akazawa S, et al : New paradigm in health information research, e-Health for Diabetes in the Western Pacific. In : ELSERVIER Excerpta Medica International Congress Series 1227 (ed by Aoki N, et al), p 3-9, 123-126, International Conference on the Western Pacific Diabetes Information Network (WPDIN), 2000.
9) Akazawa S, et al : An Approach to New Paradigm in E-Health Security. (未刊)
10) 赤澤好温ほか : 糖尿病及びその合併症の予防と疫学に関する研究, 平成9年度厚生省長期慢性疾患総合研究事業, 糖尿病調査研究報告書, p13-97, 1998.
11) 葛谷英嗣 : ハイリスク者を対象とした生活習慣介入によるインスリン非依存型糖尿病の予防に関する研究, 平成10年度-12年度総合研究報告書, 厚生科学研究費補助金健康科学総合研究事業, 2000.
12) 厚生省, 21世紀における国民健康づくり運動 (健康日本21) の推進について, 2. 糖尿病, 健康日本21企画検討会, 健康日本21計画策定検討会報告書, 財団法人健康体力づくり事業財団, p139-145, 2000.
13) 金澤康徳 : 日本人の糖尿病. 臨牀と研究 79 (1) : 5-10, 2002.
14) 田代眞一, 赤澤好温 : 安定型ヘモグロビンA1cを指標としたわが国の糖尿病患者の推計. 平成3年度厚生省糖尿病調査研究事業報告書, p19-23, 厚生省, 1992.
15) 藤島正敏ほか : 心血管症発症リスクとしての耐糖能異常. 糖尿病 41 (Suppl 2) : A45-A47, 1998.
16) Diabetes Prevention Program Research Group : Reduction in the incidence of Type 2 Diabetes with lifestyle intervention or metformin. N Engl J Med 346 (6) : 393-403, 2002.
P.108 掲載の参考文献
1) 葛谷健ほか : 糖尿病の分類と診断基準に関する委員会報告. 糖尿病 42 : 385-404, 1999.
2) Kobayashi T, et al : Immunogenetis and clinical characterization of slowly progressive IDDM. Diabetes Care 16 : 780-788, 1993.
4) Kawasaki E, Eisenbarth GS : Multiple autoantigens in the prediction and pathogenesis of type I diabetes. Diabetes Nutr Metab 9 : 188-198, 1996.
5) Solimena M, et al : Autoantibodies to glutamic acid decarboxylase in a patient with Stiffman syndrome, epilepsy, and Type I diabetes mellitus. N Engl J Med 318 : 1012-1020, 1988.
6) Kawasaki E, et al : Autoantibodies to glutamic acid decarboxylase in patients with autoimmune thyroid disease : relation to competitive insulin autoantibodies. J Autoimmun 8 : 633-643, 1995.
10) Takeda H, et al : Clinical, autoimmune, and genetic features in Japanese adult-onset diabetic patients with GAD autoantibodies. Diabetes Care (in press)
11) Tuomi T, et al : Clinical and genetic characteristics of type 2 diabetes with and without GAD antibodies. Diabetes 48 : 150-157, 1999.
12) Niskanen LK, et al : GAD antibodies in NIDDM : Ten year follow-up from the diagnosis. Diabetes Care 12 : 1557-1565, 1995.
15) Ikegami H, Ogihara T : Genetics of insulin-dpendent diabetes mellitus. Endocr J 43 : 605-613, 1996.
P.117 掲載の参考文献
1) King H, et al : Global burden of diabetes, 1995-2025. Prevalence, numerical estimates, and projections. Diabetes Care 21 : 1414-1431, 1998.
3) 伊藤千賀子 : NIDDMの発症過程. 医学のあゆみ 156 : 968-971, 1991.
4) Matthews DR, et al : Homeostasis model assessment : insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 : 412-419, 1985.
5) 原均 : 日本人2型糖尿病の不均一性-インスリン分泌不全とインスリン抵抗性-. 糖尿病 41 (Suppl 2) : A21-25, 1999.
6) 葛谷健ほか : 糖尿病の分類と診断. 基準に関する委員会報告. 糖尿病 42 : 385-404, 1999.
8) Cederholm J, Wibell L : Impaired glucose tolerance : influence by environmental and hereditary factors. Diabetes Metab 17 : 295-299, 1991.
P.127 掲載の参考文献
1) Obesity : Preventing and managing the global epidemic : Report of a WHO consultation on obesity Word Health Organization, Geneba, 1998.
2) 日本肥満学会肥満症診療のてびき編集委員会編 : 肥満症 診断・治療・指導のてびき, 医歯薬出版, 1993.
3) Yoshiike N, et al : Descriptive epidemiology of body mass index in Japanese adult a representative sample from the National Nutrition Survey 1990-1994. Int J Obes 22 : 684-687, 1998.
4) 吉池信男ほか : Body mass indexに基づく肥満の程度と糖尿病, 高血圧, 高脂血症の危険因子との関連-多施設共同研究による疫学的検討-. 肥満研究 6 : 4-17, 2000.
5) 松澤佑次ほか : 新しい肥満の判定と肥満症の診断基準. 肥満研究 6 : 18-28, 2000.
6) WHO Western Pacific Region, International Association for the Study of Obesity : The Asia-Pacific Perspective ; Redefining obesity and its treatment, Health Communications Australia Pty Limited, Sydney, 2000.
7) 健康・栄養情報研究会編 : 国民栄養の現状, 第一出版, 2001.
8) 厚生省保健医療局編 : 国民栄養の現状, 第一出版, 1971.
9) 清原裕ほか : 一般住民における肥満の頻度の時代的推移と肥満度が生命予後に及ぼす影響. 久山町研究 4 : 5-11, 1998.
10) 厚生労働省編 : 国民衛生の動向, 厚生統計協会, 2001.
11) Kissebah AH, et al : Relation of body fat distribution to metabolic complication of obesity. J Clin Endocrinol Metab 54 : 254-260, 1982.
13) 厚生労働省編 : 健康日本21, 2000.
P.136 掲載の参考文献
1) Laakso M : Hyperglycemia as a risk factor of cardiovascular disease in type 2 diabetes. Prim Care 26 (4) : 829-839, 1999.
2) King GL, Brownlee M : The cellular and molecular mechanisms of diabetic complications. Endocrinol Metab Clin North Am 25 : 255-270, 1996.
3) Cooper ME, et al : Attenuation of diabetes-associated mesenteric vascular hypertrophy with perindopril : Morphological and molecular biological studies. Metabolism 47 : 24-27, 1998.
5) Craighead JE : Diabetes. In : Essential Pathology, 2nd ed (ed by Emanuel R, John LF), p 627-634, JB Lippincott, Philadelphia, 1995.
6) Tanaka S, et al : Evidence of primary, 3-cell destruction by T-cells and β-cell differentiation from pancreatic ductal cells in diabetes associated with active autoimmune chronic pancreatitis. Diabetes Care 24 (9) : 1661-1667, 2001.
9) Everhart JE, et al : Medial arterial calcification and its association with mortality and complications of diabetes. Diabetologia 31 (1) : 16-23, 1988.
10) Cooper ME, Johnston CI : Optimizing treatment of hypertension in patients with diabetes. JAMA 283 : 3177-3179. 2000.
11) Pugliese G, et al : Upregulation of mesangial growth factor and extracellular matrix synthesis by advanced glycation end products via receptor-mediated mechanism. Diabetes 46 (11) : 1881-1887, 1997.
12) 原満ほか : 糖尿病性腎症の病理. 日本臨牀 55 (増刊号 : 糖尿病 (1)) : 783-788, 1997.
14) Yamagishi S, et al : Advanced glycation end products-driven angiogenesis in vitro. J Biol Chem 272 (13) : 8723-8730, 1997.
15) Bilbao JM : Peripheral nerves. In : Ackerman's Surgical Pathology, 8th ed (ed by Rosai J), p 2365-2397, Mosby, St. Louis, 1996.
16) 浦信行. 島本和明 : 透析患者の高血圧. Annual Review腎臓 (長澤俊彦ほか編), p 120-123, 中外医学社, 1999.
P.144 掲載の参考文献
1) Glycolysis and Gluconeogenesis. In : Biochemistry, 5th ed (ed by Berg TM, et al), p 425-464, W. H. Freeman and Co., New York, 2002.
2) Glycogen. In : Biochemistry, 5th ed (ed by Berg TM, et al), p 577-600, W. H. Freeman and Co., New York, 2002.
4) Cherrington AD : Control of glucose uptake and release by the liver in vivo. Diabetes 48 : 1198-1214, 1999.
6) Shulman RG, Rothman DL : 13C NMR of intermediary metabolism : implications for systemic physiology. Ann Rev Physiol 63 : 15-48, 2001.
9) Sugden MC, Holness MJ : Interactive regulation of the pyruvate dehydrogenase complex and the carnitine palmitoyltransferase system. FASEB J 8 : 54-61, 1994.
10) McGarry JD : What if Minkowski had been ageusic? An alternative angle on diabetes. Science 258 : 766-770, 1992.
11) McGarry JD : Dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes 51 : 7-18, 2002.
13) Ruderman NB, et al : Malonyl-CoA, fuel sensing, and insulin resistance. Am J Physiol 276 (Endocrinol Metab 39) : E1-E18, 1999.
14) McGany JD, Dobbins RL : Fatty acids, lipotoxicity and insulin secretion. Diabetologia 42 : 128-138, 1999.
P.152 掲載の参考文献
1) Sower JR, Lester MA : Diabetes and cardiovascular disease. Diabetes Care 22 (Suppl 3) C14-C20, 1999.
2) ADA Positional statement : Management of dyslipidemia in adults with diabetes. Diabetes Care 25 (Suppl 1) : S74-S77, 2002.
4) Tsutsumi K, et al : Correction of hypertriglycesidemia with low high-density lipoprotein cholesterol by the novel compound NO-1886, a lipoprotein-promoting agent, in STZ-induced diabetes rats. Diabetes 44 : 414-417, 1995.
5) Krone W, et al : Opposite effects of insulin and catecholamines on LDL-receptor activity in human mononuclear leukocytes. Diabetes 37 : 1386-1391, 1988.
6) 大久保実ほか : インスリン非依存性型糖尿病 (NIDDM) 患者の血清コレステロール値に及ぼす卵摂取の影響について. 糖尿病 33 : 9-52, 1990.
7) Yamada N, et al : Plasma lipid abnormalities and risk factors for coronary artery disease in Japanese. Diabetes Res Clin Pract 24 (Suppl) : S215-S220, 1994.
8) Haward BV : Lipoprotein metabolism in diabetes mellitus. J Lipid Res 28 : 613-618, 1987.
9) Ostlund RE Jr, et al : Quantitative relationship between plasma lipids and glycohemoglobin in type 1 patients. Diabetes Care 12 : 332-336, 1989.
10) Georgopolus A, Rosenigard AM : Abnormalities in the metabolism of postprandial and fasting triglyceride-rich lipoprotein subfractions in normal and insulin-dependent diabetic subjects : effect of sex. Metabolism 38 : 781-789, 1989.
11) Okubo M, Murase T : Hypertriglyceridemia and HDL cholesterol in Japanese patients with NIDDM. Diabetes 45 (Suppl 3) : S123-S125, 1996.
12) 村勢敏郎 : 糖尿病における脂質代謝異常-リポ蛋白リパーゼの役割を中心に-. 糖尿病合併症 15 : 13-20, 2001.
13) Campos H, et al : Difference in low density lipoprotein subfractions and apolipoproteins in premenopausal and postmenopausal women. J Clin Endcrinol Metab 67 : 30-35, 1988.
14) Kesaniemi YA, et al : Receptor-mediated catabolism of low-density lipoprotein in men. Quantitation using glucosylated low-density lipoprotein. J Clin Invest 71 : 950-959, 1983.
16) Evans LM, et al : Post-prandial lipaemia with the production of triglyceride-rich lipoproteins results in enhanced oxidative stress and deterioration in endothelial function in non-insulin-dependent diabetes. Atherosclerosis 141 : 186-190, 1998.
17) Austin MA, et al : Small, dense low density lipoproteins, the insulin resistance syndrome and non-insulin-dependent diabetes. Curr Opin Lipidol 7 : 167-171, 1996.
18) Hiraga T, et al : Prospective study of lipoprotein (a) as a risk factor for atherosclerotic cardiovascular disease in patients with diabetes. Diabetes Care 18 : 211-214, 1995.
P.159 掲載の参考文献
1) American Diabetes Association : Evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications. Diabetes Care 25 (Suppl 1) : S50-S60, 2002.
2) American Diabetes Association : Diabetic nephropathy. Diabetes Care 25 (Suppl 1) : S85-S89, 2002.
3) Jefferson LS : Role of insulin in the regulation of protein synthesis. Diabetes 29 : 487-496, 1980.
4) Rodriguez T, et al : The increased skeletal muscle protein turnover of the streptozotocin diabetic rat is associated with high concentrations of branced-chain amino acids. Biochem Mol Med 61 : 87-94, 1997.
5) Ashford AJ, Pain VM : Effect of diabetes on the rates of synthesis and degradation of ribosomes in rat muscle and liver in vivo. J Biol Chem 261 : 4059-4065, 1986.
6) Ashford AJ, Pain W : Insulin stimulation of growth in diabetic rats. J Biol Chem 261 : 4066-4070, 1986.
7) Harmon CS, et al : Effects of starvation, diabetes and acute insulin treatment on the regulation of polypeptide-chain initiation in rat skeletal muscle. Biochem J 223 : 687-696, 1984.
8) Towle CA, et al : Insulin promoted decrease in the phosphorylation of protein synthesis initiation factor eIF-2. Biochem Biophys Res Commun 121 : 134-140, 1984.
10) Kimball SR, et al : Insulin and diabetes cause reciprocal changes in the association of eIF-4E and PHAS-1 in rat skeletal muscle. Am J Physiol 270 : C705-C709, 1996.
12) Boirie Y, et al : Tissue-specific regulation of mitochondrial and cytoplasmic protein synthesis rates by insulin. Diabetes 50 : 2652-2658, 2001.
13) De Feo P : Hormonal regulation of human protein metabolism. Eur J Endocrinol 135 : 7-18, 1996.
14) Nair KS, et al : Effect of poor diabetic control and obesity on whole body protein metabolism in man. Diabetologia 25 : 400-403, 1983.
15) Pacy PJ, et al : Failure of insulin infusion to stimulate fractional muscle protein synthesis in type I diabetic patients. Diabetes 38 : 618-624, 1989.
16) Bennet WM, et al : Inability to stimulate skeletal muscle or whole body protein synthesis in type I (insulin-dependent) diabetic patients by insulin-plus-glucose during amino acid infusion : studies of incorporation and turnover of tracer L- [1-13C] leucine. Diabetologia 33 : 43-51, 1990.
18) De Feo P, et al : Phisiological increments in plasma insulin concentrations have selective and different effects on synthesis of hepatic proteins in normal humans. Diabetes 42 : 995-1002, 1993.
20) Nair KS, et al : Effect of intravenous insulin treatment on in vivo whole body leucine kinetics and oxygen consumption in insulin-deprived type-I diabetic patients. Metabolism 36 : 491-495, 1987.
22) Mitch WE, et al : Evaluation of signals activating ubiquitin-proteasome proteolysis in a model of muscle wasting. Am J Physiol 276 (Cell Physiol 45) : Cl132-Cl138, 1999.
24) Lecker SH, et al : Ubiquitin conjugation by the N-end rule pathway and mRNAs for its components increase in muscles of diabetic rats. J Clin Invest 104 : 1411-1420, 1999.
25) Galban VD, et al : Role of ubiquitin-proteasome-dependent proteolytic process in degradation of muscle protein from diabetic rabbits. Mol Cell Biochem 225 : 35-41, 2001.
26) Gougeon R, et al : Effect of NIDDM on the kinetics of whole-body protein metabolism. Diabetes 43 : 318-328, 1994.
27) Gougeon R, et al : Effect of oral hypoglycemic agents and diet on protein metabolism in type 2 diabetes. Diabetes Care 23 : 1-8, 2000.
P.166 掲載の参考文献
1) Murray RK, et al : ハーバー生化学25版 (上代淑人監訳), p 257-268, 丸善, 2001.
2) McGarry JD, Foster DW : Ketogenesis. In : Ellenberg and Rifkin's diabetes mellitus, 5th ed (ed by Porte D, Sherwin RS), p 19-28, Appleton & Lange, Stamford, 1997.
3) 堀田饒 : 肝ケトン体産生とケトン体代謝. 内分泌・糖尿病科 1 : 413-422, 1995.
4) 稲田浩ほか : 小児糖尿病児の日常管理における血中ケトン体測定の臨床的意義. 小児科臨床 44 : 2713-2717, 1991.
5) Wildenhoff KE : The renal excretion of acetoacetate and 3-hydroxybutyrate during absolute fasting. Acta Med Scand 192 : 475-479, 1972.
6) McGarry JD, Foster DW : Hormonal control of ketogenesis. Biochemical consideration. Arch Intern Med 137 : 495-501, 1977.
8) McGarry JD, et al : Carnitine palmitoyltransferase I. The site of inhibition of hepatic acid oxidation by malonyl-CoA. J Biol Chem 253 : 4128-4136, 1978.
P.171 掲載の参考文献
1) Herman JB, Goldbourt U : Uric acid and diabetes mellitus : Observation in a population study. Lancet ii : 240-243, 1982.
3) Zimmet P : Kelly West lecture l991. Challenges in diabetes epidemiology-From West to the rest. Diabetes Care 15 : 232-252, 1992.
6) V-Markkola H, Y-Jarvinen H : Hyperuricemia and insulin resistance. J Clin Endocrinol Metab 78 : 25-29, 1994.
7) 植田太郎ほか : 高尿酸血症とインスリン抵抗性の相互関連. 日本臨牀 54 : 3293-3296, 1996.
8) 岩谷征子ほか : 尿酸代謝異常. 日本臨牀 58 : 430-434, 2000.
9) Iwatani M, et al : Troglitazone decreases serum uric acid concentrations in type II diabetic patients and non-diabetics. Diabetologia 43 : 814-815, 2000.
10) Trevisan R, et al : Role of insulin and atrial naturiuretic peptide in sodium retention in insulin-treated IDDM patients during isotonic volume expansion. Diabetes 39 : 289-298, 1990.
12) Galvan AQ, et al : Effect of insulin on uric acid excretion in humans. Am J physiol 268 : E1-E5, 1995.
13) 野崎秀一, 松沢佑次 : 肥満と高尿酸血症. 臨床科学 32 : 796-801, 1996.
14) Bakker SJ, et al : The potential role of adenosine in the pathophysiology of the insulin resistance syndrome. Atherosclerosis 155 : 283-290, 2001.
P.178 掲載の参考文献
1) 橋詰直孝 : 糖尿病とビタミン. ビタミン 68 : 661-668, 1994.
2) 佐藤祐造, 北越香織 : ビタミン代謝異常. 日本臨牀 55 (増刊 : 糖尿病 (1)) : 641-647, 1997.
4) Durbey S, et al : Increased urinary albumin and retinol-binding protein in type 1 diabetes. Diabetes Care 20 : 84-89, 1997.
6) 佐藤祐造 : 活性酸素と運動 (糖尿病の運動療法). 最新医学 55 : 344-350, 1996.
7) Okada M, et al : Effect of diabetes on vitamin B6 requirement in experimental animals. Diabetes Obes Metab 1 : 221-225, 1999.
8) 堀田饒 : 糖尿病性神経障害. 臨牀と研究 79 : 57-61, 2002.
9) Harrmann W : The importance of hyperhomocysteinemia as a risk factor for diseases : an overview. Clin Chem Lab Med 39 : 666-674, 2001.
10) Price KD, et al : Hyperglycemia-induced ascorbic acid deficiency promotes endothelial dysfunction and the development of atherosclerosis. Atheroscrerosis 158 : 1-12, 2001.
12) Hypponen E, et al : Intake of vitamin D and risk of type 1 diabetes : a birth-cohort study. Lancet 358 : 1476-1478, 2001.
13) Ruhe RC, McDanald RB : Use of antioxidant nutrients in the prevention and treatment of type 2 diabetes. J Am Coll Nutr 20 : 363S-369S, 2001.
14) Gaede P, et al : Double-blind, randomized study of the effect of combined treatment with vitamin C and E on albuminuria in type 2 diabetic patients. Diabet Med 18 : 756-760, 2001.
15) 坂本信夫, 佐藤祐造 : ビタミン代謝異常. 日本臨牀 48 (増刊 : 糖尿病 (上)) : 692-699, 1990.
P.184 掲載の参考文献
1) Saito T, et al : Neurohypophyseal function in patients with non-insulin dependent diabetes mellitus. In : Recent Progress in Posterior Pituitary Hormones 1988 (ed by Yoshida S, Share L), p 387-394, Elsevier Science Pub BV, Amsterdam, 1988.
3) Hillier TA, et al : Hyponatremia : Evaluating the correction factor for hyperglycemia. Am J Med 106 : 399-403, 1999.
4) Clausen T, Kohn P : The effect of insulin on the transport of sodium and potassium in rat soleus muscle. J Physiol (Lond) 265 : 19-42, 1977.
5) Quinones-Galvan A, Ferranini E : Renal effects of insulin in man. J Nephrol 10 : 188-191, 1997.
7) De Fronzo RA : Hyperkalemia and hyporeninemic hypoaldosteronism. Kidney Int 17 : 118-134, 1980.
8) McNair A, et al : Hyponatremia and hyperkalemia in reladon to hyperglycemia in insulin-treated diabetic out-patients. Clin Chim Acta 120 : 243-250, 1982.
9) Saito T, et al : Inverse distribution of serum sodium and potassium in uncontrolled inpatients with diabetes mellitus. Endocr J 46 : 75-80, 1999.
10) Lorber D : Nonketotic hypertonicity in diabetes mellitus. Med Clin North Am 79 : 39-52, 1995.
12) Popli S, et al : Asymptomatic, nonketotic, severe hyperglycemia with hyponatremia. Arch Intern Med 150 : 1962-1964, 1990.
13) Tanaka S, et al : Paradoxical glucose infusion for hypernatraemia in diabetic hyperglycemia hyperosmolar syndrome. J Intern Med 248 : 165-169, 2000.
14) Beck LH : Should the actual or the corrected serum sodium be used to calculate the anion gap? Cleve Clin J Med 68 : 673-674, 2001.
15) Adrogue HJ, et al : Determinant of potassium levels in diabetic ketoacidosis. Medicine 65 : 163-172, 1986.
P.191 掲載の参考文献
1) 荒川泰行ほか : 成人病とミネラル・微量元素. ミネラル・微量元素の栄養学 (鈴木継美, 和田攻編), p179-226, 第一出版, 1994.
2) 和田攻 : 微量元素と糖・脂質代謝 (Over View). 内分泌・糖尿病科 6 : 109-117, 1998.
3) Grant AP, McMullen JK : The effect of brewers yeast containing glucose tolerance factor on the responce to treatment in type 2 diabetes. A shortcontrolled study. Ulster Med J 51 : 110-114, 1982.
4) Rabinowitz MB, et al : Effects of chromium and yeast supplements on carbohydrate and lipid metabolism in diabetes men. Diabetes Care 6 : 319, 1983.
5) Elias AN, et al : Use of the artificial beta cell (ABC) in the assessment of peripheral insulin sensitivity ; Effect of chromium supplementation in diabetic patient. Gen Pharmacol 15 : 535-539, 1984.
6) Davies S, et al : Age-related decreases in chromium levels in 51, 655 hair, sweat, and serum samples from 40,872 patients-implications for the prevention of cardiovascular disease and of type II diabetes mellitus. Metabolism 46 : 469-473, 1997.
7) Anderson AR, et al : Elevated intakes of supplemental chromium improve glucose and insulin variables in individuals with type 2 diabetes. Diabetes 46 : 1786-1791, 1997.
8) 林洋一ほか : インスリン抵抗性が考えられる2型糖尿病におけるクロム補給の効果. Biomed Res Trace Elements 12 : 307-308, 2001.
9) Paolisso G, Barbagallo M : Hypertension, diabetes mellitus, and insulin resistence, the role of intracellular magnesium. Am J Hypertens 10 : 346-355, 1997.
10) Tuvemo T, et al : Serum magnesium and protein concentrations during the first five years of insulin-dependent diabetes in children. Acta Paediatr Suppl 418 : 7-10, 1997.
11) Navarro M, et al : Serum and urine selenium concentrations as indications of body status in patients with diabetes mellitus. Sci Total Environ 22 : 79-85, 1999.
12) Ruiz C, et al : Selenium, zinc and copper in plasma of patients with type 1 diabetes mellitus in different metabolic control states. J Trace Elem Med Biol 12 : 91-95, 1998.
13) Leonhardt W, et al : Impact of concentrations of glycated hemoglobin, alpa-tocopherol, copper, and manganese on oxidation of low-density lipoproteins in patients with type I diabetes, type II diabetes and control subjects. Clin Chim Acta 29 : 173-186, 1996.
14) 桜井弘 : バナジウムによる糖尿病の制御. Biomed Res Trace Elements 11 : 311-312, 2000.
15) 丁文軍ほか : 富士山の地下水に含まれるバナジウムの糖尿病動物に対する影響. Biomed Res Trace Elements 11 : 419-420, 2000.
P.196 掲載の参考文献
1) 岡崎亮ほか : 糖尿病における内分泌異常. 日本臨牀 55 : 667-672, 1997.
3) Mohamed-Ali V, et al : Insulin-like growth factor binding protein-1 in NIDDM : relationship with the insulin resistance syndrome. Clin Endocrinol (Oxf) 50 : 221-228, 1999.
5) Goodman-Gruen D, Barrett-Connor E : Sex differences in the association of endogenous sex hormone levels and glucose tolerance status in older men and women. Diabetes Care 23 : 912-918, 2000.
6) Stellato RK, et al : Testosterone, sex hormone-binding globulin, and the development of type 2 diabetes in middle-aged men : prospective results from the Massachusetts male aging study. Diabetes Care 23 : 490-494, 2000.
7) Nestler JE : Regulation of human dehydroepiandrosterone metabolism by insulin. Ann N Y Acad Sci 747 : 73-81, 1995.
9) Barrett-Connor E, Ferrara A : Dehydroepiandrosterone, dehydroepiandrosterone sulfate, obestiy, waist-hip ratio, and noninsulin-dependent diabetes in postmenopausal women : the Rancho Bernardo study. J Clin Endocrinol Metab 81 : 59-64, 1996.
10) 岡崎亮 : 糖尿病における骨代謝. 内分泌・糖尿病 12 : 308-313, 2001.
11) Rix M, et al : Impact of peripheral neuropathy on bone density in patients with type 1 diabetes. Diabetes Care 22 : 827-831, 1999.
12) van-Daele PL, et al : Bone density in non-insulin-dependent diabetes mellitus. The Rotterdam Study. Ann Intern Med 122 : 409-414, 1995.
17) Campos Pastor MM, et al : Intensive insulin therapy and bone mineral density in type 1 diabetes mellitus : a prospective study. Osteoporos Int 11 : 455-459, 2000.
P.204 掲載の参考文献
1) 寺田秀夫 : 血小板異常. 日本臨牀 55 (増刊 : 糖尿病 (1)) : 673-680, 1997.
2) Johnson M, et al : Vascular prostacyclin may be reduced in diabetes in man. Lancet i : 325-326, 1979.
3) Dolleny CT, et al : Circulating prostacyclin may be reduced in diabetes. Lancet ii : 1365-1367, 1979.
4) 松野一彦, 寺田秀夫 : 後天性血小板機能異常. 臨床病理 29 : 364-371, 1981.
5) 新倉春男 : 血小板の機能と疾患. 日本医事新報 3775 : 18-23, 1996.
6) 中村克已, 磯部淳一 : わかり易い止血・血栓検査, p5, 振興医学出版社, 1993.
7) 柏木厚典 : 高血糖による細小血管障害症・進展の機序と臨床. Medical Practice 18 : 1600-1607, 2001.
8) 森本隆典 : 糖尿病による止血血栓異常. Complication 5 : 176-182, 2000.
9) 西川政勝 : 血栓症の成因-血小板の関与. 血小板と血栓症-基礎と臨床, p38-39, 日本医師会雑誌カラー図説, 2001.
10) Tshoepe D, et al : Platelet-leukocyte-cross-talk in diabetes mellitus. Horm Metab Res 29 : 631-635, 1997.
11) Bridges JM, et al : An effect of D-glucose on platelet stickness. Lancet ii : 75-77, 1965.
12) Hellem AI : Adenosine phosphate induced platelet adhesiveness in diabetes mellitus with complication. Acta Med Scand 190 : 291-297, 1971.
13) Kwaan HC, et al : Platelet aggregation in diabetes mellitus. J Lab Clin Med 80 : 236-238, 1972.
14) Hara T, et al : An aldose reductase inhibitor, TAT, reduced ADP-induced platelet hyperaggregation in streptozotocin-induced diabetic rats with neuropathy. J Lab Clin Med 126 : 541-547, 1995.
15) Ziboh VA, et al : Increased biosynthesis of thromboxane A2 by diabetic platelet. Eur J Clin Invest 9 : 223-228, 1979.
16) Weiss HJ, et al : Heterogeneity in storage pool deficiency studies on granule-bound substances in 18 patients including variants deficient in alphagranules, platelet factor 4, beta-thromboglobulin, and platelet derived growth factor. Blood 54 : 1296-1319, 1979.
17) Kaplan KL, Owen J : Plasma levels of beta-thromboglobulin and platelet factor 4 as indices of platelet activation in vivo. Blood 57 : 199-202, 1981.
18) 海津嘉蔵 : 糖尿病と血栓症. 内科 86 : 946-952, 1997.
19) 日高弘義ほか : 血管内膜肥厚と血小板・平滑筋細胞増殖. 血小板と細胞接着, p59-73, 金芳堂, 1995.
20) Nomura S, et al : Platelet-derived microparticles may influence the development of atherosclerosis in diabetes mellitus. Atherosclerosis 116 : 235-240, 1995.
21) Gordon JL, et al : Platelets in Biology and Pathology, p 131, North-Holland, Amsterdam, 1976.
22) 西川正勝ほか : 止血血栓, 病的血栓形成機序と血小板. 日内会誌 89 : 1054-1061, 2000.
23) 橋本俊彦, 梅田文夫 : 糖尿病とプロスタグランジン (PG) 代謝. 医薬ジャーナル 36 : 1664-1668, 2000.
P.209 掲載の参考文献
1) 寺田秀夫 凝固系・線溶系異常. 日本臨牀 48 (増刊 : 糖尿病 (1)) : 746-751, 1990.
2) 寺田秀夫 凝固・線溶系異常. 日本臨牀 55 (増刊 : 糖尿病 (1)) : 681-687, 1997.
3) 松田 保 血栓症の発生, 病態と血小板・凝固線溶能. 臨床成人病 25 : 416-421, 1995.
4) Canda OP, Arkin CF : Hyperfibrinogenemia. An important risk factor for vascular complications in diabetes. Diabetes Care 15 : 1245-1250, 1992.
5) Mansfield MW, et al : Circulating levels of factor VII, fibrinogen, and von Willebrand factor and features of insulin resistance in first-degree relatives of patients with NIDDM. Circulation 94 : 2171-2176, 1996.
6) Schafer AI : The hypercoagulable states. Ann Intern Med 102 : 814-828, 1985.
7) Calles-Escandon J, et al : Type 2 diabetes : one disease, multiple cardiovascular risk factor. Coron Artery Dis 10 : 23-30, 1999.
8) Auwerx J, et al : Tissue-type plasminogen activator antigen and plasminogen activator inhibitor in diabetes mellitus. Arteriosclerosis 8 : 68-72, 1988.
9) Fisher DM, et al : Effects of acute insulin-induced hypoglycemia on haemostasis, fibrinolysis and haemorhology in insulin-dependent diabetic patients and control subjects. Clin Sci 80 : 525-531, 1991.
10) Panahloo A, Yudkin JS : Diminished fibrinolysis in diabetes mellitus and its implication for diabetic vascular disease. Coron Artery Dis 7 : 723-731, 1996.
11) 森本隆典 : 糖尿病による止血血栓異常. Complication 5 : 176-182, 2000.
12) Matsuda T, et al : Mechanism on disorders of coagulation and fibrinolysis in diabetes. Diabetes 45 (Suppl 3) : 109-110, 1996.
13) 石井秀美 : トロンボモジュリン-その臨床的意義. Annual Riview血液 2001, p 248-256, 中外医学社, 2001.
15) Aso Y, et al : Mechanisms of elevation of serum and urinary concentrations of soluble thrombomodulin in diabetic patients : possible application as a marker for vascular endothelial injury. Metabolism 47 : 362-365, 1998.
16) 谷長行ほか : 血中トロンボモジュリン値測定の糖尿病での臨床的意義. 過去5年間の観察から. 糖尿病 41 : 267-275, 1998.
17) Williams E, et al : Electron microscopical studies of vessels in diabetic peripheral neuropathy. J Clin Pathol 33 : 462-470, 1980.
18) Carr ME : Diabetes mellitus A hypercoagulable state. J Diabetes Complications 15 : 44-54, 2001.
P.214 掲載の参考文献
2) Howell SL, et al : Regulation of insulin secretion : the role of second messengers. Diabetologia 37 (52) : S30-S35, 1994.
3) Biden TJ, et al : Ca2+ -mediated generation of inositol 1, 4, 5-trisphosphate and inositol 1, 3, 4, 5-tetrakisphosphate in pancreatic islets. Studies with K+, glucose and carbamylcholine. J Biol Chem 262 : 3567-3571, 1987.
4) Persaud SJ, et al : Activation of protein kinase C is essential for sustained insulin secretion in response to cholinergic stimulation. Biochim Biophys Acta 1091 : 120-122, 1991.
6) Zawalich WS, et al : Influence of cAMP and calcium on 3H-inositol efflux, inositol phosphate accumulation, and insulin release from isolated rat islets. Diabetes 37 : 1478-1483, 1988.
10) Saltiel AR, Cuatrecasas P : Insulin stimulates the generation from hepatic plasma membranes of modulators derived from an inositol glycolipid. Proc Natl Acad Sci USA 83 : 5793-5797, 1986.
12) Sanchez-Arias JA, et al : Changes in the insulin-sensitive glycosyl-phosphatidyl-inositol signaling system with aging in rat hepatocytes. Eur J Biochem 211 : 431-436, 1993.
13) Suzuki S, et al : Urinary chiro-inositol excretion is an index marker of insulin sensitivity of Japanese type 2 diabetes. Diabetes Care 17 : 1465-1468, 1994.
15) Greene DA, Lattimer SA : Sorbitol, phosphoinositides, and sodium-potassium-ATPase in the phatogenesis of diabetic complications. N Engl J Med 316 : 599-606, 1987.
16) Hermenegildo C, et al : Sustained recovery of Na+, K+ -ATPase activity in sciatic nerve of diabetic mice by administration of H7 or calphostic C inhibitors of protein kinase C. Diabetes 42 : 257-263, 1992.
17) Bell ME, et al : Metabolism of phospholipids in peripheral nerve from rats with chronic streptozotocin-induced diabetes. J Neurochem 39 : 192-200, 1982.
18) Berti-Matterra LN, et al : Alteration of phosphoinositide metabolism, protein phosphorylation, and carbohydrate levels in sciatic nerve from Wistar fatty diabetic rats. Diabetes 38 : 373-378, 1989.
20) Sakai Y, et al : Calcium mobilization and phosphatidylinositol turnover in vas deferens smooth muscle of diabetic rats. Eur J Pharmacol 162 : 475-481, 1989.
21) Xiang H, McNeil JH : α1-adrenoceptor-mediated phosphoinositide breakdown and inotropic responses in diabetic hearts. Am J Physiol 260 : H557-H562, 1991.
22) Ishii H, et al : Changes in phosphoinositide turnover, Ca2+ mobilization, and protein phosphorylation in platelets from NIDDM patients. Diabetes 39 : 1561-1568, 1990.
23) Ishii H, et al : Increased intracellular calcium mobilization in platelets from patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 34 : 332-336, 1991.
24) Jethmalani SM, et al : Platelet phosphoinositide tumover in streptozotocin-induced diabetes. Prostaglandins Leukot Essent Fatty Acids 50 : 339-346, 1994.
25) Bastyr EJ, et al : Decreased platelet phosphoinositide turnover and enhanced platelet activation in IDDM. Diabetes 38 : 1097-1102, 1989.
26) Ishizuka T, et al : Differential effect of the antidiabetic thiazolidinediones troglitazone and pioglitazone on human platelet aggregation mechanism. Diabetes 47 : 1494-1500, 1998.
P.221 掲載の参考文献
3) Maeno Y, et al : IDL can stimulate atherogenic gene expression in cultured human vascular endothelial cells. Diabetes Res Clin Pract 48 : 127-138, 2000.
4) Nishio Y, et al : Altered transcription factors activities and their related gene expression in cardiac tissues of diabetic rats. Diabetes 47 : 1318-1325, 1998.
5) Yerneni KK, et al : Hyperglycemia-induced activation of nuclear transcription factor kappa B in vascular smooth muscle cells. Diabetes 48 : 855-864, 1999.
6) Cosentino F, Luscher TF : Endothelial dysfunction in diabetes mellitus. J Cardiovasc Pharmacol 32 : 554-561, 1998.
7) Hink U, et al : Mechanisms underlying endothelial dysfunction in diabetes mellitus. Circ Res 88 : e14-e22, 2001.
9) Nishikawa T, et al : Normalization mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 404 : 787-790, 2000.
11) Kashiwagi A, et al : Endothelium specific activation of NAD (P) Hoxidase in aortas of exogenously hyperinsulinemic rats. Am J Physiol 277 : E976, 1999.
12) Shinozaki K, et al : Abnormal biopterin metabolism is a major cause of impaired endothelium-dependent relaxation through nitric oxide/O2- imbalance in insulin-resistant rat aorta. Diabetes 48 : 2437-2445, 1999.
13) Shinozaki K, et al : Oral administration of tetrahydrobiopterin prevents endothelial dysfunction and vascular oxidative stress in the aortas of insulin-resistant rats. Circ Res 87 : 566-573, 2000.
14) Cines DB, et al : Endothelial cell in physiology and in the pathophysiology of vascular disorders. Blood 91 : 3527-3561, 1998.
16) Mullarkey CJ, et al : Free radical generation by early glycation products : Amechanism for accelerated atherogenesis in diabetes. Biochem Biophys Res Commun 173 : 932-939, 1990.
17) Fu M-X, et al : The advanced glycation end-product, N- (carboxymethyl) lysine (CML), is a product of both lipid peroxidation and glycoxidation reactions. J Biol Chem 271 : 9982-9986, 1996.
18) Baynes JW, Thorpe SR : Role of oxidative stress in diabetic complications. A new perspective on an old paradigm. Diabetes 48 : 1-9, 1999.
19) Schmidt AM, et al : Advanced glycation end products interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice : Apotential mechanism for the accelerated vasculopathy of diabetes. J Clin Invest 96 : 1395-1403, 1995.
20) Ichikawa K, et al : Advanced glycation end products induced tissue factor expression in human monocyte-like U937 cells and increased tissue factor expression in monocytes from diabetic patients. Atherosclerosis 136 : 281-287, 1998.
22) Craven PA, et al : Increase in diacylglycerol mass in isolated glomeruli by glucose from de novo synthesis of glycerolipids. Diabetes 39 : 667-674, 1990.
23) Koya D, et al : Characterization of PKCβ isoform activation on the gene expression of transforming growth factorβ, extracellular matrix components, and prostanoids in the glomeruli of diabetic rats. J Clin Invest 100 : 115-126, 1997.
24) Ishii H, et al : Amelioration of vascular dysfunctions in diabetic rats by an oral PKCβ inhibitor. Science 272 : 728-731, 1996.
25) Koya D, et al : Amelioration of accelerated diabetic mesangial expansion by treatment with a PKCβ inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes. FASEB J 14 : 439-447, 2000.
26) Klann E, et al : A role for superoxide in protein kinase C activation and induction of long-term potenciation. J Biol Chem 273 : 4516-4522, 1998.
30) Takeda N : Mitochondrial DNA mutations in diabetic hearts. Diabetes Res Clin Pract 31 : S123-S126, 1996.
31) Ballinger SW, et al : Hydrogen peroxide-and peroxynitrite-induced mitochondrial DNA damage and dysfunction in vascular endothelial and smooth muscle cells. Circ Res 86 : 960-966, 2000.
33) Parisi MA, Clayton DA : Similarity of human mitochondrial transcription factor 1 to high mobility group proteins. Science 252 : 341-352, 1982.
34) Xu B, Clayton DA : Assessment of a yeast protein necessary for mitochondrial transcription initiation. Nucleic Acids Res 20 : 1053-1059, 1992.
35) Fisher RP, et al : Atranscription factor required for promoter recognition by human mitochondrial RNA polymerase. Accurate initiation at the heavy-and light-strand promoters dissected and reconstituted in vitro. J Biol Chem 267 : 11330-11338, 1985.
37) Kubes P, et al : Nitric oxide : an endogenous modulator or leukocyte adhesion. Proc Natl Acad Sci USA 88 : 4651-4655, 1991.
39) Szabo C, et al : Endothelial dysfunction in a rat model of endotoxin shock. J Clin Invest 100 : 723-735, 1997.
40) Yamamoto H, et al : Streptozotocin and alloxan induce DNA strand breaks and poly (ADP-ribose) synthetase in pancreatic islets. Nature 294 : 284-286, 1981.
42) Moncada S, Higgs EA : Molecular mechanisms and therapeutic strategies related to nitric oxide. FASEB J 9 : 1319-1330, 1995.
49) Juhan-Vague I, et al : Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis. Diabetologia 34 : 457-462, 1991.
51) Guangyuan Z, Quon MJ : Insulin-stimulated production of nitric oxide is inhibited by wortmannindirect measurement in vascular endothelial cells. J Clin Invest 98 : 894, 1996.
53) Sinozaki K, et al : Coronary endothelial dysfunction in the insulin-resistant state is linked to abnormal pteridine metabolism and vascular oxidative stress. J Am Coll Cardiol 38 : 1821-1828, 2001.
54) Chakraborti S, Chakraborti T : Oxidant-mediated activation of mitogen-activated protein kinases and nuclear transcription factors in the cardiovascular system : a brief overview. Cell Signal 10 : 675-683, 1998.
55) Watts GF, Playford DA : Dyslipoproteinaemia and hyperoxidative stress in the pathogenesis of endothelial dysfunction in non-insulin dependent diabetes mellitus : an hypothesis. Atherosclerosis 141 : 17-30, 1998.
56) Maeno Y, et al : IDL can stimulate atherogenic gene expression in cultured human vascular endothelial cells. Diabetes Res Clin Pract 48 : 127-138, 2000.
57) Katoh M, et al : Cardiac angiotensin II receptors are upregulated by long-tenn inhibition of nitric oxide synthesis in rats. Circ Res 83 : 743-751, 1998.
58) Giacchetti G, et al : The tissue renin-angiotensin system in rats with fructose-induced hypertension : overexpression of type 1 angiotensin II receptor in adipose tissue. J Hypertens 18 : 695-702, 2000.
59) Ting HH, et al : Vitamin C improves endothelium-dependent vasodilatation in patients with non-insulin-dependent diabetes mellitus. J Clin Invest 97 : 22-28, 1997.
61) Booth G, et al : Mechanisms of amelioration of glucose-induced endothelial dysfunction following inhibition of protein kinase C in vivo. Diabetes 51 : 1556-1564, 2002.
62) Vaughan CJ, et al : The evolving role of statins in the management of atherosclerosis. J Am Coll Cardiol 35 : 1-10, 2000.
63) Enseleit F, et al : Vascular protective effects of angiotensin converting enzyme inhibitors and their relation to clinical events. J Cardiovasc Phramacol 37 : S21-30, 2001.
P.234 掲載の参考文献
1) 葛谷健ほか : 糖尿病の分類と診断基準に関する委員会報告. 糖尿病 42 : 385-404, 1999.
2) Major RH : Classic Descriptions of Disease, 3rd ed, CC Thomas, Springfield, 1945.
3) 中川昌一 : 糖尿病の病型と診断に関する考え方の変遷. 臨床成人病 29 : 1285-1294, 1999.
4) 平山章 : 糖尿病. 現代病理学大系 (飯島宗一編), 3. 代謝障害, p29-48, 中山書店, 1985.
5) 平田幸正 : 糖尿病の治療, 文光堂, 1991.
6) 中川昌一 : 糖尿病の症候論. 日本臨牀 55 (増刊 : 糖尿病 1) : 581-592, 1997.
7) Freeman AG : Symptoms and clinical aspects of diabetes mellitus. Br Med J 1 : 1149-1154, 1958.
9) Guyton AC, Hall JE : Textbook of Medical Physiology, 10th ed, p 805-807, WB Saunders, Philadelphia, 2000.
11) 垂井清一郎 : 糖尿病の疾患概念. 糖尿病学の進歩 (日本糖尿病学会編), 13, p13, 診断と治療社, 1980.
13) UK Prospective Diabetes Study : Intensive blood-glucose control with sulfonylurea or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS33). Lancet 352 : 837-853, 1998.
14) Nathan DM : Some answers, more controversy from UKPDS. Lancet 352 : 832-833, 1998.
15) Coutinho M, et al : The relationship between glucose and incident of cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 indiViduals followed for 12.4 years. Diabetes Care 22 : 233-240, 1999.
P.239 掲載の参考文献
1) 平田幸正 : 診断 (口渇, やせ, 体重, 手の所見). 糖尿病の治療, p 182-209, 文光堂, 1991.
2) 阿部正和, 平田幸正 : 診断 (発見のきっかけ, 問診と診察). 糖尿病, 新しい考えかたからマネージメントの実際まで (第2版), p50-69, 医学書院, 1984.
3) 堀田饒 : 糖尿病性ケトアシドーシスの診断と治療. 糖尿病カレントレビュー, p13-39, 医歯薬出版, 1990.
4) 植木輝一 : 歯周疾患の病態生理に関する研究-特に糖尿病患者における歯槽骨および中手骨吸収状態と糖尿病コントロール状態を中心に-. 日大医誌 43 : 803-813, 1984.
5) 葛谷健ほか : 糖尿病の分類と診断基準に関する委員会報告. 糖尿病 42 : 385-404, 1999.
P.249 掲載の参考文献
1) 冲中重雄 : 診断学総論. 冲中重雄, 高橋忠雄, 大島研三著, 内科診断学 (6版), p1-2, 医学書院, 東京, 1964.
2) 吉利和 : 診断学総論. 吉利和編著, 新内科診断学, 改訂4版, p1-12, 金芳堂, 京都, 1984.
3) Cooppan R : General approach to the treatment of diabetes. In : Joslin's Diabetes Mellitus, 13th ed (ed by Kahn CR, Weir GC), p 397-399, Lea & Febiger, Philadelphia, 1994.
4) 小坂樹徳 : 症候論, 自覚症状とその問診*病歴聴取. 小坂樹徳 (監), 内科学症候篇, p11-16, 診断と治療社, 東京, 1982.
5) 羽倉稜子, 吉田洋子 : 糖尿病患者の家族歴. 日本臨牀 55 (増刊 : 糖尿病 1) : 574-578, 1997.
6) Hagura R, et al : Diagnosis of diabetes using clinical factors in subjects with GTT borderline. Diabetes Res Clin Pract 50 (Suppl 1) : S3-4, 2000.
7) 小坂樹徳ほか : 糖尿病の診断に関する委員会報告. 糖尿病 25 : 859-866, 1982.
10) Fajans SS : Classification and natural history of genetic diabetes mellitus. In : Diabetes Mellitus : Diagnosis and Treatment, III (ed by Fajans SS, Sussman KE), p 89-93, American Diabetes Association, Alexandria, 1971.
P.255 掲載の参考文献
1) 五十嵐仁子ほか : 糖尿病検診によって発見された糖尿病, 耐糖能障害の糖尿病性慢性合併症に関する検討. 糖尿病 41 : 159-163, 1998.
4) 葛谷健ほか : 糖尿病の分類と診断基準に関する委員会報告. 糖尿病 42 : 385-404, 1999.
5) Kosaka K, et al : A prospective study of health check examinees for the development of non-insulin-dependent diabetes mellitus : relationship of the incidence of diabetes with the initial insulinogenic index and degree of obesity. Diabet Med 13 (Suppl 6) : S120-S126, 1996.
7) DECODE Study Group on behalf of the European Diabetes Epidemiology Study Group : Will new diagnostic criteria for diabetes mellitus change phenotype of patients with diabetes? Reanalysis of European epidemiological data. Br Med J 317 : 371-375, 1998.
10) The DECODE Study Group on behalf of European Diabetes Epidemiology Group : Glucose tolerance and mortality : comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 354 : 617-621, 1999.
12) Dinneen SF, et al : Effects of changing diagnostic criteria on the risk of developing diabetes. Diabetes Care 21 : 1408-1413, 1998.
13) Gabir MM, et al : The 1997 American Diabetes Association and 1999 World Health Organization criteria for hyperglycemia in the diagnosis and prediction of diabetes. Diabetes Care 23 : 1108-1112, 2000.
15) Leiter LA, et al : Diabetes Screening in Canada (DIASCAN) Study. Diabetes Care 24 : 1038-1043, 2001.
17) Engelgau MM, et al : Screening for type 2 diabetes. Diabetes Care 23 : 1563-1580, 2000.
18) 富永真琴 : 糖負荷試験とヘモグロビンA1c. からだの科学 (増刊 : 糖尿病 2001), p 19-22, 日本評論社, 2001.
20) 石田和史ほか : 空腹時血糖値, HbA1cと75gOGTT 2時間血糖値の関連から見た糖尿病スクリーニング検査の検討. 糖尿病 41 (Suppl 2) : A65-A67, 1998.
21) 伊藤千賀子 : 糖尿病の予防と管理. 疫学研究によるアプローチ, p13-15, 診断と治療社, 2001.
22) Ko GTC, et al : Combined use of fasting plasma glucose and HbA1c predicts the progression to diabetes in Chinese subjects. Diabetes Care 23 : 1770-1773, 2000.
P.262 掲載の参考文献
1) The Expert Committee on the Diabetes and Classification of Diabetes Mellitus : Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 20 : 1183-1197, 1997.
3) 葛谷健ほか : 糖尿病の分類と診断基準に関する委員会報告. 糖尿病 42 : 385-404, 1999.
4) Kobayashi T, et al : Time course of islet cell antibodies and B-cell function in noninsulin-dependent stage of type 1 diabetes. Diabetes 36 : 510-517, 1987.
5) 小林哲郎 : Slowly progressive IDDM. 糖尿病-専門医にきく最新の臨床- (岩本安彦, 山田信博編), p44-45, 中外医学社, 1997.
6) Kobayashi T, et al : Immunogenetic and clinical characterization of slowly progressive IDDM. Diabetes Care 16 (5) : 780-788, 1993.
7) Kobayashi T, et al : Small doses of subcutaneous insulin as a strategy for preventing slowly progressive beta-cell failure in islet cell antibody-positive patients with clinical features of NIDDM. Diabetes 45 (5) : 622-626, 1996.
8) Kobayashi T, et al : Insulin Intervention to Preserve Cells in Slowly Progressive Insulin-Dependent (Type 1) Diabetes Mellitus. Ann N Y Acad Sci. (in press)
10) Tanaka S, et al : A novel subtype of type 1 diabetes mellitus. N Engl J Med 342 (24) : 1835-1837, 2000.
11) 日本糖尿病学会編 : 糖尿病遺伝子診断ガイド, 文光堂, 2001.
P.270 掲載の参考文献
1) Altshuler D, et al : The common PPARγ Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 26 : 76-80, 2000.
3) Hanis CL, et al : A genome-wide search for human non-insulin-dependent (type 2) diabetes genes reveals a major susceptibility locus on chromosome 2. Nat Genet 13 : 161-166, 1996.
5) Mori Y, et al : Genome-wide search for type 2 diabetes in the Japanese affected sib-pairs confirms susceptibility genes on 3q, 15q and 20q and identifies two new candidate Loci on 7p and 11p. Diabetes 51 : 1247-1255, 2002.
6) Ghosh S, et al : The Finland-United States investigation of non-insulin-dependent diabetes mellitus genetics (FUSION) study. I. An autosomal genome scan for genes that predispose to type 2 diabetes. Am J Hum Genet 67 : 1174-1185, 2000.
7) Zouali H, et al : A susceptibility locus for early-onset non-insulin dependent (type 2) diabetes mellitus maps to chromosome 20q, pro) dmal to the phosphoenolpyruvate carboxykinase gene. Hum Mol Genet 6 : 1401-1408, 1997.
P.275 掲載の参考文献
1) 岩崎直子 : 遺伝子多型 (4) 糖尿病. 臨床病理 49 : 161-164, 2001.
3) Altshuler D, et al : The common PPARγ Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 26 : 76-80, 2000.
4) Mori H, et al : The Pro12Ala substitution in PPAR-gamma is associated with resistance to development of diabetes in the general population : Possible involvement in impairment of insulin secretion in individuals with type 2 diabetes. Diabetes 50 : 891-894, 2001.
7) Tang Y, et al : Improvement in insulin resistance and the restoration of reduced PDE3B gene expression by pioglitazone in adipose tissue of obese, diabetic KKAy mouse. Diabetes 48 : 1830-1835, 1999.
8) Niiya T, et al : Activation of mouse phosphodiesterase 3B promoter by adipocyte differentiation in 3T3-L1 cells. FEBS Lett 505 : 136-140, 2001.
9) Osawa H, et al : Systematic search for single nucleotide polymorphisms in the insulin gene : Evidence for a high frequency of g. -23T > A in Japanese subjects. Biochem Biophys Res Commun 286 : 451-455, 2001.
10) Osawa H, et al : Asystematic search for single nucleotide polymorphisms in the insulin receptor gene : Association of an SNP with hyperlipidemia in Japanese type 2 diabetic subjects. Clin Genet 60 : 479-481, 2001.
11) Osawa H, et al : Systematic search for single nucleotide polymorphisms (SNPs) in the resistin gene : The absence of evidence for the association of three identified SNPs with Japanese type 2 diabetes. Diabetes 51 : 863-866, 2002.
12) Hanis CL, et al : A genome-wide search for human non-insulin-dependent (type 2) diabetes genes reveals a major susceptibility locus on chromosome 2. Nat Genet 13 : 161-166, 1996.
15) Ghosh S, et al : The Finland-United States investigation of non-insulin-dependent diabetes mellitus genetics (FUSION) study. I. An autosomal genome scan for genes that predispose to type 2 diabetes. Am J Hum Genet 67 : 1174-1185, 2000.
16) Parker A, et al : A gene conferring susceptibility to type 2 diabetes in conjugation with obesity is located on chromosome 18p11. Diabetes 50 : 675-680, 2001.
17) Wiltshire S, et al : A genomewide scan for loci predisposing to type 2 diabetes in a UK population (the Diabetes UK Warren 2 repository) : Analysis of 573 pedigrees provides independent replication of a susceptibility locus on chromosome 1q. Am J Hum Genet 69 : 553-569, 2001.
18) Meigs JB, et al : A genome-wide scan for loci linked to plasma levels of glucose and HbA1c in a community-based sample of Caucasian pedigrees. The Framingham Offspring Study. Diabetes 51 : 833-840, 2002.
P.281 掲載の参考文献
2) Taira M, et al : Human diabetes associated with a deletion of the tyrosine kinase domain of the insulin receptor : domain of the insulin receptor. Science 245 : 63-66, 1989.
3) Shimada F, et al : Insulin-resistant diabetes associated with partial deletion of insulin-receptor gene. Lancet 335 : 1179-1181, 1990.
7) Horikawa Y, et al : Mutation in hepatocyte nuclear factor-1beta gene (TCF2) associated with MODY. Nat Genet 17 : 384-385, 1997.
10) Simomura H, et al : Nonsense mutation of islet-1 gene (Q310X) found in a type 2 diabetic patient with a strong family history. Diabetes 49 : 1597-1600, 2000.
12) Hanis CL, et al : A genome-wide search for human non-insulin-dependent (type 2) diabetes genes reveals a major susceptibility locus on chromosome 2. Nat Genet 13 : 161-166, 1996.
P.288 掲載の参考文献
1) Hanis CL, et al : A genome-wide search for human non-insulin-dependent (type 2) diabetes genes reveals a major susceptibility locus on chromosome 2. Nat Genet 13 : 161-166, 1996.
5) Mori Y, et al : Genome-wide search for type 2 diabetes in Japanese affected sib-pairs confirms susceptibility genes on 3q, 15q and 20q and identifies two new candidate loci on 7p and 11p. Diabetes 51 : 1247-1255, 2002.
6) Ghosh S, et al : Type 2 diabetes : evidence for linkage on chromosome 20 in 716 Finnish affected sib pairs. Proc Natl Acad Sci USA 96 : 2198-2203, 1999.
10) Wiltshire S, et al : A genomewide scan for loci predisposing to type 2 diabetes in a UK population (the Diabetes UK Warren 2 Repository) : analysis of 573 pedigrees provides independent replication of a susceptibility locus on chromosome 1q. Am J Hum Genet 69 : 553-569, 2001.
12) Kubota N, et al : PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Mol Cell 4 : 597-609, 1999.
14) Mori H, et al : The Pro12→Ala substitution in PPAR-gamma is associated with resistance to development of diabetes in the general population : possible involvement in impairment of insulin secretion in individuals with type 2 diabetes. Diabetes 50 : 891-894, 2001.
16) Hayakawa T, et al : S20G mutation of the amylin gene in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract 49 : 195-197, 2000.
P.297 掲載の参考文献
1) 松田一郎 (監), 福嶋義光 (編) : 遺伝医学と遺伝サービスにおける倫理的諸問題に関して提案された国際的ガイドライン (WHO Human Genetics Programme : Proposed international guidelines on ethical issues in medical genetics and genetic services, 1998). http://genetopia.md.shinshu-u.ac.jp/guide.htm#g5
2) 千代豪昭 : 遺伝カウンセリング-面接の理論と技術-, p1-270, 医学書院, 2000.
3) Harper PS : Diabetes mellitus. In : Practical Genetic Counselling (5th ed), p 268-270, Butterworth Heinemann, Oxford, 1998.
P.307 掲載の参考文献
1) Muller W : Die Ausscheidung des Zuckers im Harne des gesunden Menschen nach Genuss von Kohlenhydraten. Arch f d ges Physiol 34 : 576, 1884.
2) Bang I : Der Blutzucker, JF Bergmann, Wiesbaden, 1913. (Fitz : Arch Intern Med, 1914, xiv, p 133)
3) MacLean H, Wesselow OIV : The estimation of sugar tolerance. Q J Med 14 : 103, 1920-21.
4) 村地悌二 : 坂口食はどのようにして生まれたか. Diabetes Journal 1 : 39, 1973.
5) Sakaguchi K : Beitrage Zur Diabetesforschung. I. Mitteilung, Uber den Einfluss von Menge, Art und Zeit der Kohlenhydratzufuhr auf den Blutzuckergehalt beim gesunden Menschen. 東京帝国大学医科大学紀要 20 : 345, 1918.
6) Spence JC : Some observations on sugar tolerance, with special reference to variations found at different ages. Q J Med 14 : 314, 1921.
7) 葛谷信貞ほか : 糖負荷試験による糖尿病診断基. 準委員会報告-糖尿病の診断に用いるための糖負荷試験の判定基準についての報告. 糖尿病 13 : 1, 1970.
9) WHO Expert Committee on Diabetes Mellitus, Second Report, Technical Report Series 646, WHO, Geneva, 1980.
10) 小坂樹徳ほか : 糖尿病の診断に関する委員会報告. 糖尿病 25 : 859-866, 1982.
11) 葛谷健ほか : 糖尿病の分類と診断基準に関する委員会報告. 糖尿病 42 : 385-404, 1999.
12) Hagura R, et al : Effects of 100, 75, 50 and 25g glucose load on insulin response and blood glucose in NIDDs and normal subjects. Diabetes Res Clin Pract (Suppl 1) : S216, 1985.
14) 羽倉稜子ほか : 軽い耐糖能異常者の予後からみた管理のあり方. 糖尿病学 1999 (小坂樹徳編), p 169-180, 診断と治療社, 1999.
15) Kosaka K, et al : Insulin response to oral glucose load is consistently decreased in established non-insulin-dependent diabetes mellitus : the usefulness of decreased early insulin response as a predictor of non-insulin-dependent diabetes mellitus. Diabet Med 13 : S109-119, 1996.
P.311 掲載の参考文献
1) Samols E, et al : Promotion of insulin secretion by glucagon. Lancet ii : 415-416, 1965.
2) 三家登喜夫ほか : 糖尿病患者におけるinsulin依存度の評価-Glucagon静注負荷時の血漿CPR反応より-. 糖尿病 28 : 713, 1985.
3) 葛谷健 : 糖尿病とその病型をどう診断するか. 日本医師会雑誌 116 : 1401-1404, 1996.
4) Madsbad S, et al : Outcome of the glucagon test depends upon the prevailing blood glucose concentration in type 1 (insulin-dependent) diabetic patients. Acta Med Scand 222 : 71-74, 1987.
5) Miki H, et al : Glucagon-glucose (GC) test for the estimation of the insulin reserve in diabetes. Diabetes Res Clin Pract 18 : 99-105, 1992.
P.317 掲載の参考文献
P.324 掲載の参考文献
5) Saad MF, et al : Differences between the tolbutamide-boosted and the insulin-modified minimal model protocols. Diabetes 46 : 1167-1171, 1997.
6) Rostami-Hodjegan A, et al : Population-based modeling to demonstrate extrapancreatic effects of tolbutamide. Am J Physiol 274 : E758-E771, 1998.
7) Saad MF, et al : A comparison between the minimal model and the glucose clamp in the assessment of insulin sensitivity across the spectrum of glucose tolerance : Insulin Resistance Atherosclerosis Study. Diabetes 43 : 1114-1121, 1994.
8) Hansen T, et al : Decreased tolbutamide-stimulated insulin secretion in healthy subjects with sequence variants in the high-affinity sulfonylurea receptor gene. Diabetes 47 : 598-605, 1998.
9) Hansen L, et al : Amino acid polymorophisms in the ATP-regulatable inward recitifier Kir6.2 and their relationships to glucose-and tolbutamide-induced insulin secretion, the insulin sensitivity index, and NIDDM. Diabetes 46 : 508-512, 1997.
P.329 掲載の参考文献
1) 松田文子ほか : 尿C-ペプチド, 糖尿病学1989 (小坂樹徳編), p316-339, 診断と治療社, 1989.
2) 松田文子ほか : 正常者と糖尿病患者の24時間尿C-ペプチド免疫活性 (CPR) と排泄率の日内変動. 糖尿病 21 : 544, 1978.
3) 松田文子ほか : 糖尿患者インスリン依存性と24時間尿C-ペプチド排泄量. 糖尿病 27 : 65-71, 1984.
4) 鎌田郁子ほか : インスリン依存性判定の指標としての1回尿C-ペプチド測定の有用性. 糖尿病 28 : 1241-1246, 1985.
P.334 掲載の参考文献
3) Saad ME et al : A comparison between the minimal model and the glucose clamp in the assessment of insulin sensitivity across the spectrum of glucose tolerance. Diabetes 43 : 1114, 1994.
4) Matthews DR, et al : Homeostasis model assessment insulin resistance and beta-cell function from fasting plasma glucose and insulin concentration in man . Diabetologia 28 : 412, 1985.
5) 鈴木正昭ほか : 非肥満2型糖尿病患者における経日糖負荷試験の解析-インスリン分泌および作用不全の指標について-. 糖尿病 27 : 559-565, 1984.
6) Matsuda M, DeFronzo RA : Insulin sensitivity indices obtained from oral glucose tolerance testing. Diabetes Care 22 : 1462-1470, 1999.
7) Takeuchi M, et al : Evaluation of factors during OGTT to correlate insulin resistance in non-diabetic subjects. Endocr J 47 : 535-542, 2000.
8) Fujioka S, et al : Contribution of intraabdominal visceral fat accumulation to the impairment of glucose and lipid metabolism in human obesity. Metabolism 36 : 54-59, 1987.
10) Kaplan NM : The deadly quartet ; Upper-body obesity, glucose intolerance, hypertriglycemia, and hypertension. Arch Intern Med 149 : 1514-1520, 1989.
11) DeFronzo RA, Ferrannini E : A hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 14 : 173-194, 1991.
P.339 掲載の参考文献
1) Olefsky JM : Insulin resistance. In : Ellenberg & Rifkin's Diabetes Mellitus, 5th ed (ed by Porte D, Sherwin SS), p 513-552, Appleton&Lange, Starnford, 1990.
2) Yalow RS, Berson SA : Immunoassay of endogenous plasma insulin in man. J Clin Invest 39 : 1157-1175, 1960.
4) Zierler KL, Rabinowitz D : Roles of insulin and growth hormone, based on studies of forearm metabolism in man. Medicine 42 : 385-402, 1963.
7) Reaven GM : Insulin resistance in non-insulin-dependent diabetes mellitus. Does it exist and can it be measured? Am J Med 74 : 3-17, 1983.
10) Donner CC, et al : Presentation of a new method for specific measurements of in vivo insulin-stimulated glucose disposal in human. Comparison of this new approach with insulin clamp and minimal model techniques. J Clin Endocrinol Metab 60 : 723-726, 1985.
11) Ponchuner M, et al : A comparison of the artificial pancreas (glucose controlled infusion system) and a manual technique for assessing insulin sensitivity during euglycaemic clamping. Diabetologia 26 : 420-425, 1984.
12) Lundbaek K : Intravenous glucose tolerance as a tool in definition and diagnosis of diabetes mellitus. Br Med J 1 : 1507-1513, 1962.
14) Hirst S, et al : Reproducibility of the short insulin tolerance test. Diabet Med 10 : 839-842, 1993.
16) Garber AJ, et al : The role of adrenergic mechanisms in the substrate and hormonal response to insulin-induced hypoglycemia in man. J Clin Invest 58 : 7-15, 1976.
17) Rizza RA, et al : Role of glucagon, catecholamines, and growth hormone in human glucose counterregulation. Effects of somatostatin and combined alfa and beta adrenergic blockade on plasma glucose recovery and glucose flux rates after insulin-induced hyperglycemia. J Clin Invest 64 : 62-71, 1979.
18) Gerich J, et al : Hormonal mechanisms in acute glucose counterregulation : the relative roles of glucagon, epinephrine, norepinephrine, growth hormone, and cortisol. Metabolism 29 (Suppl 1) : 1164-1175, 1980.
20) Akinmokun A, et al : The short insulin tolerance test for determination of insulin sensitivity : A comparison with the euglycaemic clamp. Diabet Med 9 : 432-437, 1992.
P.349 掲載の参考文献
1) 中川理 : In vivoにおけるインスリン抵抗性の指標. 糖尿病 42 : 111-113, 1999.
2) 河盛隆造 : NIDDMにおけるインスリン抵抗性. Mebio 9 : 30-34, 1998.
3) 浅野道子, 山田信博 : 動脈硬化の1次2次予防とインスリン抵抗性. ホルモンと臨床 49 : 279-284, 2001.
8) Turner RC, et al : Insulin deficiency and insulin resistance interaction in diabetes : Estimation of their relative contribution by feedback analysis from basal plasma insulin and glucose concentrations. Metabolism 28 : 1086-1096, 1979.
9) Matthews DR, et al : Homeostasis model assessment : insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 : 412-419, 1985.
10) Haffner SM, et al : A prospective analysis of the HOMA model. Diabetes Care 19 : 1138-1141, 1996.
11) Matsuda M, DeFronzo RA : Insulin sensitivity indices obtained from oral glucose tolerance testing. Diabetes Care 22 : 1462-1470, 1999.
12) 江口 英行ほか : インスリン抵抗性の疫学. 糖尿病 42 : 115-117, 1999.
13) 松澤佑次ほか : 糖尿病発症高危険群におけるインスリン抵抗性とその生活習慣基盤に関する多施設共同追跡調査-介入対象としての内臓肥満の意義の確立-. 厚生省健康科学総合研究報告書, 2001.
14) 富永真琴 : 糖尿病の病態と検査. 医学検査 50 : 1-7, 2001.
15) 小野利夫ほか : HOMA指数の適用範囲について-インスリン抵抗性と空腹時血糖値の関係からの考察-. 糖尿病 42 : 1005-1011, 1999.
16) 伊藤千賀子 : インスリン値とインスリン抵抗性. 血糖値をみる・考える A. わずかの血糖上昇も有害か (島健二編), p144, 南江堂, 2000.
18) Haffner SM, et al : Incidence of type II diabetes in Mexican Americans predicted by fasting insulin and glucose levels, obesity, and body-fat distribution. Diabetes 39 : 283-288, 1990.
19) Arner P, et al : Different aetiologies of type 2 (non-insulin-dependent) diabetes mellitus in obese and non-obese subjects. Diabetologia 34 : 483-487, 1991.
20) 菊池方利 : NIDDMにおけるインスリン分泌障害. Mebio 9 : 35-40, 1998.
21) 細島弘行, 内田健三 : 肥満を伴う境界型症例におけるインスリン抵抗性指標化の試み-Matthews理論の応用-. 糖尿病 41 : 433-441, 1998.
23) 河原玲子ほか : 肥満糖代謝異常者における血漿レプチン濃度とインスリン抵抗性の関連. 糖尿病 41 : 443-447, 1998.
24) 細島弘行 : 2型糖尿病男女患, 者におけるインスリン抵抗性とレプチン値との関係. 糖尿病 43 : 853-859, 2000.
25) 持原友紀ほか : 糖尿病患者における血中レプチンと有意相関を示したHOMA-R, CETP, LPLmassの病態背景について. 生物試料分析科学会誌. (印刷中)
28) Hedblad B, et al : Relation between insulin resistance and carotid intima-media thickness snd stenosis in non-diabetic subjects. Results from a cross-sectional study in Malmo, Sweden. Diabet Med 17 : 299-307, 2000.
29) 植田太郎ほか : インスリン非依存型糖尿病におけるインスリン抵抗性と冠動脈疾患危険因子の集積. 糖尿病 37 : 177-185, 1994.
P.355 掲載の参考文献
1) 石田俊彦ほか : インスリン抵抗性の評価. 内科 78 : 616-623, 1996.
2) 三家登喜夫ほか : グルコースクランプ法, ミニマルモデル等によるインスリン抵抗性の解析. 日本臨牀 56 (増刊 : 糖尿病 3) : 431-436, 1998.
8) 上田量也 : 日本人インスリン非依存型糖尿病におけるインスリン抵抗性とβ3アドレナリン受容体遺伝子変異 (Try64Arg) に関する研究. 和歌山医学 51 : 193-200, 2000.
9) Bergman RN, et al : Equivalence of the insulin sensitivity index in man derived by the minimal model method and euglycemic glucose clamp. J Clin Invest 76 : 790-800, 1987.
P.361 掲載の参考文献
3) Kawamori R, et al : Quantitative determination of hepatic glucose uptake using an innovative approach : effect of strict glycemic regulation and exercise in diabetic subjects. J Nutr Sci Vitaminol (Tokyo) 37 (Suppl) : S35-42, 1991.
4) Matsuhisa M, et al : The effect of pioglitazone on hepatic glucose uptake measured With indirect and direct methods in alloxan-induced diabetic dogs. Diabetes 46 (2) : 224-231, 1997.
5) Kawamori R, et al : Effect of strict metabolic control on glucose handling by the liver and peripheral tissues in non-insulin-dependent diabetes mellitus. Diabetes Res Clin Pract 23 (3) : 155-161, 1994.
6) Kawamori R, et al : Fasting plus prandial insulin supplements improve insulin secretory ability in NIDDM subjects. Diabetes Care 12 (10) : 680-685, 1989.
7) Radziuk J, et al : Initial splanchnic extraction of ingested glucose in normal man. Metabolism 27 (6) : 657-669, 1978.
8) Shen SW, et al : Related articles comparison of impedance to insulin-mediated glucose uptake in normal subjects and in subjects with latent diabetes. J Clin Invest 49 (12) : 2151-2160, 1970.
10) Ikebuchi M, et al : Related articles. Modified method using a somatostatin analogue, octreotide acetate (Sandostatin) to assess in vivo insulin sensitivity. Endocr J 43 (1) : 125-130, 1996.
P.368 掲載の参考文献
1) Niessner H, Beutler E : Fluorometric analysis of glycolytic intermediates in human red blood cells. Biochem Med 8 : 123-134, 1973.
2) 桑島正道 : 赤血球解糖系検査. 日本臨牀 37 (増刊 : 現代臨床機能検査) : 1705-1707, 1979.
3) Kunst A, et al : UV-methods with hexokinase and glucose-6-phosphate dehydrogenase. In : Methods of Enzymatic Analysis (ed by Bergmeyer HU, et al), VI, p 163-172, Verlag Chemie, Weinheim, 1984.
4) Absorption coefficients of NAD (P) H. In : Methods of Enzymatic Analysis (ed by Bergmeyer HU, et al), II, p 510-511, Verlag Chemie, Weinheim, 1983.
5) 第34回臨床検査精度管理調査結果報告書 (平成12年度), p338-339, 日本医師会, 2001.
6) 桑島正道ほか : 検査室での血中グルコース濃度の測定プロセスと測定値の信頼度. 血糖値をみる・考える (島健二編), p33-40, 南江堂, 2000.
7) 桑島正道 : 血糖測定器の血糖測定原理. プラクティス 18 : 502-505, 2001.
8) 堀田史健ほか : 簡易血糖自己測定器ノボアシストの基礎的比較検討. 医学と薬学 41 : 153-159, 1999.
9) 中尾隆之ほか : 簡易血糖自己測定器メディセーフの評価. 医学と薬学 41 : 1049-1053, 1999.
10) 中尾隆之ほか : 簡易血糖自己測定器デキスターZの評価. 医学と薬学 38 : 1259-1266, 1997.
11) 中野博司ほか : 電極法による簡易血糖測定器2機種の測定値に関する検討. 医学と薬学 41 : 497-502, 1999.
12) 大川久枝ほか : 簡易血糖測定器「プレシジョンQ・I・D」を用いた改良型電極「プレシジョンプラス」 の基礎的検討. 医学と薬学 42 : 131-138, 1999.
14) Feldman B, et al : FreeStyle(TM) : A small-volume electrochemical glucose sensor for home blood glucose testing. Diabetes Technology&Therapeutics 2 : 221-229, 2000.
P.377 掲載の参考文献
1) 葛谷健 インスリン 分子メカニズムから臨床へ, 講談社サイエンティフィク, 1996.
3) Given BD, et al : Biochemical and clinical implication of proinsulin conversion intermediates. J Clin Invest 76 : 1398-1405, 1985.
4) Yalow RS, Berson AS : Plasma insulin concentrations in nondiabetic and early diabetic subjects ; determination by a new sensitive immunoassay technique. Diabetes 9 : 254-260, 1960.
5) Stephen DL, et al : Importance of validation of immunoassays for intact proinsulin. Clin Chem Lab Med 39 : 631-633, 2001.
6) 小坂樹徳 : 糖尿病におけるインスリン初期分泌反応. Diabetes Frontier 6 : 7-22, 1995.
7) Kosaka K, et al : Insulin response to oral glucose load is consistently decreased in established non-insulin-dependent diabetes mellitus : the usefulness of decreased early insulm response as a predictor of non-insulin-dependent diabetes mellitus. Diabet Med 13 : S109-S119, 1996.
8) Weyer C, et al : A high fasting plasma insulin concentration predicts type 2 diabetes independent of insulin resistance. Diabetes 49 : 2094-2101, 2001.
9) Rhodes CJ, et al : What β-cell defect could lead to hyperproinsulinemia in NIDDM? Some clues from recent advances made in understanding the proinsulin processing mechanism. Diabetes 43 : 511-517, 1994.
10) Shimizu M, et al : Age-related alteration of pancreatic beta-cell function. Increased proinsulin and proinsulin-to-insulin molar ratio in elderly, but not in obese, subjects without glucose intolerance. Diabetes Care 19 : 8-11, 1996.
11) Fritsche A, et al : Relationship among age, proinsulin conversion, and β-cell function in nondiabetic humans. Diabetes 51 (Suppl 1) : S234-S239, 2002.
12) Owens DR, Luzio SD : Insulin secretion and sensitivity in newly diagnosed NIDDM Caucasians in the UK. Diabet Med 13 : S19-S24, 1996.
13) Kahn SE, et al : Release of incompletely processed proinsulin is the cause of the disproportionate proinsulinemia of NIDDM. Diabetes 46 : 1725-1732, 1997.
14) Stumvoll M, et al : Functional significance of the UCSNP-43 polymorphism in the CAPN10 gene for proinsulin processing and insulin secretion in nondiabetic Germans. Diabetes 50 : 2161-2163, 2001.
P.383 掲載の参考文献
1) 松田文子 : 血中, 尿中C-ペプチドの測定. 臨床検査 26 : 523-530, 1982.
2) Polonsky KS, et al : Use of biosynthetic human C-peptide in the measurement of insulin secretion rates in normal volunteers and type 1 diabetes. J Clin Invest 77 : 98-105, 1986.
3) 日本臨床検査薬協会 (編) : 体外診断用医薬品集, 薬事日報社, 1997, 追補版, 2001.
4) Kajinuma H, et al : Urinary excretion of C-peptide in relation to renal function. In : Proinsulin, Insulin, C-peptide (ed by Baba S, et al), p 183-189, Excerpta Medica, Amsterdam, 1979.
5) 謝勲東ほか : 糖尿病患者における経口ブドウ糖負荷試験時の血清free CPR反応. 糖尿病 26 : 941-947, 1983.
6) 鎌田郁子ほか : 糖尿病患者のインスリン依存性判定の指標としてのグルカゴン負荷時血清C-ペプチド反応. 糖尿病 28 : 827-831, 1985.
7) 熊倉忍ほか : 糖尿病患者のインスリン依存性判定の指標としての朝食後2時間の血清C-ペプチド値. Peptide Hormones in Pancreas 8 : 219-223, 1988.
P.388 掲載の参考文献
1) Berson SA, et al : Insulin 131I metabolism in human subjects : determination of insulin binding globulin in the circulation of insulin treated subjects. J Clin Invest 35 : 170, 1956.
2) Pav J, et al : Insulin antibodies. Lancet ii : 221, 1963.
3) 平田幸正 : インスリン自己免疫を示した自発性低血糖の1例. 糖尿病 13 : 312, 1972.
4) Palmer JP, et al : Insulin antibodies in insulin-dependent diabetics before insulin treatment. Science 222 : 1337, 1983.
5) Wilkin TJ, et al : Autoantibodies against human insulin. Br Med J 288 : 349, 1984.
6) Koch M, et al : Semi-quantitative assessment of anti-insulin total IgG and IgG sub-classes in insulin-immunized patients using a highly sensitive immunochemical micromethods. Diabetologia 29 : 720, 1986.
7) 平田幸正 : 抗インスリン抗体. 日本臨牀 42 (増刊 : 臨床免疫handbook) : 1451, 1984.
8) Nakagawa S, et al : A simple method for the determination of serum free insulin levels in insulin treated patients. Diabetes 22 : 590, 1973.
9) Asplin CM, et al : Detection and quantification of insulin-binding antibodies. In : Methods in Diabetes Research, Vol II (ed by Clarke WL, et al), John Wiley & Sons, New York, 1986.
10) Wilkin TJ, et al : Systematic variation and differences in insulin-autoantibody measurements. Diabetes 38 : 172, 1989.
11) Sodoyez-Goffaux F, et al : Advantages and pitfalls of radioimmune and enzyme linked immunosorbent assays of insulin antibodies. Diabetologia 31 : 694, 1988.
12) Thakur AK, et al : Graphical analysis of ligand binding systems. Anal Biochem 107 : 279, 1980.
13) Kahn CR, Rosenthal AS : Immunologic reaction to insulin : insulin allergy, insulin resistance and the autoimmune insulin syndrome. Diabetes Care 2 : 283, 1979.
14) 平田幸正 : 抗インスリン抗体. 日本臨牀 43 (増刊 : 広範囲血液・尿化学検査, 免疫学的検査 (下)) : 263, 1985.
15) Van Haeften TW : Clinical significance of insulin antibodies in insulin-treated diabetic patients. Diabetes Care 12 : 641, 1989.
16) Dahl-Jorgensen K : Increase in insulin antibodies during continuous subcutaneous insulin infusion and multiple-injection therapy in contrast to conventional treatment. Diabetes 36 : L1987.
18) Nielsen D, et al : Comparison of insulin binding characteristics between antibodies to exogenous insulin and insulin autoantibodies (Abstract). Clin Res 38 : 124A, 1990.
19) Serreze DV, et al : Molecular mimicry betWeen insulin and retroviral antigen p73. Development of cross-reactive autoantibodies in sera of NOD and C57BL/Ksj db/db mice. Diabetes 37 : 351-358, 1988.
20) Neifing JL, et al : Insulin (auto) antibodies from human IDDM cross-react with retroviral antigen p73 (Abstract). Clin Res 40 : 35A, 1992.
21) Vardi P, et al : Competitive insulin autoantibody assay. Prospective evaluation of subjects at high risk for development of type I diabetes mellitus. Diabetes 36 : 1286, 1987.
22) Srikanta S, et al : Autoimmunity to insulin, beta cell dysfunction, and development of insulin-dependent diabetes mellitus. Diabetes 35 : 139, 1986.
23) Atkinson MA, et al : Are insulin autoantibodies markers for insulin-dependent diabetes mellitus? Diabetes 35 : 894, 1986.
24) Neifing JL et al : Prospective evaluation of β-cell function in insulin autoantibody-positive relatives of insulin-dependent diabetic patients. Metabolism 42 : 482, 1993.
25) Olsson LM, et al : Predictive value of islet cell and insulin autoantibodies for type 1 (insulin-dependent) diabetes mellitus in a population-based study on newly-diagnosed diabetic and matched control children. Diabetologia 35 : 1068, 1992.
26) Roll U, et al : Associations of anti-GAD antibodies and insulin autoantibodies in first-degree relatives of type 1 diabetic patients. Diabetes 43 : 154, 1994.
27) Rayner ML, et al : Detection of insulin antibodies in newly diagnosed type 1 diabetic children after "acid-striping" of sera. Diabetes Res 6 : 1, 1987.
28) Bilbao JR, et al : Anti-insulin activity in normal newborn cord-blood serum : absence of IgG-mediated insulin binding. Diabetes 46 : 713, 1997.
30) Bonifacio E, et al : International workshop on lessons from animal models for human type 1 diabetes. Identification of insulin but not glutamic acid decarboxylase or IA-2 as specific autoantigens of humoral autoimmunity in nonobese diabetic mice. Diabetes 50 : 2451, 2001.
P.393 掲載の参考文献
1) Bottazo G, et al : Islet-cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies. Lancet ii : 1279-1282, 1974.
2) Kobayashi T, et al : The prevalence of islet cell antibodies in Japanese insulin-dependent and non-insulin-dependent diabetic patients studied by indirect immunofluorescence and by a new method. Diabetes 35 (3) : 335-340, 1986.
3) Mire-Sluis AR, et al : The development of a World Health Organisation international standard for islet cell antibodies : the aims and design of an international collaborative study. Diabetes Metab Res Rev 15 (1) : 72-77, 1999.
5) Gianani R, et al : Prognostically significant heterogeneity of cytoplasmic islet cell antibodies in relatives of patients with type I diabetes. Diabetes 41 : 347-353, 1992.
6) Sai P, et al : Quantification of human cytoplasmic islet-cell antibodies which cross-react with mouse pancreas : afollow up study in type 1 (insulin-dependent) diabetic patients and in first-degree relatives. Diabetologia 36 : 778-784, 1993.
8) Timsit J, et al : Islet cell antibody heterogeneity among type 1 (insulin-dependent) diabetic patients. Diabetologia 35 : 792-795, 1992.
9) Richter W, et al : Human monoclonal islet cell antibodies from a patient with insulin-dependent diabetes mellitus reveal glutamate decarboxylase as the target antigen. Proc Natl Acad Sci USA 89 : 8467-8471, 1992.
10) Richter W, et al : Human monoclonal islet specific autoantibodies share features of islet cell and 64 kDa antibodies. Diabetologia 36 : 785-790, 1993.
12) Rabin DU, et al : Islet cell antigen 512 is a diabetes-specific islet autoantigen related to protein tyrosine phosphatases. J Immunol 152 : 3183-3188, 1994.
13) Christie MR, et al : Validity of screening for individuals at risk for type I diabetes by combined analysis of antibodies to recombinant proteins. Diabetes Care 20 : 965-970, 1997.
14) Colman PJ, et al : Binding of cytoplasmic islet cell antibodies is blocked by human pancreatic glycolipid extracts. Diabetes 37 : 645-652, 1989.
15) Gillard BK, et al : Antibodies against ganglioside GT3 in the sera of patients with type I diabetes mellitus. J Immunol 142 : 3826-3832, 1989.
17) Aguilar-Diosdado M, et al : Potential autoantigens in IDDM : Expression of carboxypeptidase-H and insulin but not glutamate decarboxylase on the β-cell surface. Diabetes 43 : 418-425, 1994.
18) Kasimiotis H, et al : Antibodies to SOX 13 (ICA12) are associated with type 1 diabetes. Autoimmunity 33 (2) : 95-101, 2001.
19) Steinbrenner H, et al : Autoantibodies to ICA 12 (SOX-13) are not specific for Type I diabetes. Diabetologia 43 (11) : 1381-1384, 2000.
20) Lohmann T, et al : Titre and combination of ICA and autoantibodies to glutamic acid decarboxylase discriminate two clinically distinct types of latent autoimmune diabetes in adults (IADA). Diabetologia 44 (8) : 1005-1010, 2001.
21) Kobayashi T, et al : GAD antibodies seldom disappear in slowly progressive IDDM. Diabetes Care 19 (9) : 1031, 1996.
22) Desailloud R, et al : Autoimmune markers in slow type 1 diabetes : confrontation to type 1 diabetes. Diabetes Metab 26 (5) : 353-360, 2000.
23) Winnock F, et al : Autoantibodies to a 38-kDa glycosylated islet cell membrane-associated antigen in (pre) type 1 diabetes : association with IA-2 and islet cell autoantibodies. Diabetes Care 24 (7) : 1181-1186, 2001.
24) Kobayashi T, et al : Small doses of subcutaneous insulin as a strategy for preventing slowly progressive β-cell failure in islet cell antibody-positive patients with clinical features of NIDDM. Diabetes 45 : 622-626, 1996.
P.399 掲載の参考文献
1) Leslie RDG, et al : Autoantigens IA-2 and GAD in type 1 (insulin-dependent) diabetes. Diabetologia 42 : 3-14, 1999.
3) 日本糖尿病学会 (編) : 糖尿病治療ガイド 2000, 文光堂, 2000.
5) Blu D-F, et al : Two human glutamate decarboxylase, 65-kD GAD and 67-kD GAD, are each encoded by a single gene. Proc Natl Acad Sci USA 89 : 2115-2119, 1992.
6) Baekkeskov S, et al : Autoantibodies in newly diagnosed diabetic children immunoprecipitation human pancreatic islet cell protein. Nature 298 : 167-169, 1982.
7) Schmidli RS, et al : Disease sensitivity and specificity of 52 assays for glutamic acid decarboxylase antibodies. Diabetes 44 : 636-640, 1995.
8) Turner R, et al : UKPDS 25 : autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. Lancet 350 : 1288」293, 1997.
9) Zimmet P, et al : Crucial points at diagnosis. Type 2 diabetes or slow onset type 1 diabetes. Diabetes Care 22 (Suppl 2) : B59-B64, 1999.
10) Christie MR, et al : Detection of pancreatic islet 64,000M (r) autoantigens in insulin-dependent diabetes distinct from glutamate decarboxylase. J Clin Invest 92 : 240-248, 1993.
11) Verge CF, et al : Combined use of autoantibodies (IA-2 autoantibody, GAD autoantibody, insulin autoantibody, cytoplasmic islet cell antibodies) in type 1 diabetes. Combinational Islet Autoantibody Workshop. Diabetes 47 : 1857-1866, 1998.
12) Savola K, et al : IA-2 antibodies-asensitive marker of IDDM with clinical onset in childhood and adolescence. Diabetologia 41 : 424-429, 1998.
13) Kaufman DL, et al : Report from the 1st international NOD mouse T-cell workshop and the follow-up mini-workshop. Diabetes 50 : 2459-2463, 2001.
14) Bingley PJ, et al : Prediction of IDDM in the general population. Strategies based on combinations of autoantibody markers. Diabetes 46 : 1701-1710, 1997.
15) Mire-Sluis AR, et al : The World Health Organization International Collaborative Study for islet cell antibodies. Diabetologia 43 : 1282-1292, 2000.
P.404 掲載の参考文献
2) Blecher M : Receptors. Antibodies and disease. Clin Chem 30 : 1137, 1984.
3) 厚生省特定疾患ホルモン受容体異常調査研究班 (班長井村裕夫) 統計調査による.
4) Kobayashi M, et al : Characterization of anti-insulin receptor antibody action : Biologic activity and kinase activity. In : Best Approach to the Ideal Therapy of Diabetes Mellitus (ed by Shigeta Y, et al), p195, Excerpta Medica, Amsterdam, 1987.
5) Karlsson FA, et al : Desensitization of the insulin receptor at an early post-receptor step by prolonged exposure to antireceptor antibody. Proc Natl Acad Sci USA 81 : 7446, 1984.
6) Flier JS, et al : Antibodies that impair insulin receptor binding in an unusual diabetic syndrome with severe insulin resistance. Science 190 : 63, 1975.
7) 小林正, 石橋修 : インスリン抗体とインスリンレセプター抗体の測定と臨床的意義. 臨床病理 33 : 513-518, 1985.
8) 荷見澄子, 大森安恵 : 抗インスリン受容体抗体. 日本臨牀 53 (増刊 : 広範囲血液・尿化学検査, 免疫学的検査 (下)) : 458-460, 1995.
9) 植田太郎, 荷見澄子 : 抗インスリン受容体抗体. 日本臨牀 57 (増刊 : 広範囲血液・尿化学検査, 免疫学的検査 (4)) : 364-367, 1999.
P.409 掲載の参考文献
1) Kobold U, et al : Candidate reference methods for hemoglobin A1c based on peptide mapping. Clin Chem 43 : 1944-1951, 1997.
2) 島健二ほか : グリコヘモグロビンの標準化に関する委員会報告 (IV). 糖尿病 40 : 321-326, 1997.
3) 糖尿病関連検査の標準化に関する委員会からのお知らせ : 現在のヘモグロビンA1cの標準品 (Lot 1) の供給停止および新たに認証した標準物質 (Lot 2) について. 糖尿病 44 (3) : 2001.
4) 富永真琴, 梅本雅夫 : 糖尿病の新しい診断基準とHbA1c, およびその標準化. 検査と技術 29 : 415-420, 2001.
5) 富永真琴ほか : ヘモグロビンA1c標準物質JDS Lot 2のNGSP値について. 糖尿病 45 : 385-388, 2002.
6) Goldstein DE, et al : Glycated hemoglobin estimation in the 1990s : A review of assay methods and clinical interpretation. In : The Diabetes Annual 18 (ed by Marshall SM, Home PD), p 193-212, Elsevier, Amsterdam, 1994.
7) 島健二ほか : グリコヘモグロビンの標準化に関する委員会報告. 糖尿病 37 : 855-864, 1994.
8) 葛谷健ほか : 糖尿病の分類と診断に関する委員会報告. 糖尿病 42 : 385-404, 1999.
9) 日本糖尿病学会 (編) : 糖尿病治療ガイド 2000, 文光堂, 2000.
10) 糖尿病治療の目標と指針. 糖尿病 45 (Suppl 1) : 13-16, 2002.
11) 日本公衆衛生協会 : 糖尿病の指導区分に関する検討, 2001.
P.414 掲載の参考文献
1) Yamanouchi T, et al : Origin and disposal of 1,5-anhydroglucito1, a major polyol in the human body. Am J Physiol 263 : E268-E273, 1992.
2) Sakuma M, et al : Purification and some properties of a hepatic NADPH-dependent reductase that specifically acts on 1,5-anhydro-D-fructose. J Biochem 123 : 189-193, 1998.
3) Yu S, et al : α-1,4-Glucan lyases producing 1,5-anhydro-D-fructose from starch and glycogen have sequence similarity to α-glucosidases. Biochim Biophys Acta 1433 : 1-15, 1999.
4) Carabaza A, et al : Glucose has to be phosphorylated to activate glycogen synthase, but not to inactivate glycogen phosphorylase in hepatocytes. FEBS Lett 296 : 211-214, 1992.
5) 朴明俊ほか : 糖尿病患者におけるacarboseの1,5-anhydroglucitolに及ぼす影響. Diabetes Frontier 8 : 230-233, 1997.
6) Shiga Y, et al : Escherichia coli phosphorylates 1,5-anhydroglucitol and releases 1,5-anhydroglucitol 6-phosphate when glucose is absent in the medium. J Biochem 119 : 173-179, 1996.
8) Yamanouchi T, et al : Common reabsorption system of 1,5-anhydro-D-glucitol, fructose, and mannose in rat renal tubule. Biochim Biophys Acta 1291 : 89-95, 1996.
9) Yamanouchi T, et al : Acute glucosuria after continuous glucocorticoid loading in the rat in vivo. Eur J Pharmacol 341 : 257-263, 1998.
10) Yamanouchi T, et al : Transport of 1,5-anhydro-D-glucitol into insulinoma cells by a glucose-sensitive transport system. Biochim Biophys Acta 1474 : 291-298, 2000.
11) Ahren B, et al : 1,5-anhydro-D-fructose increases glucose tolerance by increasing glucagon-like peptide-1 and insulin in mice. Eur J Pharmacol 397 : 219-225, 2000.
12) Taguchi T, et al : Effects of 1,5-anhydro-D-fructose on selected glucose-metabolizing enzymes. Biotechnol Appl Biochem 18 : 275-283, 1993.
13) Yamanouchi T, et al : Clinical usefulness of serum 1,5-anhydroglucitol in monitoring glycaemic control. Lancet 347 : 1514-1518, 1996.
14) 山内俊一 : 1,5-AG. 血糖値をみる・考える (島健二編), p 70-78, 南江堂, 2000.
P.418 掲載の参考文献
1) Diabetes Control and Complications Trial Research Group : The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329 : 977-986, 1993.
2) 田原保宏, 島健二 : 糖化蛋白の評価. Recent Progress on Diabetes Diagnosis Marker 3 : 43, 1994.
3) Tahara Y, Shima K : The response of GHb to stepwise plasma glucose change over time in diabetic patients. Diabetes Care 16 : 1313-1314, 1993.
4) Shima K, et al : High-performance liquid chromatographic assay of serum glycated albumin. Diabetologia 31 : 627, 1988.
5) 前畑英介ほか : HPLC2段カラム法によるGlycated Albumin自動分析装置 (GAA-200) の評価. 日本臨床検査自動化学会雑誌 17 (1) : 3-6, 1992.
6) Yasukawa K, et al : High-performance affinity chromatography system for the rapid, efficient assay of glycated albumin. J Chromatogr 597 : 271-275, 1992.
7) 大島一洋 : 糖化アルブミンの測定法. 検査と技術 20 (7) : 487, 1992.
8) Cavallo-Perin P, et al : Urinary excretion of glycated albumin in insulin-dependent diabetic patients with micro-and macroalbuminuria. Clin Nephrol 38 (1) : 9-13, 1992.
9) 大島一洋ほか : 糖化アルブミンの測定法. 検査と技術 20 (7) : 487, 1992.
10) Hogemann B, et al : Concentrations of 7S collagen and laminin P1 in sera of patients with diabetes mellitus. Min Wochenschr 64 : 382-385, 1986.
11) Pietschman P, et al : Serum concentration of laminin P1 in diabetics with advanced nephropathy. J Clin Pathol 41 : 929, 1988.
12) 中山秀隆ほか : Affinity chromatographyによるglycosylated albumin測定の基礎的検討. 糖尿病 25 : 963, 1982.
13) 石神達三ほか : ラミニン. 日本臨牀 47 : 183, 1989.
14) 藤田知代ほか : 新しい酵素法によるグリコアルブミン測定試薬の評価. 医学と薬学 47 : 141, 2002.
15) 山内俊一 : 糖尿病-血糖コントロールの指標. 臨床成人病 27 (1) : 171, 1997.
16) 藤原和代ほか : 糖尿病妊婦における血糖コントロール指標としての糖化アルブミンの有用性. 糖尿病 37 : 107, 1994.
17) 大島一洋ほか : 糖化アルブミン. 綜合臨牀 40 : 1403, 1991.
18) 矢野正生ほか : 1,5AG, HbA1C, FBG組み合わせによる耐糖能障害スクリーニングの検討. 糖尿病 38 : 255, 1995.
19) 安川恵子ほか : グリコアルブミン. 臨床検査 40 : 1275, 1996.
20) 田原保宏 : 血糖値に代わる検査. 血糖値をみる・考える (島健二編), p62, 南江堂, 2000.
P.432 掲載の参考文献
2) Schwartzkroin PA : Mechanisms underlying the anti-epileptic efficacy of the ketogenic diet. Epilepsy Res 37 : 171, 1999.
3) Harano Y, et al : Sensitive and simplified method for the differential determination of serum levels of ketone bodies. Clin Chim Acta 134 : 327, 1983.
4) Harano Y, et al : Direct automated assay method for serum or urine levels of ketone bodies. Clin Chim Acta 151 : 177, 1985.
5) Harano Y, et al : Development of stable film test for rapid estimation of blood or plasma 3-hydroxybutyrate. Diabetes Care 13 : 522, 1990.
6) Harano Y, et al : Ketone bodies as markers for type I diabetes and their value in the monitoring of diabetic control. Diabetologia 26 : 343, 1984.
7) McGarry JD, et al : Regulation of ketogenesis and the renaissance of carnitine palmitoyl-transferase. Diabetes Metab Rev 5 : 271, 1989.
8) Harano Y, et al : Phosphorylation of carnitine palmitoyltransferase and activation by glucagon in isolated rat hepatocytes. FEBS Lett 188 : 267, 1985.
9) Harano Y, et al : Carnitine palmitoyltransferase activities (1 & 2) and the rate of palmitate oxidation in liver mitochondria from diabetic rats. Arch Biochem Biophys 153 : 426, 1972.
10) Brady L, Brady PS : Regulation of carnitine palmitoyltransferase synthesis in spontaneously diabetic BB Wistar rats. Diabetes 38 : 65, 1989.
11) Cook GA, et al : Altered sensitivity of carnitine palmitoyltransferase to inhibition by malonyl CoA in ketotic diabetic rats. Biochem J 219 : 337, 1984.
12) Park EA, Cook GA : Differential regulation in the heart of mitochondrial carnitine palmitoyltransferase-1 muscle and liver isoforms. Mol Cell Biochem 180 : 27, 1998.
13) Kosugi K, et al : Mechanism of adrenergic stimulation of hepatic ketogenesis. Metabolism 32 : 1081, 1983.
14) Kojima H, et al : Asuppressive role of C-kinase for the stimulation of hepatic ketogenesis by glucagon and epinephrine. FEBS Lett 201 : 271, 1986.
15) Wiggam MI, et al : Treatment of diabetic ketoacidosis using normalization of blood 3-hydroxybutyrate concentration as the endpoint of emergency management. A randomized controlled study. Diabetes Care 20 : 1347, 1997.
16) Hale PJ, et al : Metabolic effects of bicarbonate in the treatment of diabetic ketoacidosis. Br Med J 289 : 1035-1038, 1984.
17) Harano Y, et al : Role of vasopressin in the pathophysiology of non-ketotic hyperosmolar diabetic coma. In : Recent Progress in Posterior Pituitary Hormones (ed by Yoshida S, Share L), p 395, Elsevier, Amsterdam, 1988.
18) 原納優 : 糖尿病性昏睡-高浸透圧性昏睡への提言-. 日本医事新報 3387 : 123, 1989.
19) 日比晶ほか : 急性疾患小児における血中ケトン体. 日本小児科学会雑誌 94 (10) 12196-2202, 1990.
20) 野中共平 : 糖尿病の臨床現場で考える. 糖尿病記録号 1, 医学図書出版, 1996.
P.439 掲載の参考文献
1) Foster DW : Lactic acidosis. In : Principls of Internal Medicine (ed by Braunwald E, et al), p 1797-1800, McGraw-Hill, New York, 1985.
3) Poole RC, et al : Studies of the membrane topology of the rat erythrocyte H+/lactate cotransporter (MCT1). Biochem J 320 : 817-824, 1996.
4) 戸谷誠之, 永島慶子 : ピルビン酸・乳酸. 分析化学ライブラリー III (北村元仕ほか編), p 50-65, 岩波書店, 1982.
5) 戸谷誠之 : 乳酸. 検査と技術 18 : 74-75, 1990.
6) 池本正生ほか : 固定化ピルビン酸オキシダーゼおよび固定化乳酸酸化酵素をもちいた血中ピルビン酸・乳酸の自動蛍光測定法. 京都大学医療短期大学部紀要 8 : 19-26, 1988.
7) Tsuchida T, et al : Biothec Bioeng 27 : 837-841, 1985.
8) Bleiberg B : Determination of plasma lactic acid concentration and specific activity using high-performance liquid chromatography. J Chromatogr 568 : 301-308, 1991.
9) Carenter MW, Sady SA : Exercise in pregnancy. In : Principles of Prevental-Neonetal Metabolism (ed by Cowett RM), p 237-249, Springer-Verlag, New York, 1991.
10) 赤塚正文ほか : インスリン非依存型糖尿病における術中輸液としての酢酸リンゲル液と乳酸リンゲル液の比較. 麻酔と蘇生 33 : 97-101, 1997.
11) 森本昌親 : インスリン非依存性糖尿病における治療効果の年齢別比較. Prog Med 17 : 2150-2153, 1997.
12) 宮澤由香里ほか : 糖尿病運動療法と簡易乳酸測定器による乳酸値測定. リハビリテーション医学 35 : 842, 1998.
P.444 掲載の参考文献
1) Jack CM, et al : Non-enzymatic glycosylation of low-density lipoprotein. Results of affinity chromatography method. Diabetologia 31 : 126-127, 1988.
2) Shea EA, et al : Immunogenic detection of glycated apolipoprotein B with site specific monoclonal antibodies. J Immunol Methods 162 : 85-95, 1985.
3) Schleicher E, et al : Non-enzymatic glycosylation of human serum lipoprotein. FEBS Lett 129 : 1-4, 1981.
6) Witztum JL, et al : Non-enzymatic glycosylation of low-density lipoprotein alters its biologic activity. Diabetes 31 : 283-291, 1982.
7) Triau J, et al : Impaired hepatocyte binding, uptake and degradation of glycosylated low density lipoproteins. Biochim Biophys Acta 877 : 359-365, 1986.
8) Bowie A, et al : Glycosylated low density lipoprotein is more sensitive to oxidation : implications for the diabetic patient. Atherosclerosis 102 : 63-67, 1993.
9) Sakurai T, Tsuchiya S : Superoxide production from nonenzymatically glycated protein. FEBS Lett 236 : 406-410, 1988.
10) Lopes-Virella MA, et al : Glycosylation of low-density lipoprotein enhances cholesterol ester synthesis in human monocyte-derived macrophages. Diabetes 37 : 550-557, 1988.
12) Lopes-Virella MF, et al : The uptake of LDL-IC by human macrophages : predominant involvement of the Fc gamma RI receptor. Atherosclerosis 135 : 161-170, 1997.
13) Takeda H, et al : Abnormalities in platelets and vascular endothelial cells induced by glycated lipoproteins. Intern Med 31 : 746-751, 1995.
14) Ren S, Shen GX : Impact of antioxidants and HDL on glycated LDL-induced generation of fibrinolytic regulators from vascular endothelial cells. Arterioscler Thromb Vasc Biol 20 : 1688-1693, 2000.
P.450 掲載の参考文献
1) Kolaczynski JW, Caro JF : Insulin-like growth factor-1 therapy in diabetes : Physiologic basis, clinical benefits, and risks. Ann Intern Med 120 : 47-55, 1994.
2) Orskov H : Somatostatin, growth hormone, insulin-like growth factor-1, and diabetes : Friends or foes? Metabolism 45 : 91-95, 1996.
3) Winter RJ, et al : Somatomedin activity and diabetic control in children with insulin-dependent diabetes. Diabetes 28 : 952-954, 1979.
4) Janssen JAMJL, et al : Free and total insulin-like growth factor 1 (IGF-1), IGF-binding protein-1 (IGFBP-1), and IGFBP-3 and their relationships to the presence of diabetic retinopathy and glomerular hyperfiltration in insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 82 : 2809-2815, 1997.
7) Grant MB, et al : The efficacy of octreotide in the treatment of severe nonproliferative and early proliferative diabetic retinopathy. Diabetes Care 23 : 504-509, 2000.
9) Dillis DG, et al : Association of elevated IGF-I levels with increased retinopathy in late-onset diabetes. Diabetes 40 : 1725-1730, 1991.
10) Chantelau E : Evidence that upregulation of serum IGF-1 concentration can trigger acceleration of diabetic retinopathy. Br J Ophthalmol 82 : 725-730, 1998.
11) Henricsson M, et al : Progression of retinopathy after improved metabolic control in type 2 diabetic patients. Diabetes Care 22 : 1944-1949, 1999.
12) Grant M, et al : Insulin-like growth factors in vitreous. Studies in control and diabetic subject with neovasculization. Diabetes 35 : 416-420, 1986.
13) Meyer-Schwickerath R, et al : Vitreous levels of the insulin-like growth factors I and II, and the insulin-like growth factor binging Protein 2 and 3, increase in neovascular eye disease. Studies in non-diabetic and diabetic subjects. J Clin Invest 92 : 2620-2625, 1993.
15) Tattersall RB, Pyke DA : Growth in diabetic children. Studies in identical twins. Lancet ii : 1105-1109, 1973.
P.454 掲載の参考文献
1) Morrow JD, et al : A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc Natl Acad Sci USA 87 : 9383-9387, 1990.
2) Davi G, et al : In vivo formation of 8-Epi-prostaglandin F2 alpha is increased in hypercholesterolemia. Arterioscler Thromb Vasc Biol 17 : 3230-3235, 1997.
4) Wang Z, et al : Immunological characterization of urinary 8-epi-prostaglandin F2 alpha excretion in man. J Pharmacol Exp Ther 275 : 94-100, 1995.
5) Migdalis IN, et al : Plasma levels of endothelin, lipid peroxides and prostacyclin in diabetic patients with macroangiopathy. Diabetes Res Clin Pract 54 : 129-136, 2001.
6) Marra G, et al : Early increase of oxidative stress and reduced antioxidant defenses in patients with uncomplicated type 1 diabetes. Diabetes Care 25 : 370-375, 2002.
7) 島崎弘幸 : 過酸化脂質. 日本臨牀 57 (増刊 : 広範囲血液・尿化学検査, 免疫学的検査 1) : 55-58, 1999.
8) Davi G, et al : In vivo formation of 8-iso-prostaglandin f2alpha and platelet activation in diabetes mellitus : effects of improved metabolic control and vitamin E supplementation. Circulation 99 : 224-229, 1999.
9) Gopaul NK, et al : Oxidative stress could precede endothelial dysfunction and insulin resistance in Indian Mauritians with impaired glucose metabolism. Diabetologia 44 : 706-712, 2001.
11) Gokkusu C, et al : Oxidant and antioxidant systems in NIDDM patients : influence of vitamin E supplementation. Endocr Res 27 : 377-386, 2001.
12) Devaraj S, et al : Divergence between LDL oxidative susceptibility and urinary F (2)-isoprostanes as measures of oxidative stress in type 2 diabetes. Clin Chem 47 : 1974-1979, 2001.
13) Meagher EA, et al : Effects of vitamin E on lipid peroxidation in healthy persons. JAMA 285 : 1178-1182, 2001.
P.461 掲載の参考文献
2) 坂本美一 : 生化学検査. 糖質・糖代謝関係. ミオイノシトール. 日本臨牀 57 (増刊 : 広範囲血液・尿化学検査, 免疫学的検査 1) : 631-633, 1999.
4) Greene DA : Myo-inositol : The mystery molecule of diabetic complications. Clin Diabetes 3 : 80-81, 1985.
5) Yancey PH, et al : Living with water stress : evaluation of osmolyte systems. Science 217 : 1214-1222, 1982.
9) Raccah D, et al : Effect of the aldose reductase inhibitor tolrestat on nerve conduction velocity Na+/K+ -ATPase activity, and polyols in red blood cells, sciatic nerve, kidney cortex, and kidney medulla of diabetes rats. J Diabetes Complications 12 : 154-162, 1998.
13) Winegrad AI : Banting lecture 1986. Does a common mechanism induce the diverse complications of diabetes? Diabetes 36 : 396-406. 1987.
14) Zhu X, Eichberg J : A myo-inositol pool utilized for phosphatidylinositol synthesis is depleted in sciatic nerve from rats with streptozotocin-induced diabetes. Proc Natl Acad Sci USA 87 : 9818-9822, 1990.
17) Koya D, et al : Characterization of protein kinse Cβisoform activation on the gene expression of transforming growth factor-β, extracellular matrix components, and prostanoids in the glomeruli of diabetic rats. J Clin Invest 100 : 115-126, 1997.
18) Porcellati F, et al : Human Na'-myo-inositol cotransporter gene : alternate splicing generates diverse transcripts. Am J physiol 274 : C1215-C1225, 1998.
P.468 掲載の参考文献
1) 河津捷二ほか : 糖尿病とラミニン代謝異常. Diabetes Frontier 3 : 237-244, 1992.
2) 伴野群一ほか : ラミニン, コラーゲン. 日本臨牀 56 (増刊 : 糖尿病 3) : 135-143, 1998.
3) 顧建国ほか : ラミニン結合性インテグリンを介するシグナル伝達とその制御. 生化学 73 : 1207-1214, 2001.
4) 新山忠彦ほか : ラミニン. 日本臨牀 57 (増刊 : 広範囲血液・尿化学検査, 免疫学的検査 1) : 292-294, 1999.
8) 加藤典弘ほか : 血中あるいは尿中IV型コラーゲン, ラミニン, タイプIIIプロコラーゲンペプチドによる糖尿病性腎症の非侵襲的評価と鑑別. 糖尿病 35 : 339-345, 1992.
10) 水田敏彦 : IV型コラーゲン. 日本臨牀 57 (増刊 : 広範囲血液・尿化学検査, 免疫学的検査 1) : 299-302, 1999.
12) Cohen MP, et al : Serum type rV collagen in diabetic patients at risk for nephropathy. Diabetes Care 24 : 1324-1327, 2001.
14) 谷川久一, 上野隆登 : タイプIIIプロコラーゲン-N-ペプチド (P III P). 日本臨牀 57 (増刊 : 広範囲血液・尿化学検査, 免疫学的検査 1) : 303-306, 1999.
P.473 掲載の参考文献
2) Suzuki K, et al : Structure and expression of human thrombomodulin, a thrombin receptor on endothelium acting as a cofactor for protein C activation. EMBO J 6 : 1891, 1987.
3) Ishii H, et al : Establishment of enzyme immunoassay of human thrombomodulin in plasma and urine using monoclonal antibodies. Thromb Haemost 63 : 157, 1990.
4) Yamamoto S, et al : Urinary thrombomodulin, its isolation and characterization. J Biochem 113 : 433, 1993.
5) Suzuki K, et al : A domain composed of epidermal growth factor-like structures of human thrombomodulin is essential for thrombin binding and for protein C activation. J Biol Chem 264 : 4875, 1989.
6) 石井秀美ほか : 血中トロンボモジュリン測定の意義. 臨床病理 37 : 266, 1989.
7) Iwashima Y, et al : Elevation of plasma thrombomodulin levels in diabetic patients with early diabetic nephropathy. Diabetes 39 : 983, 1990.
8) Tanaka A, et al : Increased thrombomodulin values in plasma of diabetic men with microangiopathy. Clin Chem 37 : 269, 1991.
9) Shimano H, et al : Elevated serum and urinary thrombomodulin levels in patients with non insulin dependent diabetes mellitus. Clin Chim Acta 225 : 89, 1994.
10) 由井克昌ほか : 糖尿病における血中トロンボモジュリンの検討-血清クレアチニン値による補正の試み-. 糖尿病 37 : 725, 1994.
11) Gruden G, et al : Thrombomodulin levels in insulin dependent diabetic patients with microalbuminuria. Diabet Med 12 : 258, 1995.
12) Matsuoka T, et al : Serum thrombomodulin as a marker of diabetic macroangiopathy. Diabetes Care 18 : 731, 1995.
13) 西田堅司ほか : 糖尿病患者の血中Thrombomodulin値は大血管障害の指標となりうる, 糖尿病 44 (Suppl 1) : S-50, 2001.
14) 田中明 : 尿中トロンボモジュリン. 日本臨牀 26 (増刊 : 糖尿病 3) : 360, 1998.
P.484 掲載の参考文献
1) 朝山光太郎 : 糖尿病 : フリーラジカルと抗酸化機構の変動. 臨床検査 40 : 176-180, 1996.
2) McCord JM, Fridovich I : Superoxide dismutase ; An enzymatic function for erythro-cuprein (Hemocuprein). J Biol Chem 244 : 6049-6055, 1969.
3) Marklund SL, et al : Superoxide dismutase in extracellular fluids. Clin Chim Acta 126 : 41-51, 1982.
4) Chan PC, Bielski BH : Enzyme-catalyzed free radical reactions with nicotinamide adenine nucleotide. J Biol Chem 249 : 1317-1319, 1974.
5) 大柳善彦 : 活性酸素消去酵素の測定法. 活性酸素 (二木鋭雄, 島崎弘幸編), p139-183, 医歯薬出版, 1987.
6) Paoletti F, Mocali A : Determination of superoxide dismutase activity by purely chemical system based on NAD (P) Hoxidation. Methods Enzymol 186 : 209-221, 1990.
7) Nakano M : Assay for superoxide dismutase based on chemiluminescence of luciferin analog. Methods Enzymol 186 : 227-237, 1990.
8) 前畑英介ほか : 糖尿病患者の活性酸素・フリーラジカル種とその防御酵素 : Total Superoxide Dismutase (T-SOD) とExtracellular (EC)-SODレベルについて. けんさ 30 : 14-32, 2001.
9) Oka S, et al : Human serum immunoreactive copper, zinc-SOD assayed with an enzyme monoclonal immunosorbent in patients with digestive cancer. Clin Chim Acta 182 : 209-220, 1989.
10) 若林克己, 岩沢淳 : 時間分解蛍光免疫測定法 (TR-FIA) の紹介. 群馬核医学研会誌 4 : 83-88, 1989.
11) Asayama K, et al : Effect of vitamin E deficiency and selenium deficiency on insulin secretory reserve and free radical scavenging systems in islets : Decrease of islet manganosuperoxide dismutase. J Clin Lab Med 107 : 459-464, 1986.
12) 谷口直之ほか : 糖尿病の合併症と酸化ストレス. 糖尿病記録号, p81-87, 医学図書出版, 1966.
13) Arai K, et al : Increase in the glycosylated form of erythrocytes Cu, Zn-superoxide dismutase in diabetes and close association of the non-enzymatic glycosylation with the enzyme activity. Biochim Biophys Acta 924 : 292-296, 1987.
14) 矢野正生ほか : 糖尿病患者の赤血球および血清SOD測定の検討. 磁気共鳴と医学 10 : 59-63, 1999.
16) Sekeroglu MR, et al : The effect of dietary treatment on erythrocyte lipid peroxidation, superoxide dismutase, glutathione peroxidase, and serum lipid peroxidation in patients with type 2 diabetes mellitus. Clin Biochem 33 : 669-674, 2000.
19) Gilbert RE, et al : Urinary transforming growth factor-β in patients with diabetic nephropathy : implications for the pathogenesis of tubulointerstitial pathology. Nephrol Dial Transplant 16 : 2442-2443, 2001.
20) Craven PA, et al : Overexpression of Cu2+/Zn2+ superoxide dismutase protects against early diabetic glomerular injury in transgenic mice. Diabetes 50 : 2114-2125, 2001.
21) Kakkar R, et al : Antioxidant defense system in diabetic kidney : A time course study. Life Sci 60 : 667-679, 1997.
23) van Dam PS, et al : Effects of insulin treatment on endoneurial and systemic oxidative stress in relation to nerve conduction in streptozotocin-diabetic rats. Eur J Clin Invest 26 : 1143-1149, 1996.
24) Khan MA, et al : The effect of superoxide dismutase on nitric oxide-mediated and electrical fieldstimulated diabetic rabbit cavernosal smooth muscle relaxation. BJU Int 87 : 98-103, 2001.
25) 小堀祥二 : 糖尿病性大血管障害のリスクファクター. メディカル朝日 8 : 80-81, 1997.
26) Matsuoka T, et al : Glycation-dependent, reactive oxygen species mediated suppression of the insulin gene promotor activity in HIT cells. J Clin Invest 99 : 144-150, 1997.
27) 福井敏樹ほか : OLETFラットの初期糖尿病段階におけるSOD活性低下に伴う酸化ストレスの増加はトログリタゾンにより抑制される. 腎とフリーラジカル 5 : 94-96, 2000.
28) Ramanathan M, et al : Superoxide dismutase, catalase and glutathione peroxidase activities in the brain of streptozotocin induced diabetic rats. Indian J Exp Biol 37 : 182-183, 1999.
P.491 掲載の参考文献
1) The Diabetes Control and Complications Trial Research Group : The effect of intensive treatment of diabetes on the development and progression of longterm complications in insulin-dependent diabetes mellitus. N Engl J Med 329 : 977-986, 1993.
2) Dvomik D : Aldose Reductase-An Approach to the Prevention of Diabetic Complications, McGraw-Hill, New York, 1987.
3) Goto Y, et al : A placebo-controlled double blind study of Epalrestat (ONO-2235) in patients with diabetic neuropathy. Diabet Med 10 : 39s-43s, 1993.
5) Srivastava SK, et al : Activation of human erythrocyte, brain, aorta, muscle and ocular tissue aldose reductase. Metabolism 35 (Suppl 1) : 114-118, 1986.
6) Malone JI : Red cell sorbitol : An indication of diabetic control. Diabetes 24 : 861-864, 1980.
7) Poli T, et al : Plasma and red cell sorbitol assay in diabetic subjects. Acta Diabetol Lat 22 : 17-23, 1985.
8) Hosojima H, et al : Erythrocyte sorbitol, serum fructosamine and glycosylated hemoglobin levels in type II diabetic patients with various degrees of diabetic complications. In : Current Status of Prevention and Treatment of Diabetic Complications (ed by Sakamoto N, et al), p 325-330, Excerpta Medica, Amsterdam, 1990.
9) Flynn TG : Aldose and aldehyde reductase in animal tissues. Metabolism 35 (Suppl 1) : 105-108, 1986.
10) Crabbe MJC, et al : Erythrocyte glyceraldehyde reductase levels in diabetics with retinopathy and cataract. Lancet ii : 1268-1270, 1980.
11) 細島弘行ほか : 糖尿病におけるポリオール代謝. 異常について-赤血球ソルビトール, SDH, GARについての検討. 糖尿病 32 (Suppl 1) : 218, 1989.
12) Nishimura C, et al : Quantitative determination of human aldose reductase by enzyme-linked immuno-sorbent assay. Immunoassay of human aldose reductase. Biochem Pharmacol 46 : 21-28, 1993.
13) Hamada Y, et al : Crucial role of aldose reductase activity and plasma glucose level in sorbitol accumulation in erythrocytes from diabetic patients. Diabetes 40 : 1223-1240, 1991.
14) Barretto OC, et al : Reduced levels of erythrocyte sorbitol dehydrogenase activity in human diabetics. Braz J Med Biol Res l8 : 477-479, 1985.
15) 細島弘行ほか : 糖尿病および耐糖能. 異常患者における経口糖負荷試験の赤血球ソルビトール値に及ぼす影響. 医学のあゆみ 148 : 423-424, 1989.
16) Sima AAF, et al : Regeneration and repair of myelinated fibers in suraLnerve biopsy specimens from patients with diabetic neuropathy treated with sorbinil. N Engl J Med 319 : 548-555, 1988.
18) 細島弘行ほか : 糖尿病網膜症の進展と血糖コントロール, 赤血球ソルビトール値との関係-8年間追跡調査-. 眼紀 47 : 1059-1063, 1996.
19) Tilton RG, et al : Inhibition of sorbitol dehydrogenase. Effects on vascular and neural dysfunction in streptozotocin-induced diabetic rats. Diabetes 44 : 234-242, 1995.
P.497 掲載の参考文献
1) 黒木昌寿, 川上正舒 : 糖尿病細小血管症-成因解明と進展阻止. 糖尿病学 2000 (小坂樹徳編), p128-136, 診断と治療社, 2000.
2) Ulrich P, Cerami A : Protein glycation, diabetes, and aging. Recent Prog Horm Res 56 : 1-21, 2001.
3) Vlassara H, Palace MR : Diabetes and advanced glycation endproducts. J Intern Med 251 : 87-101, 2002.
4) Degenhardt TP, et al : Chemical modification of proteins by methylglyoxal. Cell Mol Biol 44 : 1139-1145, 1998.
5) Nakayama H, et al : Production and characterization of antibodies to advanced glycation products on proteins. Biochem Biophys Res Commun 162 : 740-745, 1989.
7) Beisswenger PJ, et al : Formation of immunochemical advanced glycosylation end products precedes and correlates with early manifestations of renal and retinal disease in diabetes. Diabetes 44 : 824-829, 1995.
8) Onorato JM, et al : Immunohistochemical and ELISA assay for biomarkers of oxidative stress in aging and disease. Ann N Y Acad Sci 854 : 277-290, 1998.
9) Berg TJ, et al : Advanced glycation end products in serum predict changes in the kidney morphology of patients with insulin-dependent diabetes. Metabolism 46 : 661-665, 1997.
12) Ono Y, et al : Increased serum levels of advanced glycation end products in NIDDM patients with diabetic complications. Diabetes Care 21 : 1027, 1998.
14) Kilhovd BK, et al : Serum levels of advanced glycation end products are increased in patients with type 2 diabetes and coronary heart disease. Diabetes Care 23 : 1441-1442, 2000.
15) Aoki S, et al : Crossline levels in serum and erythrocyte membrane proteins from patients with diabetic nephropathy. Diabetes Res Clin Pract 48 : 119-125, 2000.
P.502 掲載の参考文献
1) 吉澤都ほか : 可溶性VCAM-1. 日本臨牀 56 : 206-211, 1998.
3) De Mattia G, et al : Effects of insulin on in vitro vascular cell adhesion molecule-1 expression and in vivo soluble VCAM-1 release. Diabetologia 42 : 1235-1239, 1999.
4) Nagai Y, et al : Serum soluble adhesion molecule concentrations are not regulated by acute hyperinsulinaemia in healthy men. Diabet Med 16 : 618, 1999.
5) Marfella R, et al : Circulating adhesion molecules in humans : role of hyperglycemia and hyperinsulinemia. Circulation 101 : 2247-2251, 2000.
6) Targher G, et al : Relation between soluble adhesion molecules and insulin sensitivity in type 2 diabetic individuals : Role of adipose tissue. Diabetes Care 24 : 1961-1966, 2001.
8) Morgani M, et al : Leukocyte-endothelial interaction is augmented by high glucose concentrations and hyperglycemia in a NF-κB-dependent fashion. J Clin Invest 101 : 1905-1915, 1998.
11) Yoshizawa M, et al : Elevated serum levels of soluble vascular cell adhesion molecule-1 in NIDDM patients with proliferative diabetic retinopathy. Diabetes Res Clin Pract 42 : 65-70, 1998.
12) Limb GA, et al : Vascular adhesion molecules in vitreous from eyes with proliferative diabetic retinopathy. Invest Ophthalmol Vis Sci 40 : 2453-2457, 1999.
13) Hernandez C, et al : Vitreous levels of vascular cell adhesion molecule and vascular endothelial growth factor in patients with proliferative diabetic retinopathy : a case-control study. Diabetes Care 24 : 516-521, 2001.
15) Tummala PE, et al : Angiotensin II induces vascular cell adhesion molecule-1 expression in rat vascularture : a potential link between the renin-angiotensin system and atherosclerosis. Circulation 100 : 1223-1229, 1999.
16) Gasic S, et al : Fosinopril decreases levels of soluble vascular cell adhesion molecule-1 in borderline hypertensive type II diabetic patients with microalbuminuria. Am J Hypertens 12 : 217-222, 1999.
17) Andersen S, et al : Angiotensin II blockade is associated with decreased plasma leukocyte adhesion molecule levels in diabetic nephropathy. Diabetes Care 23 : 1031-1032, 2000.
18) Schalkwijk CG, et al : ACE-inhibition modulates some endothelial functions in healthy subjects and in normotensive type 1 diabetic patients. Eur J Clin Invest 30 : 853-860, 2000.
20) Constantin G, et al : Induction of adhesion molecules on human schwann cells by proinflammatory cytokines, an immunofluorescence study. J Neurol Sci 170 : 124-130, 1999.
21) Jager A, et al : Increased levels of soluble vascular cell adhesion molecule 1 are associated with risk of cardiovascular mortality in type 2 diabetes : the Hoorn study. Diabetes 49 : 485-491, 2000.
22) Blankenberg S, et al : Circulating cell adhesion molecules and death in patients with coronary artery disease. Circulation 104 : 1336-1342, 2001.
24) De Mattia G, et al : Reduction of oxidative stress by oral N-acetyl-L-cysteine treatment decreases plasma soluble vascular cell adhesion molecule-1 concentrations in non-obese, non-dyslipidaemic, normotensive, patients with non-insulin-dependent diabetes. Diabetologia 41 : 1392-1396, 1998.
26) 吉澤都ほか : PGI2投与前後における血中可溶性VCAM-1 (sVCAM-1) 濃度の推移に関して-糖尿病性末梢神経障害との関連-. 糖尿病 42 (Suppl 1) : S-197, 1999.
27) Marx N, et al : PPARα activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation 99 : 3125-3131, 1999.
P.508 掲載の参考文献
1) Fisher JW, Brookins J : Adenosine A2A and A2B receptor activation of erythropoietin production. Am J Physiol 281 : F826-F832, 2001.
3) Mrug M, et al : Angiotensin II stimulates proliferation of normal early erythroid progenitors. J Clin Invest 100 : 2310-2314, 2000.
6) 猪股茂樹, 盛裕之 : エリスロポエチン-糖尿病性腎症における尿細管間質病変進展度推定への応用-. 日本臨牀 56 (増刊 : 糖尿病 1) : 232-233, 1998.
7) Pratt MC, et al : Effect of angiotensin converting enzyme inhibitors on erythropoietin concentrations in healthy volunteers. Br J Clin Pharmacol 34 : 363-365, 1992.
9) Essawy M, et al : Myofibroblasts and the progression of diabetic nephropathy. Nephrol Dial Transplant 12 : 43-50, 1997.
12) Biaggioni I, et al : The anemia of primary autonomic failure and its reversal with recombinant erythropoietin. Ann Intern Med 121 : 181-186, 1994.
13) Winkler AS, et al : Erythropoietin depletion and anemia in diabetes mellitus. Diabet Med 16 : 813-819, 1999.
14) Bayes B, et al : Successful treatment of anemia of nephrotic syndrome with recombinant human erythropoietin. Nephrol Dial Transplant 13 : 1894-1895, 1998.
15) Albitar S, et al : High dose enalapril impairs the response to erythropoietin treatment in hemodialysis patients. Nephrol Dial Transplant 13 : 1206-1210, 1998.
P.513 掲載の参考文献
1) Nayak RC, et al : Cytoplasmic islet cell antibodies, evidence that target antigen is a sialoglycoconjugate. Diabetes 34 : 617-619, 1985.
2) Colman PG, et al : Binding of cytoplasmic islet cell antibodies is blocked by human pancreatic islets. Diabetes 27 : 645-652, 1988.
3) Dotta F, et al : Ganglioside expression in human pancreatic islets. Diabetes 38 : 1478-1483, 1989.
4) Dotta F, et al : NOD islet ganglioside : hyperexpression of a putative target antigen of autoimmunity and effect on beta cell destruction. Diabetologia 34 (Suppl 2) : A53, 1991.
5) Dotta F, et al : Pancreatic islet ganglioside expression in nonobese diabetic mice : Comparison with C57BL/10 mice and changes after autoimmune β-cell destruction. Endocrinology 130 : 37-42, 1992.
6) Dotta F, et al : GM2-1 pancreatic ganglioside : identification and characterization of a novel islet-specific molecule. Diabetologia 38 : 1117-1121, 1995.
7) Dotta F, et al : The GM2-1 ganglioside islet autoantigen in insulin-dependent diabetes mellitus is expressed in secrtory granules and is not β-cell specific. Endocrinology 139 : 316-319, 1998.
8) Dotta F, et al : Autoimmunity to the GM2-1 islet ganglioside before and at the onset of type I diabetes. Diabetes 45 : 1193-1196, 1996.
10) Gillard BK, et al : Antibodies against ganglioside GT3 in the sera of patients with type I diabetes mellitus. J Immunol 142 : 3826-3832, 1989.
11) Buschard K, et al : Sulphatide and sulphatide antibodies in insulin-dependent diabetes mellitus. Lancet 342 : 840, 1993.
12) Buschard K, et al : Sulphatide antigen in islets of Langerhans and in diabetic glomeruli and anti-sulphatide antibodies in type I diabetes mellitus. APMIS 101 : 963-970, 1993.
13) Buschard K, et al : Neonatal treatment of BB rats with sulphatide delays development of diabetes but dose not change incidence. APMIS 103 : 193-196, 1995.
14) 安田智子ほか : I型糖尿病 (IDDM) の予知, 診断マーカーとしての抗sulphatide抗体の評価. 糖尿病 37 (Supp11) : 288, 1995.
15) Shigeta H, et al : Serum autoantibodies against sulfatide and phospholipid in NIDDM patients with diabetic neuropathy. Diabetes Care 20 : 1896-1899, 1997.
P.519 掲載の参考文献
1) Simonsen O, et al : The blood serum concentration of cystatin C (γ-trace) as a measure of the glomerular filtration rate. Scand J Clin Lab Invest 45 : 97-101, 1985.
2) Finney H, et al : Initial evaluation of cystatin C measurement by particle-enhanced immunonephelometry on the Behring nephelometer system (BNA BN II). Clin Chem 43 (6) : 1016-1022, 1997.
3) Lofberg H, et al : Quantitation of γ-trace in human biological fluids : indications for production in the central nervous system. Scand J Clin Lab Invest 39 : 619-626, 1979.
4) Kyhse-Anderson J, et al : Serum cystatin C, determined by a rapid, automated particle-enhanced turbidimetric method, is a better marker than serum creatinine for glomerular filtration rate. Clin Chem 40 : 1921-1926, 1994.
5) Norlund L, et al : Reference intervals for the glomerular filtration rate and celLproliferation markers : Serum cystatin C and serum β2-microglobulin/cystatin C ratio. Scand J Clin Lab Invest 57 : 463-470, 1997.
6) 大原智子ほか : 健常人における血清シスタチンC値の基準範囲設定の試み. 医学と薬学 43 : 835-844, 2000.
7) Fliser D, et al : Serum cystatin C concentration as a marker of renal dysfunction in the elderly. Am J Kidney Dis 37 : 79-83, 2001.
8) Newman DJ, et al : Serum cystatin C measured by automated immunoassay : A more sensitive marker of change in GFR than serum creatinine. Kidney Int 47 : 312-318, 1995.
9) Grubb A, et al : Serum concentration of cystatin C, factor D and β2-microglobulin as a measure of glomerular mtration rate. Acta Med Scand 218 : 499-503, 1985.
11) 丹波嘉一郎ほか : 血清シスタチンCによる前向きの腎機能評価-各種腎機能パラメーターとの比較-. 日腎会誌 43 : 646-650, 2001.
12) 下条文武 : 腎機能評価の問題点と今後の方向性. BN NEWS 1 : 1-6, 1999.
13) Harmonien APT, et al : Evaluation of plasma cystatin C as a marker for glomerular filtration rate in patients with type 2 diabetes. Clin Nephrol 52 : 363-370, 1999.
15) Piwowar A, et al : Plasma cystatin C concentration in non-insulin-dependent diabetes mellitus : relation with nephropathy. Arch Immunol Ther Exp 47 : 327-331, 1997.
P.525 掲載の参考文献
1) 伊藤機一 第2章 尿・糞便検査, V. 異常尿成分の科学的検査法, 2. 糖質. 臨床検査法提要, 改訂第31版 (金井泉, 金井正光編), p159-163, 金原出版, 1998.
2) 金井正光ほか : 第6章 臨床化学検査, V. 糖質とその代謝関連物質 (有機酸), 1. グルコース (血糖) の測定. 臨床検査法提要, 改訂第31版 (金井泉, 金井正光編), p524-533, 金原出版, 1998.
3) 日本臨床化学会 試薬専門委員会 : 血清グルコース測定勧告法 (1991-4-30). 臨床化学 20 : 247-254, 1991.
5) 鈴木吉彦, 松岡健平 : 経口ブドウ糖負荷試験の解析. 日本臨牀 48 (増刊 : 糖尿病 (上)) : 553-557, 1990.
6) Goldstein DE, et al : Test of glycemia in diabetes. Diabetes Care 18 (6) : 896-909, 1995.
7) Tattersall R, Gale E : Patient self-monitoring of blood glucose and refinements of conventional insulin treatment. Am J Med 70 : 177-182, 1981.
8) Oku A, et al : T-1095, an inhibitor of renal Na+ -glucose cotransporters, may provide a novel approach to treating diabetes. Diabetes 48 : 1794-1800, 1999.
P.529 掲載の参考文献
2) Viberti G, et al : Determinants of the penetration of proteins through the glomerular barrier in insulin-dependent diabetes mellitus. Diabetes 32 (Suppl 2) : 92-95, 1983.
3) Kanauchi M, et al : Diagnostic significance of urinary transferrin in diabetic nephropathy. Jpn J Nephrol 37 : 649-654, 1995.
4) 大角誠治ほか : 高感度酵素免疫測定法を用いた健常者, 糖尿病患者の尿中IV型コラーゲンの測定. 糖尿病 39 : 523-526, 1996.
5) Takahashi M : Increased urinary fibronectin excretion in type II diabetic patients with microalbuminuria. Jpn J Nephrol 37 : 336-342, 1995.
6) Krolewski AS, et al : The changing natural history of nephropathy in type 1 diabetes Am J Med 78 : 785-794, 1985.
8) Burton C, Haris KPG : The role of proteinuria in the progression of chronic renal failure. Am J Kidney Dis 27 : 765-775, 1996.
9) Schimitz A, Vaeth M : Microalbuminuria : a major risk factor in non-insulin dependent diabetes. A 10 year follow-up study of 503 patients. Diabet Med 5 : 126-134, 1988.
10) Chan JC, et al : Abnormal albuminuria as a predictor of mortality and renal impairment in Chinese patients with NIDDM. Diabetes Care 18 : 1013-1016, 1995.
P.538 掲載の参考文献
1) Harano Y, et al : Direct automated assay method for serum or urine levels of ketone bodies. Clin Chim Acta 151 : 177, 1985.
2) Eriksson CJP : Micro method for determination of ketone bodies by head-space gas chromatography. Anal Biochem 47 : 235, 1972.
3) Owen OE, et al : Acetone metabolism during diabetic ketoacidosis. Diabetes 31 : 242, 1982.
4) Harano Y, et al : Ketone bodies as markers for type 1 (insulin-dependent) diabetes and their value in the monitoring of diabetic control. Diabetologia 26 : 343, 1984.
5) Schwab TM, et al : Screening for ketonemia in patients with diabetes. Ann Emerg Med 34 : 342, 1999.
6) Yamada K, Nonaka K : Diabetic ketoacidosis in young obese Japanese men atypical diabetes induced by sugar-containing soft drinks. Diabetes Care 19 : 671, 1996.
7) McClain DA, Crook DC : Hexosamines and insulin resistance. Diabetes 45 : 1003-1009, 1996.
8) Kinoshita O, et al : A case of diabetic non-ketotic hyperosmolar coma with an increase with plasma 3-hydroxybutyrate. Endocrinol Jpn 38 (5) : 465-470, 1991.
9) Harano Y, et al : Development of stable film test for rapid estimation of blood or plasma 3-OHBA. Diabetes Care 13 : 522, 1990.
P.544 掲載の参考文献
1) Keen H, Chlouverakis C : An immunoassay method for urinary albumin at low concentrations. Lancet ii : 913-914, 1963.
6) 糖尿病性腎症早期診断基準. 厚生省平成2年度糖尿病調査研究報告書, p215, 1991.
7) 羽田勝計 : 微量アルブミンの測定法と臨床的意義. 新・糖尿病性腎症 発症予防と進展阻止のために (繁田幸男, 海津嘉蔵編), p130-138, 医学書院, 1992.
8) 吉川隆一ほか : 微量アルブミン尿会議記録集. 糖尿病 41 : 737-776, 1998.
9) 堺秀人ほか : 尿中アルブミン濃度の正常値についての検討-糖尿病性腎症の診断指針の作成を目指して-, 日本糖尿病学会・日本腎臓病学会 糖尿病性腎症合同委員会. 糖尿病 44 : 467-472, 2001.
10) Cowell CT, et al : First morning urinary albumin concentration is a good predictor of 24-hour urinary albumin excretion in children with type 1 (insulin-dependent) diabetes. Diabetologia 29 : 97-99, 1986.
11) 熊坂一成 : 尿中微量アルブミン. 日本臨牀 57 (増刊 : 広範囲血液・尿化学検査, 免疫学的検査 (1)) : 85-88, 1999.
13) 日本糖尿病学会 (編) : 糖尿病合併症とその対策, C慢性合併症, (2) 糖尿病性腎症. 糖尿病治療ガイド 2000, p47, 文光堂, 2000.
14) Parving HH, et al : Does microalbuminuria predict diabetic nephropathy? Diabetes Care 25 (2) : 406-407, 2002.
15) 日本糖尿病学会, EBMに基づく糖尿病治療ガイドライン策定に関する委員会 : 糖尿病性腎症の治療. 糖尿病 45 (Suppl 1) : 43-48, 2002.
P.549 掲載の参考文献
1) 金井泉, 金井正光 : 臨床化学検査. 臨床検査法提要, p 508-513, 金原出版, 1998.
2) 高橋進 : クレアチニン. 日本臨牀 43 : 254-257, 1985.
3) 古川哲雄 : クレアチン, クレアチニン. 日本臨牀 38 : 573-579, 1980.
4) 横田厚 : 健康小児のクレアチン体及び尿中クレアチン体, アルギニンの排泄について. 日児誌 63 : 1720-1727, 1959.
5) 中尾俊之 : 糖尿病性腎症の低クレアチニン値透析導入者の検討. 日腎会誌 37 : 1025-1031, 1990.
6) 金井泉, 金井正光 : 腎機能検査. 臨床検査法提要, p 1470-1480, 金原出版, 1998.
7) 吉村学ほか : クレアチニン. 日本臨牀 47 : 402-406, 1989.
P.555 掲載の参考文献
1) Kanauchi M, et al : Glomerular lesions in patients with non-insulin-dependent diabetes mellitus and microalbuminuria. Intern Med 32 : 735-757, 1993.
2) 江崎淳 : 2型糖尿病におけるmicroalbuminuria, microtransferrinuriaの検討 (糸球体性か尿細管性か). 三重医 36 : 337-344, 1992.
3) 石橋不可止 : インスリン非依存性糖尿病におけるミクロアルブミン尿とミクロトランスフェリン尿の比較. 糖尿病 35 : 949-954, 1992.
4) 三崎盛治ほか : 2型糖尿病患者における尿トランスフェリン, アルブミン排泄量. 糖尿病 36 : 909-915, 1993.
5) 大間知健史 : 糖尿病性腎症における尿中微量アルブミンおよび免疫グロブリンの臨床的意義. 近畿大医誌 16 : 353-364, 1991.
6) 八嶌功ほか : 糖尿病性腎症における尿中IgG排泄量測定の意義. 日腎会誌 41 : 787-796, 1999.
7) Bernard A, et al : Urinary proteins and red blood cell membrane negative charges in diabetes mellitus. Clin Chim Acta 190 : 249-262, 1990.
8) Martin P, et al : Increased urinary excretion of transferrin in children with type I diabetes mellitus. Diabet Med 7 : 35-40, 1990.
9) Kanauchi M, et al : Diagnostic significance of urinary transferrin in diabetic nephropathy. Jpn J Nephrol 37 : 649-654, 1995.
11) 安西慶三ほか : NIDDM患者における尿中アルブミン, トランスフェリンおよびIgG測定の意義. 糖尿病 41 : 765-767, 1998.
12) 五十嵐登, 高桑聖 : Insulin-dependent diabetes mellitus (IDDM), 患者における尿中total IgG排泄-微量アルブミン尿との関連-. 小児科臨床 48 : 309-312, 1995.
13) 田中剛 : 尿蛋白定性陰性インスリン非依存性糖尿病患者における尿中微量蛋白値の臨床的意義. 三重医 30 : 305-314, 1986.
14) Mogensen CE, Solling K : Studies on renal tubular protein reabsorption : partial and near complete inhibition by certain amino acids. Scand J Clin Lab Invest 37 : 477-486, 1977.
15) 石橋不可止 : ミクロアルブミン尿を呈するインスリン非依存型糖尿病における諸種尿蛋白の糸球体濾過. 糖尿病 36 : 619-624, 1993.
16) Ishibashi F : Glomerular clearance and tubular reabsorption of IgG1 and IgG4 in microalbuminuric patients with non-insulin-dependent diabetes mellitus. Diabetes Res Clin Pract 22 : 45-51, 1993.
17) Ishibashi F : Glomerular clearance and tubular reabsorption of transferrin in microtransferrinuric patients with non-insulin-dependent diabetes. Diabetes Res Clin Pract 25 : 169-175, 1994.
19) Pietravalle P, et al : Charge selectivity of proteinuria in type 1 diabetes explored by Ig subclass clearance. Diabetes 40 : 1685-1690, 1991.
20) 佐藤賢ほか : 早期糖尿病性腎症でみられるcharge selectivityの障害-IgG/IgG4 indexによる検討. 糖尿病 40 : 165-170, 1997.
P.559 掲載の参考文献
1) Takagi K, et al : Studies on human α1-microglobulin. I. Isolation and physicochemical and immun ochemical properties. Jpn J Clin Chem 6 : 298-303, 1978.
2) Kin K, et al : β2-microglobulin levels of serum and ascites in malignant diseases. Gann 68 : 427-434, 1977.
3) Itoh Y, Kawai T : Human α1-microglobulin : Its measurement and clinical application. J Clin Lab Anal 4 : 376-384, 1990.
4) 日高祐介ほか : Behring Nepherometer Analyzerによる尿中α1-マイクログロブリンの測定. 医学と薬学 28 : 319-342, 1992.
5) 折田義正ほか : 日本腎臓学会機能 (GFR) ・尿蛋白測定委員会報告書. 日本腎臓学会誌 43 (1) : 1-19, 2001.
6) Yamamoto H, Yamada T, Itoh Y : Probable involvement of cathepsin D in the degradation of β2-microglobulin in acidic urine. Clin Chem Lab Med 38 : 495-499, 2000.
7) Koopman M, et al : Circadian rhythm of urinaryβrmicroglobulin excretion in patients with nephrotic syndrome. Nephron 45 : 140-145, 1987.
8) Itoh Y, Kawai T : Sex differences in urinary α1-microglobulin value in normal individuals. Nephron 57 : 121- 122, 1991.
9) 吉川隆一ほか : 糖尿病患者の尿中β2-マイクログロブリンの値について. 糖尿病 22 : 621-626, 1979.
11) 飯村康夫, 河合忠 : α1-マイクログロブリン, β2-マイクログロブリン. 日本臨牀 44 (増刊 : 糖尿病) : 233-238, 1986.
12) 飯村康夫ほか : 尿中NAG活性測定の基礎的検討および糖尿病患者における変動. 臨床病理 56 (臨時増刊) : 79-89, 1983.
13) Galanti LM, et al : Comparison of urinary excretion of albumin and α1-microglobulin and retinolbinding protein in diabetic patients. Diabetes Metab 22 : 324-330, 1996.
14) 木村敬子ほか : 尿蛋白陰性のインシュリン依存性糖尿病における尿中N-acetyl-β-D-glucosaminidaseの臨床的意義について. 糖尿病 29 : 995-1000, 1986.
16) Brocco E, et al : Renal structure and function in non insulin dependent diabetic patients with microalbuminuria. Kidney Int 52 : 40-44, 1997.
P.566 掲載の参考文献
3) Kanwar YS, et al : Increased permeability of the glomerular basement membrane to ferritin after removal of glycosaminoglycans (heparan sulfate) by enzyme digestion. J Cell Biol 86 : 688-693, 1980.
4) Makino H, et al : Nephritogenicity of antibodies to proteoglycans of the glomerular basement membrane-I. J Clin Invest 77 (1) : 142-156, 1986.
6) Ikeda S, et al : Changes in glomerular extracellular matrices components in diabetic nephropathy. J Diabet Complications 5 : 186-188, 1991.
7) Makino H, et al : Ultrastructural changes of extracellular matrices in diabetic nephropathy revealed by high resolution scanning and immunoelectron microscopy. Lab Invest 68 : 45-55, 1993.
8) Kanwar YS, et al : Decreased de novo synthesis of glomerular proteoglycans in diabetes : biochemical and autoradiographic evidence. Proc Natl Acad Sci USA 80 : 2272-2277, 1983.
9) Kanwar Y, et al : Biosynthetic regulation of proteoglycans by aldohexoses and ATP. Proc Natl Acad Sci USA 89 : 8621-8625, 1992.
10) Kashihara N, et al : Selective decreased de novo synthesis of glomerular proteoglycans under the influence of reactive oxygen species. Proc Natl Acad Sci USA 89 : 6309-6313, 1992.
11) Edge AS, Spiro RG : Aspecific structural alteration in the heparan sulphate of human glomerular basement membrane in diabetes. Diabetologia 43 : 1056-1059, 2000,
14) Pillarisetti S : Lipoprotein modulation of subendothelial heparan sulfate proteoglycans (perlecan) and atherogenicity. Trends Cardiovasc Med 10 : 60-65, 2000.
16) Murata K : [Proteoglycans] . Nippon Rinsho 56 (Suppl 3) : 322-328, 1998.
21) Sindelka G, et al : Glycosaminoglycans in urine of type 1 diabetic patients. Sb Lek 94 : 77-80, 1993.
22) Gambaro G, et al : High urinary excretion of glycosaminoglycans : apossible marker of glomerular involvement in diabetes. Metabolism 38 : 419-420, 1989.
23) 植田一穂ほか : 尿中グルコサミノグリカン濃度の臨床的意義. 糖尿病 (インスリン非依存型) 性早期腎症患者における検討. 日本腎臓学会誌 37 : 17-23, 1995.
P.573 掲載の参考文献
2) Lopes-Virella MF, et al : Early diagnosis of renal malfunction in diabetics. Diabetologia 16 : 165-171, 1979.
3) Ikegami H, et al : Enzymuria in non-insulin-dependent diabetic patients : signs of tubular cell dysfunction. Clin Sci (Lond) 84 : 469-475, 1993.
4) Shimojo N, et al : Comparison of N-acetyl-β-D-glucosaminidase and alanine aminopeptidase activities for evaluation of microangiopathy in diabetes mellitus. Metabolism 36 : 277-280, 1987.
5) Ishii N, et al : Diagnostic significance of urinary enzymes for diabetes mellitus and hypertension. Enzyme Protein 48 : 174-182, 1994-1995.
6) Mattenheimer H : Enzymes in renal diseases. Ann Clin Lab Sci 7 : 422-432, 1977.
7) Ching YH, Kee SC : Markers of diabetic nephropathy. J Diabetes Complications 12 : 43-60, 1998.
8) 中村桜子 : 糖尿病患者における尿中Alanine aminopeptidase排泄の臨床的意義-微量アルブミン, N-acetyl-β-D-glucosaminidaseとの比較検討-. 北海道医学雑誌 66 : 522-533, 1991.
9) 佐藤利彦 : 糖尿病患者における尿中alanine aminopeptidase (AAP) 活性-糖尿病腎症の指標としての臨床的有用性-. 阪市医誌 37 : 839-856, 1988.
10) Glancarlo S, et al : Diagnostic evaluation of alanine aminopeptidase as serum marker for detecting cancer. Cancer Biochem Biophys 12 : 199-204, 1991.
12) Jung K, Scholz D : An optimized assay of alanine aminopeptidase activity in urine. Clin Chem 26 : 1251-1254, 1980.
13) 北橋繁ほか : 尿中alanine aminopeptidase (AAP) 活性測定とその臨床的意義. 日臨検自動化会誌 12 : 62-66, 1987.
14) 内山一晃, 尾形稔 : 尿中アラニンアミノペプチダーゼ. 日本臨牀 47 (増刊 : 広範囲血液・尿化学検査, 免疫学的検査 (上)) : 366-368, 1989.
15) Jung K, et al : Age-dependent excretion of alanine aminopeptidase, alkaline phosphatase, γ-glutamyltransferase and N-acetyl-β-D-glucosaminidase in human urine. Enzyme 43 : 10-16, 1990.
17) Vanderlinde RE : Urinary enzymes measurements in the diagnosis of renal disorders. Ann Clin Lab Sci 11 : 189-201, 1981.
18) 戸村成男ほか : 原発性腎疾患における尿中酵素および尿蛋白の分析. 日腎誌 29 : 955, 1987.
19) Jung K, et al : Urinary enzymes and low-molecular mass proteins as indicator of diabetic nephropathy. Clin Chem 34 : 544-547, 1988.
P.580 掲載の参考文献
1) Caramori ML, et al : The need for early predictors of diabetic nephropathy risk. Is albumin rate sufficient? Diabetes 49 : 204-216, 2000.
2) 猪俣茂樹ほか : 糖尿病における尿蛋白分析の臨床的意義 (第3報) -Microalbuminuriaと腎病変の関連について-. 糖尿病 30 : 429-435, 1987.
5) 河津捷二ほか : ラミニン, コラーゲン. 日本臨牀 56 (増刊 : 糖尿病 3) : 365-369, 1998.
6) Takahashi M, et al : Serum and urinary laminin PI concentrations in diabetic patients with and without microangiopathies. In : Best Approach to the Ideal Therapy of Diabetes Mellitus (ed by Shigeta Y, et al), p 427, Elsevier, Amsterdam, 1987.
7) 加藤典弘ほか : 糖尿病性腎症における尿中IV型コラーゲン, ラミニン, タイプIIIプロコラーゲンペプチド測定の意義. 糖尿病合併症 5 : 251-257, 1992.
8) 加藤典弘ほか : 糖尿病性腎症における尿中IV型コラーゲン, ラミニン, タイプIIIプロコラーゲンペプチドによる糖尿病性腎症の非侵襲的評価と測定の意義. 糖尿病 35 : 339-345, 1992.
9) 河津捷二ほか : 糖尿病とラミニン代謝異常. Diabetes Frontier 3 : 237-244, 1992.
11) Torffvit O, et al : A new enzyme-linked immunosorbent assay for urine and serum concentrations of the carboxyterminal domain (NCl) of collagen IV. Application in type 1 (insulin-dependent) diabetes. Scand J Clin Lab Invest 49 : 431-439, 1988.
12) 小幡賢一ほか : 尿中IV型コラーゲンの酵素免疫測定法. 臨床検査機器・試薬 18 : 439-443, 1995.
13) 磯野元秀ほか : インスリン非依存型糖尿病患者における尿中IV型コラーゲンの解析-糖尿病性腎症の指標として-. 糖尿病 39 : 599-604, 1996.
15) 島田美貴ほか : 尿中IV型コラーゲン. 日本臨牀 56 (増刊 : 糖尿病 3) : 376-380, 1998.
16) 大角誠治ほか : 随時尿を用いた尿中IV型コラーゲン測定による糖尿病性腎症早期診断スクリーニングの検討. 医学と薬学 43 : 1189-1194, 2000.
17) Takeoka H, et al : A multifunctional transcription factor (Alp 145) regulates the smooth muscle phenotype in mesangial cells. Biochem Biophys Res Commun 252 : 290-295, 1998.
18) 平成9年度長期慢性疾患総合研究事業 (慢性腎不全) 研究報告書, p102, 厚生省, 1998.
P.585 掲載の参考文献
2) Habig WH, et al : The first enzymatic step in mercapturic acid formation. J Biol Chem 249 : 7130-7139, 1974.
3) 小杉栄次郎 : 糖尿病性腎症における尿グルタチオンS-トランスフェラーゼ (GST) 活性測定の意義. 糖尿病 39 (5) : 329-337, 1996.
4) Kamisaka K, et al : Multiple forms of human glutathione S-transferase and their affinity for bilirubin. Eur J Biochem 60 : 153-161, 1975.
5) Butera L, et al : Sex differences in the subunits glutathione-S transferase isoenzyme from rat and human kidney. Enzyme 43 : 175-182, 1990.
6) Guthenberg C, et al : Glutathione S-transferase (transferase π) from human placenta is identical or closely related to glutathione S-transferase (transferaseρ) from erythrocytes. Biochim Biophys Acta 661 : 255-260, 1981.
7) Harrison DJ, et al : Distribution of glutathione S-transferase isoenzymes in human kidney : basis for possible markers of renal injury. J Clin Pathol 42 : 624-628, 1989.
8) Overby LH, et al : Unique distribution profiles of glutathione S-transferases in regions of kidney, ureter and bladder of rabbit. Lab Invest 70 : 468-478, 1994.
9) Bomhard E, et al : Determination of urinary glutathione S-transferase and lactate dehydrogenase for differentiation between proximal and distal nephron damage. Arch Toxicol 64 : 269-278, 1990.
P.591 掲載の参考文献
1) 大庭建三ほか : NAG. 日本臨牀 56 (増刊 : 糖尿病 3) : 400-406, 1998.
2) 遠藤聡子, 熊田至 : 日立7150自動分析装置による尿中NAGの測定. 医学と薬学 21 : 967-977, 1989.
3) 古畑紀子ほか : アイソザイム分析による病態診断-アセチルグルコサミニダーゼ-. 日本臨牀 53 : 1267-1276, 1995.
4) 杉田収 : 尿中N-アセチル-β-D-グルコサミニダーゼ. 日本臨牀 57 (増刊 : 広範囲血液・尿化学的検査, 免疫学的検査 1) : 128-130, 1999.
5) Oba K, et al : Effect of age on urinary excretion of N-acetyl-β-D-glucosaminidase. J Nippon Med Sch 66 : 33-36, 1999.
6) Alderman MH, et al : Increased excretion of urinary N-acetyl-β-D-glucosaminidase in essential hypertension and its decline with antihypertensive therapy. N Engl J Med 309 : 1213-1217, 1983.
8) 皆上宏俊 : 尿中N-acety-β-D-glucosaminidaseの糖尿病性腎症診断指標としての臨床的意義. 北海道医誌 67 : 234-246, 1992.
9) 平井眞明ほか : 老年インスリン非依存型糖尿病患者における随時尿のアルブミン指数と尿中NAG指数測定の臨床的意義. 日医大誌 64 : 518-525, 1997.
10) 北橋繁ほか : 尿・血清中N-acetly-β-D-glucosaminidase (NAG) 活性の臨床的意義. 臨床病理 34 : 687-693, 1986.
11) Weitgasser R, et al : Prospective evaluation of urinary N-acetyl-β-D-glucosaminidase with respect to macrovascular disease in elderly type 2 diabetic patients. Diabetes Care 22 : 1882-1886, 1999.
12) Oba K, et al : Effect of control of blood glucose on urinary excretion of N-acetyl-β-D-glucosaminidase in elderly type 2 diabetes mellitus. J Nippon Med Sch 67 : 143-145, 2000.
13) 西浦公章ほか : 糖尿病患者における尿中シアル酸およびNAG活性. 最新医学 40 : 1265-1271, 1985.
14) Agardh C-D, et al : Urinary N-acetyl-β-D-glucosaminidase activity does not predict development of diabetic nephropathy. Diabetes Care 10 : 604-606, 1987.
15) 渡邉有三, 堀田饒 : 糖尿病尿細管間質病変 (Armanni-Ebstein腎など). 別冊日本臨牀 腎臓症候群 (下), p225-228, 日本臨牀社, 1997.
P.595 掲載の参考文献
1) 堀正二ほか : ポリグラフ検査ポリグラム. 生体・機能検査のABC. 日本医師会雑誌 120 (8) : 111-113, 1998.
2) 古池保雄, 早河敏治 : 覚醒・睡眠ポリグラフィ. 自律神経機能検査, 第3版 (日本自律神経学会編), p 258-263, 文光堂, 2000.
5) 岡尚省ほか : 収縮期血圧のスペクトル解析を用いた糖尿病患者の交感神経機能の検討. 糖尿病 36 : 829-838, 1993.
6) 高俊彦 : レーザードップラー血流波形の意義と糖尿病患者における自律神経機能検査としての臨床応用. 自律神経 34 : 335-343, 1997.
7) 磯谷治彦 : 糖尿病性自律神経障害の新しい評価法としての暗順応時瞳孔面積の測定. 糖尿病 33 : 909-916, 1990.
10) 藤原秀哉ほか : 糖尿病性自律神経障害の早期診断におけるポリグラフィーの応用 (第一報). 糖尿病 38 : 378, 1995.
11) 佐々木惠雲ほか : 糖尿病性自律神経障害の早期診断におけるポリグラフィーの応用 (第二報) -境界型耐糖能者に対する検討. 糖尿病 38 : 379, 1995.
12) 田村直俊, 島津邦男 : 循環系機能検査. Clinical Neuroscience 15 : 410-412, 1997.
P.599 掲載の参考文献
1) Shapiro LM, et al : Prospective study of heart disease in untreated maturity onset diabetes. Br Heart J 44 : 342, 1980.
2) Stevens MJ, et al : Cardiac sympathetic dysinnervation in diabetes : implications for enhanced cardiovascular risk. Circulation 98 : 961-968, 1998.
3) Ewing DJ, et al : Twenty four hour heart rate variability : effects of posture, sleep, and time of day in healthy controls and comparison with bedside tests of autonomic function in diabetic patients. Br Heart J 65 : 239-244, 1991.
4) Task Force of the European Society of Cardiology and the North American Society for Pacing and Electrophysiology, Heart Rate Variability : Standard of measurement, physiological interpretation, and clinical use. Circulation 93 : 1043-1065, 1996.
5) 西村敏博, 矢永尚士 : 心拍スペクトル解析. 臨床検査 35 : 585-590, 1991.
6) Ewing DJ, Clarke BF : Diagnosis and management of diabetic autonomic neuropathy. Br Med J 285 : 916-918, 1982.
7) 渡辺鈴子ほか : 糖尿病性神経障害と足の病変. 糖尿病 44 (Suppl 1) : S-204 (抄録), 2001.
8) Pagani M, et al : Spectral analysis of heart rate variability in the assessment of autonomic diabetic neuropathy. J Auton Nerve Syst 23 : 143-153, 1988.
9) Freeman R, et al : Spectral analysis of heart rate in diabetic neuropathy. Arch Neurol 48 : 185-190, 1991.
10) Bellavere F, et al : Power spectral analysis of heart rate variation improves assessment of diabetic autonomic neuropathy. Diabetes 41 : 633-640, 1992.
11) Yamasaki Y, et al : Assessment of early stage autonomic nerve dysfunction in diabetic subjects-application of power spectral analysis of heart rate variability. Diabetes Res 17 : 73-80, 1991.
12) 平山祐儀ほか : 神経障害を合併した糖尿病患者の心拍変動解析-アルドース還元酵素阻害薬 (Epalrestat) の効果. Diabetic Frontier 11 : 739-743, 2000.
13) 新谷宇一郎ほか : 軽症期糖尿病患者における自律神経障害の特徴. Jpn J Electrocardiol 18 : 40-45, 1998.
15) Meinhold JA, et al : Low prevalence of cardiac autonomic neuropathy in type 1 diabetic patients without nephropathy. Diabetic Med : a Journal of the British Diabetic Association 18 : 607-613, 2001.
16) Rathmann W, et al : Mortality in diabetic patients with cardiovascular autonomic neuropathy. Diabetic Med 10 : 820-824, 1993.
17) Gerritsen J, et al : Impaired autonomic function is associated with increased mortality, especially in subjects with diabetes, hypertension, or a history of cardiovascular disease : the Hoom study. Diabetes Care 24 : 1793-1798, 2001.
18) Carney RM, et al : Depression, heart rate variability, and acute myocardial infarction. Circulation 104 : 2024-2028, 2001.
20) Manzella D, et al : Chronic administration of pharmacologic doses of vitamin E improves the cardiac autonomic nerves system in patients with type 2 diabetes. Am J Clin Nutr 73 : 1052-1057, 2001.
P.605 掲載の参考文献
1) 小川徳雄 : 発汗活動に影響する中枢性および末梢性要因. 日本生理誌 48 : 1-13, 1986.
2) 菅屋潤壹 : 発汗の中枢機構 (II). 臨床脳波 32 : 189-194, 1990.
3) Ogawa T : Thermal influence on palmar sweating and mental influence on generalized sweating in man. Jpn J Physiol 25 : 525-536, 1975.
4) 齋藤博 : 温熱性. 精神性発汗試験. 自律神経機能検査, 第3版 (日本自律神経学会編), p202-208, 文光堂, 2000.
5) 北耕平 : 発汗計検査 (sudorometry). 自律神経機能検査, 第3版 (日本自律神経学会編), p 214-218, 文光堂, 2000.
6) 大橋俊夫 : 精神性発汗の連続記録による自律神経機能評価. 自律神経機能検査, 第2版 (日本自律神経学会編), p137-139, 文光堂, 1995.
7) Low PA, et al : The sympathetic nervous system in diabetic neuropathy ; A clinical and pathological study. Brain 98 : 341-356, 1975.
11) Low PA : Clinical Autonomic Disorders, p 179, Lippincott-Raven, Philadelphia, 1997.
13) Spitzer A, et al : Cardiac autonomic involvement and peripehral nerve function in patients with diabetic neuropathy. Funct Neurol 12 : 115-122, 1997.
14) 栢沼勝彦, 宇尾野公義 : 神経内科領域における臨床応用. 精神性発汗現象-測定法と臨床応用 (大橋俊夫, 宇尾野公義編), p106-119, ライフメディコム, 1993.
P.609 掲載の参考文献
1) Ewing DJ, et al : The natural history of diabetic autonomic neuropathy. Q J Med 49 : 95-108, 1980.
2) Sharpey-Schafer EP : Effects of squatting on the normal and failing circulation. Br Med J 12 : 1072-1074, 1956.
3) O'Donnell TV, McLlroy MB : The circulatory effects of squatting. Am Heart J 64 : 347-356, 1962.
4) Rossberg F, Penaz J : Initial cardiovascular response on change of posture from squatting to standing. Eur J Appl Physiol Occup Physiol 57 : 93-97, 1988.
5) Marfella R, et al : A useful tool to assess both parasympathetic and sympathetic involvement of the cardiovascular autonomic neuropathy on diabetes. Diabetes 43 : 607-612, 1994.
6) 森ユミ子ほか : Squatting testによる糖尿病自律神経障害の評価. 糖尿病 39 : 857-865, 1996.
P.613 掲載の参考文献
1) Hagbarth KE, et al : General characteristics of sympathetic activity in human skin nerve. Acta Physiol Scand 84 : 164-176, 1972.
2) Delius W, et al : General characteristics of sympathetic actiVity in human muscle nerve. Acta Physiol Scand 84 : 68-81, 1972.
3) Fagius J, Wallin BG : Sympathetic reflex latency and conduction velocities in normal man. J Neurol Sci 47 : 433-448, 1980.
4) Bini G, et al : Thermoregulatory and rhythmgenerating mechanism governing the sudomotor and vasoconstrictor outflow in human cutaneous nerves. J Physiol 306 : 537-552, 1980.
6) Knezevic W, Bajada S : Peripheral autonomic surface potential. A quantitative technique for recording sympathetic conduction in man. J Neurol Neurosurg Psychiatry 67 : 239-251, 1985.
7) Lader MH, Montagu JD : The psychogalvanic reflex : A pharmacological study of the peripheral mechanism. J Neurol Neurosurg Psychiatry 25 : 126-133, 1962.
8) Wang GH : The galvanic skin reflex : a review of old and recent works from a physiologic point of view, part one. Am J Phys Med 36 : 295, 1957.
9) Wang GH : The galvanic skin reflex : a review of old and recent works from a physiologic point of view, part two. Am J Phys Med 37 : 35, 1957.
10) Uncini A, et al : The sympathetic skin response : normal values, elucidation of afferent component and application limits. J Neurol Sci 87 : 299-306, 1988.
11) 横田隆徳 : Sympathetic skin response (交感神経皮膚反応). 自律神経機能検査, 第2版 (日本自律神経学会編), p123-128, 文光堂, 1995.
12) 渡引康弘 : Sympathetic skin response (SSR) の臨床応用に関する研究 (第1報). ヒトSSRの基礎的性質. 臨床神経 27 : 442-448, 1987.
13) 渡引康弘 : Sympathetic skin response (SSR) の臨床応用に関する研究 (第2報). 糖尿病性末梢神経障害における交感神経無髄線維機能の定量的評価法の試み. 自律神経 24 : 557-565, 1987.
14) Parisi L, et al : Estimation of the conduction velocity of sympathetic sudomotor C fibers in healthy subjects : Study of sympathetic skin reflex. Funct Neurol 16 : 231-237, 2001.
17) 北岡治子 : Sympathetic skin response (SSR). 日本臨牀 48 (増刊 : 糖尿病 (上)) : 613-617, 1990.
P.617 掲載の参考文献
2) The Consensus Committee of the American Autonomic Society and the American Academy of Neurology : Consensus statement on the definition of orthostatic hypotension, pure autonomic failure, and multiple system atrophy. Clin Auton Res 6 : 125-126, 1996.
3) 林理之 : 体位変換試験 : 起立試験 (いわゆるシェロング試験を含む) とヘッドアップ・ティルト試験. 自律神経機能検査, 第2版 (日本自律神経学会編), p4-8, 文光堂, 1995.
P.623 掲載の参考文献
1) Bleecker ML : Neurometer : A screening device for the detection of peripheral neuropathy. Occupational neurology. Course No 102, American Academy of Neurology. Neurology 35 (4. 1) : 37, 1985.
2) Masson EA, Boulton AJM : The neurometer : Validation and comparison with conventional tests for diabetic neuropathy. Diabet Med 8 : S63-66, 1991.
3) 鈴木研一ほか : Neurometerを用いた知覚検査. 末梢神経 6 (1) : 59-62, 1995.
4) Hotta N, et al : Use of the C64 quantitative tuning fork and the effect of niceritrol in diabetic neuropathy. Clin Ther 16 (6) : 1007-1015, 1994.
5) Kimura J : Electrodiagnosis in diseases of nerve and muscle. In : Principles and Practice, 2nd ed, FA Davis, Philadelphia, 1989.
6) 木村淳 : 誘発電位と筋電図. 理論と応用, 医学書院, 1990.
7) 松葉育郎ほか : 簡易型神経伝導速度測定器 (ニューロテスター) の臨床使用. プラクティス 14 : 83-88, 1997.
8) Kimura J : F-wave velocity in the central segment of the median and ulnar nerves. A study in normal subjects and in patients with Charcot-Marie-Tooth disease. Neurology 24 : 539, 1974.
P.629 掲載の参考文献
1) Humphrey LL, et al : The contribution of non-insulin-dependent diabetes to lower-extremity amputation in the community. Arch Intern Med 154 : 885-892, 1994.
2) 金澤康徳 : 糖尿病の実態と合併症の脅威. 内科 73 : 205, 1994.
3) Kida Y, et al : Is difference of arterial and venous oxygen content a possible marker for diabetic foot? Diabetes Care 11 : 515-516, 1988.
4) 佐野祐司ほか : 加速度脈波による血液循環の評価とその応用. 労働科学 61 (3) : 129-143, 1985.
5) 佐野祐司ほか : 加速度脈波による血液循環の評価とその応用 (第2報) -波形の定量化の試み-. 体力研究 68 : 17-25, 1988.
6) Miyashita K, et al : Age-related evaluation of peripheral circulation of workers with vibration exposure. Cent Eur J Public Health 3 : 22-26, 1995.
7) 上田信行ほか : 糖尿病患者における趾尖加速度脈波と経皮酸素分圧および頚動脈内膜中膜複合体との関連. 第18回加速度脈波・脈波研究会講演論文集, p141-144, 1994.
8) 上田信行ほか : 糖尿病患者における趾尖加速度脈波と他の末梢血管病変指数との比較. 糖尿病 第38回日本糖尿病学会年次学術集会プログラム・抄録集, p 230, 1995.
9) 上田信行ほか : 指尖加速度脈波を用いた糖尿病患者の末梢循環障害と治療効果に対する評価の試み. 糖尿病 第36回日本糖尿病学会年次学術集会プログラム・抄録集, p192, 1993.
10) Shintani S, et al : General pharmacological properties of cilostazol, a new antithrombotic drugs. Part 2 : effect on the peripheral organs. Arzneimittelforschung 35 (7A) : 1163-1172, 1985.
11) 高沢謙二 : 循環器系モニターとしての加速度脈波の有用性. ICUとCCU 17 (4) : 347-355, 1993.
12) Ueda N, et al : Quantitative assessment of diabetic autononic neuropathy by accelerated plethysmography. Diabetologia 40 (Suppl 1) : 564, 1997.
13) 鈴木明裕ほか : 弾性動脈の伸展度 (Distensibility) と, 加速度脈波との関係についての検討-完全房室ブロック患者のVVIペーシング時の特徴的循環動態を用いて-. 日本臨床生理学会雑誌 20 (2) : 113-123, 1990.
14) 高沢謙二, 伊吹山千晴 : 加速度脈波. 現代医療 20 : 948-955, 1988.
15) 井上典子, 伊藤千加子 : 動脈硬化の指標としての大動脈脈波速度と加速度脈波の検討. 日本臨床生理学会雑誌 29 (3) : 161-166, 1999.
P.634 掲載の参考文献
1) Lehmann ED, et al : Non-invasive assessment of cardiovascular disease in diabetes mellitus. Lancet 350 (Suppl 1) : 14-19, 1997.
4) 孫可竹, 増田善昭 : 脈波速度. 血管無侵襲診断の実際 (血管無侵襲診断法研究会将来構想委員会編), p 111-120, 文光堂, 2001.
5) Amar J, et al : Arterial stiffness and cardiovascular risk factors in a population-based study. J Hypertens 19 : 381-387, 2001.
6) Makki T, et al : Increased arterial distensibility induced by the angiotensin-converting enzyme inhibitor, lisinopril, in normotensive rats. Br J Pharmacol 111 : 555-560, 1994.
8) Levenson J, et al : Hypercholesterolaemia alters arterial and blood factors related to atherosclerosis in hypertension. Atherosclerosis 95 : 171-179, 1992.
9) Muramatsu J, et al : Hemodynamic changes associated with reduction in total cholesterol by treatment with the HMG-CoA reductase inhibitor pravastatin. Atherosclerosis 130 (1-2) : 179-182, 1997.
11) Sutton-Tyrrell K, et al : Aortic stiffness is associated with visceral adiposity in older adults enrolled in the study group of health, aging, and body composition. Hypertension 38 : 429-433, 2001.
12) Emoto M, et al : Stiffness indexes beta of the common carotid and femoral arteries are associated with insulin resistance in NIDDM. Diabetes Care 21 : 1178-1182, 1998.
13) 小暮晴一郎ほか : 大動脈脈波速度. 日本臨牀 48 (増刊 : 糖尿病 (上)) : 607-612, 1990.
14) Okada S, et al : Role of pulse wave velocity for assessing autonomic nervous system activities in reference to heart rate variability. Med Inf (Lond) 21 : 81-90, 1996.
15) Popele NM, et al : Association between arterial stiffness and atherosclerosis. The Rotterdam study. Stroke 32 : 454-460, 2001.
P.641 掲載の参考文献
1) 松岡健平 : 多発性神経障害. 糖尿病性神経障害の臨床 (平田幸正, 松岡健平編), p213, 現代医療社, 1988.
2) Smith SE, et al : Pupillary signs in diabetic autonomic neuropathy. Br Med J 2 : 924, 1978.
3) 北沢明人ほか : 糖尿病患者の瞳孔異常. 糖尿病 25 : 581, 1982.
4) 磯谷治彦 : 糖尿病性自律神経障害の新しい評価法としての暗順応時瞳孔面積の測定. 糖尿病 33 : 909, 1990.
5) 磯谷治彦ほか : 境界型および糖尿病患者の瞳孔異常-暗順応時瞳孔面積, 対光反応および薬剤点眼試験による検討-. 自律神経 31 : 514, 1994.
6) 内海隆ほか : %縮瞳量, %速度を加えた新しい分析法による対光反応の研究. 第1報. その方法の紹介と自律神経薬剤点眼による対光反応の変動パターンについて. 眼紀 49 : 229-238, 1991.
7) Smith SA, Dewhirst RR : Asimple diagnostic test for pupillary abnomality in diabetic autonomic neuropathy. Diabet Med 3 : 38, 1985.
8) 磯谷治彦ほか : 新型瞳孔計 (DK-101) の健常者における基礎的検討. 臨床検査 44 : 219, 2000.
9) 洪尚樹ほか : 電子瞳孔計 (イリスコーダ) による自律神経機能検査. Diabetes Journal 22 : 84-86, 1994.
10) 白川慎爾, 石川哲 : 瞳孔異常 (1) 最近の瞳孔計測法. 神経内科 29 : 229, 1988.
11) 内海隆 : Open-loop赤外線電子瞳孔計による対光反応の基礎的分析. 日眼会誌 83 : 1524-1529, 1979.
13) Hreidarsson AB : Acute reversible autonomic nervous system abnormalities in juvenile insulin-dependent diabetes. Diabetologia 20 : 475, 1981.
14) Jacobsen J, et al : Autonomic and somatosensory nerve function after 2 years of continuous subcutaneous insulin infusion in type 1 diabetes. Diabetes 37 : 452, 1988.
16) Isotani H, et al : Oval pupil in patients with diabetes mellitus : examination by measurement of the dark-adapted pupillary area and pupillary light reflex. Diabetes Res Clin Pract 29 : 43-48, 1995.
17) Gundersen HJG : An abnormality of the central autonomic nervous system in long-term diabetes : Absence of hippus. Diabetologia 10 : 366, 1974.
18) Sigsbee B, et al : Parasympathetic denervation of the iris in diabetes mellitus. J Neurol Neurosurg Psychiatry 37 : 1031, 1974.
19) 磯谷治彦ほか : 糖尿病患者の瞳孔-暗順応時瞳孔面積と心電図R-R間隔のPower Spectrum解析との比較-. 自律神経 31 : 655, 1994.
P.647 掲載の参考文献
1) Pecoraro RE, et al : Chronology and determinants of tissue repair in diabetic lower-extremity ulcers. Diabetes 40 : 1305-1313, 1991.
2) Orchard TJ, Strandness DE : Assessment of peripheral vascular disease in diabetes. Diabetes Care 16 : 1199-1209, 1993.
3) Polak JF : Arterial sonography : efficacy for the diagnosis of arterial disease of the lower extremity. Am J Roentgenol 161 : 235-243, 1993.
6) McCauley TR, et al : Validation of volume flow measurements with cine phase-contrast MR imaging for peripheral arterial waveforms. J Magn Reson Imaging 5 : 663-668, 1995.
11) Airaksinen KEJ, et al : Diminished arterial elasticity in diabetes : association with fluorescent advanced glycosylation end products in collagen. Cardiovasc Res 27 : 942-945, 1993.
12) Sims TJ, et al : The role of glycation cross-links in diabetic vascular stiffening. Diabetologia 39 : 946-951, 1996.
14) Simons PCG, et al : Common carotid intima-media thickness and arterial stiffness : indicators of cardiovascular risk in high-risk patients : the SMART study (Second Manifestations of ARTerial Disease). Circulation 100 : 951-957, 1999.
15) Goebel FD, et al : Monckeberg's sclerosis after sympathetic denervation in diabetic and non-diabetic subjects. Diabetologia 24 : 347-350, 1983.
16) Young MJ, et al : Medial arterial calcification in the feet of diabetic patients and matched non-diabetic control subjects. Diabetologia 36 : 615-621, 1993.
17) Oxlund H, et al : Increased aortic stiffness in patients with type 1 (insulin-dependent) diabetes mellitus. Diabetologia 32 : 748-752, 1989.
18) Salomaa V, et al : Non-insulin-dependent diabetes mellitus and fasting glucose and insulin concentrations are associated with arterial stiffness indexes : the ARIC study. Circulation 91 : 1432-1443, 1995.
19) Jensen-Urstad KJ, et al : Early atherosclerosis is retarded by improved long-term blood glucose control in patients with IDDM. Diabetes 45 : 1253-1258, 1996.
P.653 掲載の参考文献
1) 平成11年, 人口動態統計 (財団法人厚生統計協会編), 2000.
2) 坂本信夫ほか : アンケート調査による日本人糖尿病の死因-1981-1990年の10年間, 11648名での検討-. 糖尿病 39 : 221-235, 1996.
4) Burchfiel CM, et al : Glucose intolerance and 22-year stroke incidence : The Honolulu heart program. Stroke 25 : 951-957, 1994.
5) 紀田康雄ほか : 糖尿病患者の予後 (第1報) 10年間に経験した1443例の追跡結果と死亡214例の死因. 京医会誌. (in press)
6) 紀田康雄ほか : 糖尿病患者の脳血管障害の現況-各種脳血管障害の頻度, 特徴と対策-. 京医会誌 43 : 143-148, 1996.
7) Classification of Cerebrovascular Disease III. Special report from National Institute of Neurological Disorders&Stroke (NINDS). Stroke 21 : 637-676, 1990.
8) 山口武典, 豊田一則 : 脳血栓と脳塞栓の鑑別. Clinical Neuroscience 10 : 170-172, 1992.
9) 紀田康雄ほか : 心, 脳, 下肢の糖尿病マクロアンギオパチーの臨床的特徴と生命予後. 動脈硬化 26 : 241-248, 1999.
10) 紀田康雄ほか : 糖尿病性腎症と大血管障害の成因に関する代謝及び動脈硬化危険因子の比較検討. 動脈硬化 27 : 47-53, 1999.
11) 紀田康雄ほか : 網膜症の病期と臓器別マクロアンギオパチーの関係. 糖尿病大血管シンポジウム 9 : 53-56, 2000.
12) Bentsen N, et al : Chronically impaired autoregulation of cerebral blood flow in long-term diabetes. Stroke 6 : 497-502, 1975.
P.658 掲載の参考文献
1) Polak JF : Arterial sonography : efficacy for the diagnosis of arterial disease of the lower extremity. Am J Roentgenol 161 : 235-243, 1993.
2) Faglia E, et al : Angiographic evaluation of peripheral arterial occlusive disease and its role as a prognostic determinant for major amputation in diabetic subjects with foot ulcers. Diabetes Care 21 : 625-630, 1998.
5) Sims TJ, et al : The role of glycation cross-links in diabetic vascular stiffening. Diabetologia 39 : 946-951, 1996.
7) Young MJ, et al : Medial arterial calcification in the feet of diabetic patients and matched non-diabetic control subjects. Diabetologia 36 : 615-621, 1993.
8) Oxlund H, et al : Increased aortic stiffhess in patients with type 1 (insulin-dependent) diabetes mellitus. Diabetologia 32 : 748-752, 1989.
12) Shaw JE, et al : An analysis of dynamic forces transmitted through the foot in diabetic neuropathy. Diabetes Care 21 : 1955-1959, 1998.
13) Edelman SV, et al : Neuro-osteoarthropathy (Charcot's joint) in diabetes mellitus following revascularization surgery. Arch Intern Med 147 : 1504-1508, 1987.
P.664 掲載の参考文献
3) Hausdorf G, et al : Cardiomyopathy in childhood diabetes mellitus : incidence, time of onset, and relation to metabolic control. Int J Cardiol 19 : 225-236, 1988.
4) Kuikka JT, et al : Demonstration of disturbed free fatty acid metabolism of myocardium in patients with non-insulin-dependent diabetes mellitus as measured with iodine-123-heptadecanoic acid. Eur J Nucl Med 18 : 475-481, 1991.
5) Sakamoto K, et al : Mechanism of impaired left ventricular wall motion in the diabetic heart without coronary artery disease. Diabetes Care 21 : 2123-2128, 1998.
6) Heyliger CE, et al : Alterations in cardiac sarcolemmal Cae+pump activity during diabetes mellitus. Am J Physiol 252 : H540-H544, 1987.
7) Kreiner G, et al : Myocardial m- [123I] iodobenzylguanidine scintigraphy for the assessment of adrenergic cardiac innervation in patients with IDDM. Comparison with cardiovascular reflex tests and relationship to left ventricular function. Diabetes 44 : 543-549, 1995.
9) Nitenberg A, et al : Impairment of coronary microvascular dilatation in response to cold pressor-induced sympathetic stimulation in type 2 diabetic patients with abnormal stress thallium imaging. Diabetes 50 : 1180-1185, 2001.
10) Shimonagata T, et al : Metabolic changes in hibernating myocardium after percutaneous transluminal angioplasty and free fatty acid metabolism. Am J Cardiol 82 : 559-563, 1998.
11) Ohgita H, et al : Prognostic significance of cardiac I-123 metaiodobenzylguanidine imaging for mortality and morbidity in patients with chronic heart failure : A prospective study. Heart 86 : 656-660, 2001.
12) 坂本賢哉ほか : NIDDMにおける心臓交感神経機能評価-I-123MIBG心筋シンチグラフィーを用いて-. Peptide hormone in pancreas (第15回膵ホルモン研究会報告集, 矢内原昇編), p 118-122, バイオメディカルリサーチファンデーション, 1995.
13) 両角隆一ほか : NIDDMのMIBG心筋シンチグラフィーの経年変化についての検討. 第40回日本糖尿病学会抄録集, p414, 1997.
P.669 掲載の参考文献
1) Weitz JI, et al : Diagnosis and treatment of chronic arterial insufficiency of the lower extremities : a critical review. Circulation 94 : 3026-3049, 1996.
2) Suzuki E, et al : Increased arterial wall stiffhess limits flow volume in the lower extremities in type 2 diabetic patients. Diabetes Care 24 : 2107-2114, 2001.
4) Boulton AJ, et al : Venous oxygenation in the diabetic neuropathic foot : evidence of arteriovenous shunting? Diabetologia 22 : 6-8, 1982.
5) Kida Y, et al : Is difference of arterial and venous oxygen content a possible marker for diabetic foot? Diabetes Care 11 : 515-516, 1988.
7) Atkins HL, et al : Vascular imaging with 99mTc-red blood cells. Radiology 106 : 357-360, 1973.
10) Rhodes BA, et al : Assessment of peripheral vascular disease in patients with diabetes. Two case studies. Diabetes 25 : 307-314, 1976.
11) 島田孝夫 : 糖尿病性壊疽の発症機序に関する研究. 慈恵医大誌 99 : 747-756, 1984.
12) 高桜英輔ほか : 糖尿病壊疽合併患者における下肢動静脈短絡率の増加. 糖尿病 38 : 931-937, 1995.
13) Krug B, et al : Diagnostic performance of digital subtraction angiography (DSA) and magnetic resonance angiography (MRA) ; preliminary results in vascular occlusive disease of the abdominal and lower-extremity arteries. Eur J Radiol 19 : 77-85, 1995.
P.674 掲載の参考文献
1) 厚労省の二次検診通達 (基発第233号), 厚生労働省の労災保険給付の手引き.
3) Handa N, et al : Ischemic stroke events and carotid atherosclerosis. Results of the Osaka follow-up study for ultrasonographic assessment of carotid atherosclerosis (the OSAKA Study). Stroke 26 : 1781-1786, 1995.
7) Watarai T, et al : Insulin resistance contributes to carotid arterial wall thickness in patients with non-insulin dependent-diabetes mellitus. Endocr J 46 : 629-638, 1999.
8) Yamamoto M, et al : Carotid atherosclerosis and serum lipoprotein (a) concentrations in patients with NIDDM. Diabetes Care 20 : 829-831, 1997.
9) Skoglund-Andersson C, et al : LDL particle size distribution is associated with carotid intima-media thickness in healthy 50-year-old men. Arterioscler Thromb Vasc Biol 19 : 2422-2430, 1999.
10) Kawamori R, et al : Platelet activation in diabetic patients with asymptomatic atherosclerosis. Diabetes Res Clin Pract 24 : 89-95, 1994.
11) Otsuki M, et al : Circulating vascular cell adhesion molecule-1 (VCAM-1) in atherosclerotic NIDDM patients. Diabetes 46 : 2096-2101, 1997.
12) Kogawa K, et al : Angiotensin-converting enzyme gene polymorphism is associated with carotid arterial wall thickness in non-insulin-dependent diabetic patients. Diabetes 46 : 682-687, 1997.
14) Mansfield MW, et al : Plasminogen activator inhibitor-1 (PAI-1) promoter polymorphism and coronary artery disease in non-insulin-dependent diabetes. Thromb Haemost 74 : 1033-1035, 1995.
16) Hulthe J, et al : Atherosclerotic changes in the carotid artery bulb as measured by B-mode ultrasound are associated with the extent of coronary atherosclerosis. Stroke 28 : 1189-1194, 1997.
17) 山崎義光ほか : 無症候性脳梗塞と頸動脈肥厚度との関連性の検討. 糖尿病大血管障害 5 : 73-78, 1996.
19) O'Leary DH, et al : Cardiovascular Health Study Collaborative Research Group : Carotid artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. N Engl J Med 340 : 14-22, 1999.
20) Yamasaki Y, et al : Carotid intima-media thickness in Japanese type 2 diabetic subjects : Predictors of progression and relationship with incident coronary heart disease. Diabetes Care 23 : 1310-1315, 2000.
21) Salonen R, Salonen JT : Progression of carotid atherosclerosis and its determinants : apopulationbased ultrasonography study. Atherosclerosis 81 : 33-40, 1990.
23) Kodama M, et al : Antiplatelet drugs attenuate progression of carotid intima-media thickness in subjects with type 2 diabetes. Thromb Res 97 : 239-245, 2000.
24) Cocozza M, et al : Effects of picotamide, an antithromboxane agent, on carotid atherosclerotic evolution. A two-year, double-blind, placebo-controlled study in diabetic patients. Stroke 26 : 597-601, 1995.
25) Ranke C, et al : Dose-dependent effect of aspirin on carotid atherosclerosis. Circulation 87 : 1873-1879, 1993.
26) Mack WJ, et al : One-year reduction and longitudinal analysis of carotid intima-media thickness associated with colestipol/niacin therapy. Stroke 24 : 1779-1783, 1993.
27) Jukema JW, et al : Effect of lipid lowering by prevastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). Circulation 91 : 2528-2540, 1995.
28) Azen SP, et al : Effect of supplementary antioxidant vitamin intake on carotid arterial wall intima-media thickness in a controlled clinical trial of cholesterol lowering. Circulation 94 : 2369-2372, 1996.
P.680 掲載の参考文献
1) 繁田幸雄 : 糖尿病性腎症をめぐる今日の課題. 糖尿病学 (小阪樹徳, 赤沼安夫編), p194-203, 診断と治療社, 1990.
2) 日本透析医学会統計調査委員会 : わが国の慢性透析療法の現況 (1996年12月31日現在), 透析医学会, 名古屋, 1997.
3) Denton T, et al : The role of ultrasound in previously undiagnosed renal failure. Br J Radiol 57 : 673-675, 1984.
5) Platt JF : Duplex Doppler evaluation of native kidney dysfunction ; obstructive and non-obstructive disease. AJR Am J Roentgenol 158 : 1035-1042, 1992.
6) Platt JF, et al : Intrarenal arterial Doppler sonography in patients with non-obstructive renal disease : Correlation of resistive index with biopsy findings. AJR Am J Roentgenol 154 : 1223-1227, 1990.
7) Mostbeck GH, et al : Duplex Doppler sonography in renal parenchymal disease. J Ultrasound Med 10 : 189-194, 1991.
8) Kim SH, et al : Duplex Doppler US in patients with medical renal disease : Resistive index vs serum creatinine level. Clin Radiol 45 : 85-87, 1992.
9) 細島弘行ほか : 糖尿病性腎症患者における, 腎Duplex Doppler Sonographyによる腎内血管抵抗指数 (RI) 測定の意義. 糖尿病性合併症 6 : 131-136, 1994.
10) Hosojima H, et al : Intrarenal duplex Doppler sonography in type 2 diabetic patients with nephropathy. Diabetologia Croatica 24 : 13-18, 1995.
11) 細島弘行ほか : 高血圧症を伴う糖尿病患者における腎ドプラー法による腎血管抵抗指数 (RI) について. 糖尿病性合併症 8 : 208-215, 1995.
12) 細島弘行ほか : 糖尿病患者の腎重症度判定おける腎超音波ドプラー法の臨床的意義. 日本臨床生理学会雑誌 26 : 237-244, 1996.
13) 細島弘行ほか : 糖尿病性腎症患者における腎超音波ドプラー法による腎血流量の評価. 糖尿病 39 : 765-774, 1996.
14) Hosojima H, et al : Evaluation of renal blood flow with renal duplex Doppler sonography in diabetic patients with nephropathy. In : New Aspects of Pathogenesis and Treatment (ed by Kaneko T, et al), p205-208, Smith-Gordon, London, 1997.
15) Hosojima H, et al : Intrarenal resistive index (RI) and extracellular matrix in NIDDM patients with nephropathy. 9th Korea-Japan Symposium on Diabetes Mellitus, Recent Advances on the Pathogenesis and Management, p 105, Elsevier, Amsterdam, 1997.
16) Hosojima H, et al : Resistive index on renal duplex Doppler sonography in hypertensive patients with NIDDM. Diabetes 45 (Suppl 3) : s135, 1996.
17) Hosojima H, et al : Alterations of renal resistive index (RI) during 3 years in NIDDM patients with nephropathy. 16th IDF Congress, Finland, 1997.
18) 細島弘行ほか : 2型糖尿病腎症患者における腎血管抵抗の変動 : 5年間追跡調査. (投稿中)
19) Loutzenhiser R, et al : Atrial natriuretic peptide reverses afferent arteriolar vasoconstriction and potentiate efferent arteriolar vasoconstriction in the isolated perfused rat kidney. J Pharmacol Exp Ther 246 : 522-528, 1988.
20) Kimura G, et al : Intrarenal hemodynamics in patients with essential hypertension. Circ Res 69 : 421-428, 1998.
P.686 掲載の参考文献
1) 厚生統計協会 : 国民衛生の動向・厚生の指標, 特集・第38巻, 1991.
2) 坂本信夫ほか : アンケート調査による日本人糖尿病の死因-1981-1990年の10年間, 11648名での検討 . 糖尿病 39 : 221-236, 1996.
4) Asinger EW, et al : Cardiogenic brain embolism. The second report of the cerebral embolism task force. Arch Neurol 46 : 727-743, 1989.
6) No authors listed : ELAT study (embolism in left atrial thrombi) : baseline clinical and echocardiographic data. Cardiology 86 : 457-463, 1995.
7) 半田伸夫ほか : 超音波法による加齢と脳循環の評価. 綜合臨牀 40 : 1931-1936, 1991.
8) Homma S, et al : Characteristics of patent foramen ovale associated with cryptogenic stroke. A biplane transesophageal echocardiographic study. Stroke 25 : 582-586, 1994.
9) Gautier JC, et al : Paradoxical cerebral embolism with a patent foramen ovale. Cerebrovasc Dis 1 : 193-202, 1991.
10) Amarenco P, et al : The prevalence of ulcered plaques in the aortic arch in patients with stroke. N Engl J Med 326 : 221-225, 1992.
11) Cohen A, et al : Aortic plaque morphology and vascular events : a follow-up study in patients with ischemic stroke. FAPS investigators French Study of Aortic Plaque in Stroke. Circulation 96 : 3838-3841, 1997.
12) 清水義臣ほか : 頸動脈及び胸部大動脈動脈硬化病変の相互関連 : 超音波法による脳梗塞症例での検討. 第24回日本高血圧学会総会プログラム・抄録集, 日本高血圧学会, 52, 2001.
13) Agmon Y, et al : Independent association of high blood pressure and aortic atherosclerosis. A population-based study. Circulation 102 : 2087-2093, 2000.
14) Kallikazaros IE, et al : Closed relation between carotid and ascending aortic atherosclerosis in cardiac patients. Circulation 102 (19 Suppl 3) : III263-268, 2000.
15) Blackshear JL, et al : Aortic plaque in atrial fibrillation : prevalence, predictors, and thromboembolic implications. Stroke 30 : 834-840, 1999.
P.689 掲載の参考文献
1) Ogawa T, Low PA : Autonomic regulation of temperature and sweating. In : Clinical Autonomic Disorder, p 83-96, Lippincott-Raven, New York, 1997.
2) 鹿野昌彦 : 負荷サーモグラフィーについて. Biomedical Thermology 14 : 162-166, 1994.
3) 天野幾司ほか : 運動負荷サーモグラフィーによる閉塞性動脈硬化症患者の下肢血行動態の検討. Biomedical Thermology 14 : 192-195, 1994.
4) 満渕邦彦 : サーモグラフィ診断の基礎-体表温分布の正常値-. 最新医用サーモグラフィ-熱画像診断テキスト- (日本サーモグラフィ学会編), p29-39, ネオ・メディク, 1999.
P.697 掲載の参考文献
3) Hsieh SD, et al : Health risks among Japanese men with moderate body mass index. Int J Obes Relat Metab Disord 24 : 358-362, 2000.
4) 松澤佑次ほか : 新しい肥満の判定と肥満症の診断基準. 肥満研究 6 : 18-28, 2000.
5) Kosaka K, et al : A prospective study of health check examinees for the development of non-insulin-dependent diabetes mellitus : relationship of the incidence of diabetes with the initial insulinogenic index and degree of obesity. Diabet Med 13 : S120-126, 1996.
7) Croft JB, et al : Waist-to-hip ratio in a biracial population : measurement, implications, and cautions for using guidelines to define high risk for cardiovascular disease. J Am Diet Assoc 95 : 60-64, 1995.
9) Lapidus L, et al : Distribution of adipose tissue and risk of cardiovascular disease and death : a 12 year follow up of participants in the population study of women in Gothenburg, Sweden. Br Med J 289 : 1257-1261, 1984.
10) 池田義雄 : 肥満の判断. 肥満症診断・治療・指導のてびき (日本肥満学会肥満診療のてびき編集委員会編), p14-24, 医歯薬出版社, 1993.
11) Caan B, et al : Changes in measurements of body fat distribution accompanying weight change. Int J Obes Relat Metab Disord 18 : 397-404, 1994.
13) Molarius A, et al : Varying sensitivity of waist action levels to identify subjects with overweight or obesity in 19 populations of the WHO MONICA Project. J Clin Epidemiol 52 : 1213-1224. 1999.
14) Hsieh SD, Yoshinaga H : Do people with similar waist circumference share similar health risks irrespective of height? Tohoku J Exp Med 188 : 55-60, 1999.
15) Little P, Byme CD : Abdominal obesity and the "hypertriglyceridaemic waist" phenotype. It's probably not yet time to implement screening. BMJ 322 : 687-689, 2001.
16) Hsieh SD, Yoshinaga H : Abdominal fat distribution and coronary heart disease risk factors in men-waist/height ratio as a simple and useful predictor. Int J Obes Relat Metab Disord 19 : 585-589, 1995.
18) Hsieh SD, Yoshinaga H : Is there any difference in coronary heart disease risk factors and prevalence of fatty liver in subjects with normal body mass index having different physiques? Tohoku J Exp Med 177 : 223-231, 1995.
19) Lee JS, et al : A study on indices of body fat distribution for screening for obesity. Sangyo Eiseigaku Zasshi 37 : 9-18, 1995.
20) Ashwell M, et al : Ratio of waist circumference to height may be better indicator of need for weight management. BMJ 312 : 377, 1996.
21) Ashwell M, et al : Ratio of waist circum ference to height is a strong predictor of intra-abdominal fat. BMJ 313 : 559-560, 1996.
22) Hsia HH, et al : Optimal cut-off values for obesity using simple anthropometric indexes to predict cardiovascular risk factors in Taiwan (First Asia-Oceania Conference on Obesity). 肥満研究 7 : S79, 2001.
23) Hebert PR, et al : Height and incidence of cardiovascular disease in male physicians. Circulation 88 : 1437-1443, 1993.
24) Parker DR, et al : Short stature and cardiovascular disease among men and women from two southeastern New England communities. Int J Epidemiol 27 : 970-975, 1998.
25) Sawa SC, et al : Waist circumference and waist-to-height ratio are better predictors of cardiovascular disease risk factors in children than body mass index. Int J Obes Relat Metab Disord 24 : 1453-1458, 2000.
26) 原光彦ほか : 学童における動脈硬化因子の簡便な推定指標としてのウエスト身長比の有用性. 肥満研究 7 : 49-56, 2001.
27) Hsieh SD, et al : Anthropometric obesity indices in relation to age and gender in Japanese adults. Tohoku J Exp Med 191 : 79-84, 2000.
28) 謝勲東, 吉永英世 : 肥満指標と冠動脈疾患危険因子の関連性-waist/height比と他の肥満指標の検討. 健康医学 11 : 26-29, 1996.
29) Hsieh SD, et al : Regular physical activity and coronary risk factors in Japanese men. Circulation 97 : 661-665, 1998.
P.704 掲載の参考文献
1) Rebuffe-Scrive M, et al : Metabolism of adipose tissue in intraabdominal depots of nonobese men and women. Metabolism 38 : 453-458, 1989.
2) Lonnqvist F, et al : A pathogenic role of visceral fatβ3-adrenoceptors in obesity. J Clin Invest 95 : 1109-1116, 1995.
7) Kobayashi H, et al : Visceral fat accumulation contributes to insulin resistance, small-sized low-density lipoprotein, and progression of coronary artery disease in middle-aged non-obese Japanese men. Jpn Circ J 65 : 11-17, 2001.
9) 善積透ほか : CTによる腹部脂肪分布評価法の普及をめざして-標準的CT画像撮影条件の確立およびパソコン版脂肪面積計測ソフトウエアの開発-. 肥満研究 6 : 193-199, 2000.
11) 日本肥満学会肥満症診断基準検討委員会 (松澤佑次ほか) : 新しい肥満の判定と肥満症の診断基準. 肥満研究 6 : 18-28, 2000.
13) Obesity. Preventing and managing the global epidemic : Report of a WHO consultation on obesity Genova 3. Global prevalence and secular trends in obesity, 1997.
14) Kotani K, et al : Sexual dimorphism of age-related changes in whole-body fat distribution in the obese. Int J Obes 18 : 207-212, 1994.
15) 恩田智彦ほか : 内臓脂肪測定器の開発. BIO Clinica 17 : 148-151, 2002.
P.710 掲載の参考文献
1) All About Japan [家庭の医学」http://allabout.co.jp/health/familymedicine/
2) All About Japan [糖尿病] http://allabout.co.jp/health/diabetes/closeup/CU20010809A/index.htm
3) 血糖自己測定器について http://square.umin.acjp/jin/text/BS.html
4) A & T http://www.aandt.co.jp/jpn/
5) ARKRAY http://www.arkray.co.jp/
6) バイエルメディカル http://www.dm-net.co.jp/bml/index.html
7) 糖尿病情報源 100 http://www.dm-net.co.jp/joho/smbg/smbg.htm
8) キッセイ薬品工業 http://www.dm-net.co.jp/kissei/
9) 三和化学 http://www.dm-net.co.jp/skk/index.html
10) 自己血糖測定器について18巻5号プラクティス血糖自己測定 (SMBG) をめぐって http://www.ishiyaku.co.jp/search/details.asp?bookcode=001805
11) ノボノルディスクファーマ http://www.novonordisk.co.jp/
12) オーソ・クリニカル・ダイアグノスティックス http://www.ocd.co.jp/
13) ロシュ・ダイアグノスティクス http://www.rochediagnostics.jp/
14) シノテスト http://www.shino-test.co.jp/
P.717 掲載の参考文献
1) 富永真琴ほか 血糖自己測定機器の標準化と適正使用について. 糖尿病 44 (2) : 165-175, 2001.
2) 渡邊里美ほか 簡易血糖測定器「メディセーフ」の基礎的検討と使い勝手に関するアンケート結果. 新薬と臨床 47 : 102-110, 1998.
3) 中尾隆之ほか 簡易血糖自己測定器ノボアシストの評価. Diabetes Frontier 7 (3) : 328-333, 1996.
4) 門脇孝ほか : 血糖自己測定器 "デキスターZ" の検討. 基礎と臨床 31 (6) : 427-432, 1997.
5) 米久保功 : 簡易血糖測定器「アドバンテージ」の基礎的検討. 医学と薬学 37 : 485-490, 1997.
6) Feldman B, et al : A small-volume electrochemical glucose sensor for home blood glucose testing. Diabetes Technol Ther 2 : 221-229, 2000.
7) 古田真由美ほか : 健常人における75gブドウ糖負荷試験時の毛細血管・静脈血血糖値の差について. 臨床化学 22 : 35-41, 1993.
8) 桑島正道ほか : 血中グルコース濃度の測定とその誤差の要因. 日本臨牀 56 (増刊 : 糖尿病 3) : 11-18, 1998.
9) 日本糖尿病学会糖尿病関連検査の標準化に関する委員会, 日本臨床化学会糖尿病関連指標専門委員会 : SMBG測定器の校正方法プロトコル案 (Ver. 1.0), 2001.
10) 野口宗親ほか : minimum invasiveのSMBG用機器. プラクティス 18 (別冊) : 27-32, 2001.

最近チェックした商品履歴

Loading...